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Over the past decade, the transcriptomics and proteomics profilings of Chinese 
hamster ovary (CHO) cells have been extensively used for understanding 
cellular mechanisms and for identifying cell engineering targets towards an 
optimization of cell cultures. However, transcriptome and proteome reports 
have described limited success partially due to un-elucidated translational 
control mechanisms. 
 
In order to address this knowledge gap, we developed and applied a high-
resolution translatomic platform based on the combination of polysome 
profiling and microarray technologies, which measured the translational 
efficiency of every gene on a global scale. With this platform we were able to 
successfully generate the first translatome data of exponentially growing CHO 
cells and suggested highly and stably translated genes as potential key growth 
genes for genetic engineering. Furthermore, correlation analysis between 
translatome and transcriptome data indicated that more than 90% of the genes 
were potentially subjected to translational control mechanisms, notably 
regulated by the mammalian target of rapamycin (mTOR) pathway. 
 
The evaluation of the impact of the mTOR pathway on translation activity in 
CHO cells revealed that the starvation state in batch cultures had similar effect 
as rapamycin inhibition causing a shift of polysomes towards monosomes and 
a decrease in cellular growth. Conversely, nutrient supplementation in fed-
batch cultures was able to maintain the activity of the mTOR pathway as well 
as a 2-fold higher global translation activity thereby extending cellular growth 
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by 5 days and increasing final recombinant protein titer by 4-fold. The mTOR 
pathway appeared thus to influence the fate of CHO cell cultures via 
translational control mechanisms which were further investigated by 
comparing the translatome of rapamycin-treated versus untreated control with 
our translatomics platform. 
 
Upon rapamycin treatment, the level of short nucleolar RNA U19 (snoRNA 
U19), which guides the two most conserved pseudouridylation modifications 
on 28S ribosomal RNA (rRNA) was found to be reduced by 2-fold. A design 
of experiment (DOE) analysis of snoRNA overexpression in CHO cells 
provided the first insight into a potential mTOR pathway regulation mechanisn 
of translation activity via inducible rRNA modification and a model was 
proposed. 
 
These findings demonstrate how a translatomics-based strategy enabled the 
identification of key cell growth genes in recombinant CHO cultures, thereby 
guiding to the discovery of a new mechanism of the crucial mTOR pathway 
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Chapter 1: Introduction 
 
1.1. Background 
Chinese hamster ovary (CHO) cells are one of the most commonly used 
mammalian host cell lines by biopharmaceutical industries for the production 
of recombinant proteins of therapeutic interest (Jayapal et al. 2007). With over 
116 recombinant proteins approved by the Food and Drug Administration 
since the 80s, for the treatment of diseases like cancer and arthritis (Aggarwal 
2007), biopharmaceuticals represent today a key market that generated 53.8 
billion US$ sales revenue in 2011 in the USA (Aggarwal 2012). This 
economical success has also strongly benefited the local Singapore economy 
by providing several hundreds of jobs for the production of recombinant 
proteins (Wong and Yap 2007). 
 
In order to meet the increasing demand for such recombinant proteins, effort 
have been made for significantly enhancing the production capacity of CHO 
cell cultures (Barnes and Dickson 2006). Some of the major improvements 
were achieved by empirically designed strategies (Kim et al. 2012a; Lim et al. 
2010b; Wurm 2004) without clear understanding of the underlying cellular 
mechanisms. The lack of such crucial understanding has hindered the 
development of knowledge-based strategies to fully optimize and control cell 
culture processes. To address this limitation, several ‘‘-omics’’ profiling 
technologies such as transcriptomics and proteomics have been successfully 
utilized to gain a more in-depth insight into these cellular mechanisms 
(Kuystermans et al. 2007; Omasa et al. 2010). 
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Interestingly, studies of the transcriptome and/or proteome of CHO cells under 
various conditions have commonly reported a general lack of correlation 
between mRNA and proteins levels (Nissom 2006). This was also observed in 
various human cell lines and yeast (de Nobel et al. 2001; Gygi et al. 1999; 
Pradet-Balade et al. 2001). Therefore, some translational control mechanisms 
seemed to be determinant in regulating the flow of information between 
mRNA and proteins levels in cells (Pradet-Balade et al. 2001). 
 
Cells have evolved translational control mechanisms in order to adjust their 
translation activity, which is an energy-intensive process (Shimizu et al. 
2001), with respect to the resource availability. Hence by controlling 
translation, cells ensure an appropriate coupling of cell growth and 
metabolism with their surrounding environmental conditions (Dethlefsen and 
Schmidt 2007). One of the major regulators of translational control is the 
mammalian target of rapamycin (mTOR) signaling pathway (Ma and Blenis 
2009). 
 
Based on the documented and promising potential of the mTOR pathway 
towards enhancing growth (Sarbassov et al. 2005; Schmelzle and Hall 2000), 
Dressen and Fussenegger (2011) recently exploited the mTOR pathway as a 
cell-engineering target. Over-expression of a human TOR complex in CHO 
cells transiently expressing monoclonal antibodies led to increased growth, 
viability and productivity in micro-carrier type of culture. However, in that 
report, the mTOR pathway activity was not assessed and it remained unknown 
how increasing the level of TOR complex actually contributed to the 
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enhancement of cell phenotype. Furthermore, altering the level of mTOR 
pathway players may only partially affect phosphorylation cascade events, the 
actual molecular signals of the mTOR pathway. As a result, the molecular 
mechanisms of the mTOR pathway in CHO cells need to be investigated in 
order to fully decipher its role in bioprocessing relevant characteristics. As a 
matter of fact, Lee and Lee (2012) recently demonstrated that the mTOR 
pathway extended cellular viability via autophagy induction after rapamycin 
treatment thereby illustrating the importance of understanding the mTOR 
pathway’s molecular mechanisms in CHO cell cultures. 
 
These observations highlight the necessity to comprehend the translational 
control of genes via the mTOR pathway in CHO cells, as that may direct us 
towards the design of strategies to enhance bioprocesses for improved 
recombinant protein production. 
 
1.2. Thesis objective 
The objective of the thesis is to understand translational control mechanisms 
in CHO cells and consequently investigate new strategies for improving cell 
growth via a “translatomic” approach. 
 
The scope involved: 
1. Establishing the first translatome map of genes which support cellular 
growth of CHO cells as a novel approach to (A) discover and propose cell 
engineering targets as well as (B) to establish the state of correlation 
between transcriptome and translatome (chapter 4). 
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2. Evaluating the impact of mTOR pathway translational control on growth 
and productivity of CHO cell cultures upon rapamycin inhibition and 
nutrient supply induction (chapter 5). 
 
3. Elucidating new players of mTOR pathway mediated translational control 
by analyzing translatome profile of rapamycin treated CHO cells and by 




1.3. Thesis organization 
The thesis consists of a total of 7 chapters. 
 
Chapter 1 introduces the context of the thesis and details the objective and 
scopes. 
 
Chapter 2 presents a review of literature on four areas: (1) transcriptomic and 
proteomic landscape in CHO cells evidencing the existence of discrepancies 
due to translational control mechanisms that can be adequately addressed with 
translatomics as reported for other organisms; (2) general translational control 
in eukaryotes with a focus on mTOR pathway in (3); as well as (4) snoRNAs 
biology and relevance to the mTOR pathway translational control. 
 




Chapter 4 describes the development of a polysome profile platform resulting 
in the first CHO translatome data and proposes cell-engineering targets. 
 
Chapter 5 reports the evaluation of the mTOR pathway impact on translation 
regulation in CHO cell cultures and how it affects growth and productivity. 
 
Chapter 6 documents the identification and subsequent engineering of 
snoRNA U19 as a potential effector of the mTOR pathway translational 
control mechanisms, which led to the suggestion of a biological model. 
 
Chapter 7 summarizes the important conclusions resulting from this thesis 





Chapter 2: Literature Review 
 
Firstly, this literature review provides the state of the art of transcriptomics 
and proteomics in CHO cells as an indication of strong scientific interest in 
systems-level understanding as well as an evidence of discrepancies between 
these two “-omics” due to translational control mechanisms. Translatomics 
solutions, like the one applied in chapter 4, to study translational control are 
also reviewed. Secondly, the general context of translational control, which 
regulates the translatome in eukaryotes, is described and leads to the third 
point focusing on the mTOR pathway mechanisms that were specifically 
investigated in chapter 5. Finally, the fourth point provides biological 
backgrounds on snoRNAs and reviews the increasing amount of evidence of 
snoRNAs being involved in gene expression regulation and possibly related to 
the mTOR pathway, where a mechanistic model was suggested in chapter 6. 
 
2.1. Translatome: the missing gap between 
transcriptome and proteome 
Proteins are produced from the genetic information (DNA) via the two 
biosynthetic steps known as transcription and translation (Figure 2.1). 
Transcription takes place in the cellular nucleus by RNA polymerases. After 
post-transcriptional processing events such as splicing that removes non-
coding regions (Black 2003) and addition of a 7-methylguanosine cap in front 
of the 5’ end of the mRNA (5’cap; Kapp and Lorsch 2004), the mRNA is 
transported from the nucleus to the cytoplasm where translation takes place. 
Once formed, proteins may undergo post-translational modifications such as 
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phosphorylation or glycosylation before being used inside cells, secreted or 
degraded (Walsh et al. 2005), which results in the overall cellular phenotype. 
Since the past decade, functional genomics has been increasingly utilized to 
describe this complex relationship between genome and phenotype in cellular 
systems (Borrebaeck 1998; Evans et al. 1997). Various “-omics” technologies 
have been employed to support functional genomics by characterizing the 
transcriptome and proteome in cells (Geschwind and Konopka 2009; Glinski 
and Weckwerth 2006), which is also known as the ‘-omics’ cascade (Figure 
2.1). This enables the understanding of the multi-leveled cellular regulation in 
response to stimuli and environmental or genetic. 
 
 
Figure 2.1: Biosynthesis of protein in eukaryotic cells and corresponding “-
omics” cascade. 
Translatome:





DNA Genome:“What can happen”
Transcriptome:
“What seems to happen”
Proteome:






The typical experimental design for “-omics” studies in CHO cells compare 
cellular states between a control and an altered condition inducing a desired 
phenotypic change at the transcript and protein expression levels, respectively 
(Kuystermans et al. 2007; O'Callaghan and James 2008). The altered condition 
can be a different growth phase, the feeding of supplements, a decrease in 
culture temperature or genetic modifications. Thereafter, the differentially 
expressed transcripts or proteins due to the altered condition are assumed to be 
involved in cellular mechanisms leading to the observed phenotype change. 
Figure 2.2 summarizes the growing number of publications related to the 
proteome and transcriptome of CHO cells. 
 
 
Figure 2.2: Trends of the cumulative number of publication reporting 
transcriptome and/or proteome data in CHO cells  
(Only transcriptome based on microarray technology was considered). 
 
The first systems-level analysis of a CHO cell line was a proteomic study 
performed by Lee et al. (1996) using two dimensional electrophoresis, in order 




























1995 2000 2005 2010
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factors such as insulin and fetal calf serum. Interestingly, the first 
transcriptome data for CHO cells was reported only ten years later by Baik et 
al. (2006) describing the molecular response of cells to temperature shift from 
37 to 30°C. To date, there are a total of 11 and 22 transcriptomic and 
proteomic CHO analyses respectively. This steady increase underscores the 
strong interest of the bioprocessing community towards systems-level 
understanding. The next two sections will describe the literature of 
transcriptome and proteome analysis in CHO cells (Table 2.1). 
 
Table 2.1: Survey of all reported CHO transcriptome and proteome analysis. 
Reference Experimental condition Ta Pb 
Lee et al. (1996) 
Growth factor supplements  
20 ng.mL-1 fibroblast growth factor 
or 1 pg.mL-1 insulin or 10% calf serum 
- + 
Champion et al. (1999) Exponential growth phase - + 
Kaufmann et al. (1999) Temperature shift (37 to 30°C) - + 
Lee et al. (2003) Hyperosmotic pressure (450 mOsm.kg-1) - + 
Van Dyk et al. (2003) Butyrate (0.5 mM) and zinc sulphate (80µM) treatment - + 
Hayduk et al. (2004) 70–80% confluence cells - + 
Hayduk et al. (2005) Clones selected at 0, 20, 200, 640, and 5120 nM methotrexate - + 
Baik et al. (2006) Temperature shift (37 to 33°C) + + 
Li et al. (2006) Dimethyl Sulfoxide (DMSO) treatment (1.5% v/v)  - + 
Nissom et al. (2006) High vs. low GFP producers + + 
Wong et al. (2006) Batch vs. fed-batch cultures + - 
De Leon Gatti et al. 
(2007) Butyrate treatment (0.5, 1, and 2 mM) + - 
Pascoe et al. (2007) Clone consuming vs. Clone not consuming lactate - + 
Doolan et al. (2008) Control vs. PACE transfected cells (higher productivity) + - 
Meleady et al. (2008) Control vs. PACE transfected cells (higher productivity) - + 
Yee et al. (2008) Butyrate treatment (1 mM) + + 
Kumar et al. (2008) Temperature shift (37 to 31°C) - + 
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Table 2.1 continued 
Reference Experimental condition Ta Pb 
Carlage et al. (2009) High vs. low producers - + 
Yee et al. (2009) Temperature shift (37 to 33°C) + - 
Kantardjeff et al. (2010)c Butyrate treatment (2 mM) at 33°C + - 
Lee et al. (2010) Exponential growth phase - + 
Doolan et al. (2010) Fast vs. slow growth rate cells + + 
Klausing et al. (2011) Butyrate treatment (2 mM) + - 
Kim et al. (2011)  Hydrolasate supplements to serum free medium - + 
Meleady et al. (2011) Stable productivity clones vs. unstable productivity clones - + 
Wei et al. (2011)  Death growth phase - + 
Doolan et al. (2012) Stable productivity clones vs. unstable productivity clones + - 
Carlage et al. (2012) Exponential vs. stationary growth phase  - + 
Kim et al. (2012) Hyperosmotic pressure (17 to 510 mOsm.k-1) + Betaine - + 
a (T): transcriptome  
b (P): proteome 
c The proteomic aspect discussed in the paper focused only on the secretion kinetic of 
the recombinant antibody but not on the proteome itself. As a result, it was 
considered as transcriptome contribution only 
 
2.1.1. Transcriptome: “What seems to happen” 
Transcriptome is a quantitative measurement of transcripts on a global scale at 
a given time point via microarrays. Microarrays are arrays that contain a large 
number of probes (typically 10 to 30 thousands) which target specific 
transcripts by means of pairing hybridization (Gresham et al. 2008). The 
number and specificity of probes on arrays has dramatically increased over the 
past decade thanks to the progress of probe synthesis and microarrays 
technologies as well as the sequencing advancements of the CHO genome 
(Jacob et al. 2009). For example, the first reported CHO transcriptome data 
(Baik et al. 2006) were actually generated with a rat specific microarrays of 
5,029 probes and a mouse specific microarrays of 7,140 probes targeting 1,655 
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and 4,643 known genes respectively. Because of the partial sequence 
homology between rat/mouse and CHO genes (Yee et al. 2008b), the data 
analysis was limited to general cellular process groups. Shortly after, Nissom 
et al. (2006) synthesized the first reported CHO specific microarrays 
containing 14,592 cDNA probes based on Expressed Sequence Tag (EST; 
Wlaschin et al. 2005) targeting 7,559 unique CHO genes, for the comparison 
between high and low Green Fluorescent Protein (GFP) producers. Seventy-
seven transcripts were observed as differentially regulated of which 41 had 
known annotated functions including up-regulation of transcripts coding for 
the enzymes responsible for opening the DNA HMGN3 and HMGB1, as well 
as for the ribosomal protein RPS2 and RPS27 of the 40S subunit of ribosomes. 
 
Using similar CHO-EST microarrays, a targeted transcriptomic approach was 
used to track the transcript regulation accompanying the onset of apoptosis 
between batch and fed-batch cultures (Wong et al. 2006a). Seven core 
apoptotic genes were detected as differentially expressed including, Faim, 
Agl2, Fadd and Requiem. These genes were then engineered to successfully 
enhance the apoptosis resistance of CHO cells (Lim et al. 2010a; Wong et al. 
2006b). 
 
Butyrate treatment, an histone deacetylation inhibitor often utilized as additive 
to stimulate recombinant protein production by improving gene accessibility 
(Jiang and Sharfstein 2008), altered the expression of 25 genes notably 
involved in apoptosis and protein folding (De Leon Gatti et al. 2007). Another 
study which identified 742 differentially expressed transcripts upon butyrate 
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treatment confirmed the importance of apoptosis and protein folding 
functional clusters as well as cell cycle, protein transport and lipid metabolism 
(Yee et al. 2008a). The transcriptome of CHO cells with increased specific 
productivity resulting from butyrate treatment and a temperature shift at 33°C 
showed 900 differentially regulated genes largely enriched in the secretory 
pathway including the Golgi apparatus, cytoskeleton protein binding and small 
GTPase-mediated signal transduction functional clusters (Kantardjieff et al. 
2010). During a study involving temperature shift only, 237 transcripts were 
altered with significant up-regulation in protein trafficking (including genes 
Kpna3, Rab5A, Gga3, Clta) and cytoskeleton re-organization (Yee et al. 
2009). This lower number of altered transcripts due to temperature shift alone 
as compared to the combined effects of butyrate and temperature seemed to 
indicate that butyrate has a greater impact on genes expression. Of interest, 
there were seven genes including Pitpna, Timm8b, Napg, Gga3, Arl1, Vdp and 
Ap1g1, displaying analogous changes between Yee et al. (2008a) and 
Kantardjeff et al. (2010) studies. Similarly, thirty-five genes were common in 
both Yee et al. (2008a) and Yee et al. (2009) transcriptome data. These genes 
are likely related to productivity of CHO cells since they were common to 
both productivity-increasing strategies of temperature shift and/or butyrate 
treatment. The latest publication on butyrate treatment reported a total number 
of 1,461 transcripts differentially regulated with the 10 highest fold change 





The effect of cell engineering on transcriptome regulation was also studied by 
comparison between an engineered cell line overexpressing the Paired Amino 
acid Cleaving Enzyme (PACE) and the untransfected control. PACE is known 
to increase the rate of post translational processing and hence increase 
productivity (Roe et al. 2004). Transcriptome data indicated that 1,076 
transcripts were differentially expressed with most significant impact on the 
endoplasmic reticulum and the Golgi apparatus (Doolan et al. 2008), which 
was in agreement with the expected role of PACE. The same authors reported 
two other studies (Doolan et al. 2012; Doolan et al. 2010) where they 
compared fast and slow growing cell lines to identify genes which drive fast 
growth; and stable and unstable clones to identify genes for high stability. 
High growth rate phenotype in CHO cells was observed to correlate with the 
differential expression of 118 annotated transcripts (Doolan et al. 2010) while 
long term maintenance of productivity was reported to involve the differential 
expression of 19 genes (Doolan et al. 2012). 
 
In the recent years, along with the development of high throughput sequencing 
technologies, a new approach to directly sequencing transcripts instead of 
probing them on microarrays has been employed to generate transcriptome 
data (Becker et al. 2011; Jacob et al. 2010). However, this approach, still in its 
infancy poses bioinformatic challenges such as the need to properly assemble 
such high number of sequence reads. As a result, the more robust and 




2.1.2. Proteome: “What makes it happen” 
Proteome is a quantitative measurement of protein level on a global scale 
through proteomics. Proteomics is the second main “-omics” together with 
transcriptomics, which has attracted growing interest in CHO cells over the 
past decade. This section reviews the key proteomics contributions which are 
important to understand the general context of the “-omics” family in CHO 
cells to which translatomics was integrated. 
 
After the first exploration of the proteome which was based on immuno-
identification of proteins (Lee et al. 1996), Champion et al. (1999) established 
a primary CHO specific map of 25 proteins. Such mapping efforts are 
necessary for accurate identification of proteins via the high throughput mass 
spectrometry (MS) technique, and was further extended with 224 (Hayduk et 
al. 2004) and 179 (Lee et al. 2010) proteins identified by MS/MS. Currently, 
with the recent sequencing of the full CHO-K1 genome (Xu et al. 2011), the 
capacity of protein identification was increased by 8-fold (Baycin-Hizal et al. 
2012). 
 
A shift of temperature to 30°C was observed to alter the quantity and 
postranslational modification of 11 unidentified proteins (Kaufmann et al. 
1999). A similar temperature shift to 33°C significantly modified the quantity 
of 9 identified proteins involved in protein folding and metabolism out of a 
total of 26 identified proteins (Baik et al. 2006). Six proteins including VIM, 
GAPDH, LGALS1, ACTB, PHB and TPII, were also identified in another 
proteomic analysis involving temperature shift to 31°C which identified a total 
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of 23 differentially regulated proteins (Kumar et al. 2008). Increase in osmotic 
pressure at 450 mOsm.kg-1, which induced a slower cellular growth but a 
concomitant augmentation of specific productivity (from 15 to 35 pg.cell-
1.day-1), correlated with the up-regulation of the proteins GAPDH and 
pyruvate kinase (Lee et al. 2003). Nine years later, the same research team, 
looked again at the effect of osmotic pressure but with the addition of betaine 
as an osmoprotectant to minimize the decrease of cellular growth, and could 
identify 16 proteins differentially regulated including up-regulation of 
GAPDH and a pyruvate kinase (Kim et al. 2012b) as observed in their 
previous study (Lee et al. 2003). These two identified proteins probably led to 
increased metabolic energy for recombinant protein production. 
 
Butyrate treatment induced the expression of four proteins GRP75, ENO, C1 
and TXN supporting an increase in metabolic requirement of CHO cells (Van 
Dyk et al. 2003). On the other hand, the chemical Dimethyl Sulfoxide 
(DMSO) which was shown to enhance CHO cells productivity (Liu et al. 
2001), led to the down-regulation of 6 identified proteins mainly related to 
glycolysis and protein folding including triosephosphate isomerase (TIP), 
glyceraldehyde 3-phosphate hydrogenase (GAPDH) and aldolase (ALDO). 
The decreased quantity of these enzymes implied that DMSO could alter the 
distribution of substrate metabolism towards recombinant protein production 
(Li et al. 2006b). Moreover, the cellular mechanisms underlying gene 
amplification with methotrexate, a major selection drug for Dihydrofolate 
Reductase (DHFR) expression system in CHO cells, were monitored at the 
proteomic level (Hayduk and Lee 2005). Seventeen proteins involved in 
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translation, energy pathways, chaperons and cytoskeletal proteins were 
differentially regulated. 
 
Overexpression of PACE in cells changed the quantity of 60 identified 
proteins which were involved in chaperone activity, protein folding, assembly 
and secretion as well as protein translation (Meleady et al. 2008). In a 
proteomic analysis of lactate-consuming CHO cells, glycolytic enzymes were 
differentially expressed and supported the metabolic shift as well as proteins 
related to cell structure and protein processing (Pascoe et al. 2007). 
 
In a proteomic analysis of CHO cells engineered with the apoptosis inhibitor 
Bcl-XL, 32 proteins were differentially expressed and were involved in 
protein metabolism, transcription and cytoskeleton functional clusters (Carlage 
et al. 2009). In another study, twelve differentially expressed proteins involved 
in glucose metabolism, protein translation and folding were identified through 
comparison between high and low producer CHO cells (Meleady et al. 2011). 
Proteomic analyses across the exponential and the stationary growth phases 
were used to monitor the dynamic of proteins associated with growth and 
apoptosis. Fifty nine proteins were identified including molecular chaperone 
and isomerases GRP78 and PDI and cell growth markersMCM2 and MEM5 
with dynamic changes (Carlage et al. 2012). 
 
Proteins are the drivers of biochemical reactions and therefore are major 
effectors of the cellular phenotype. The proteome provides information on 
what enables the phenotype while the transcriptome shows what genes seem to 
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be expressed in cells. This distinction highlights the utility of the proteome 
approach, which is able to specifically detect the final gene product rather than 
an intermediate mRNA product as stated by Van Dyk et al. (2003). 
 
2.1.3. Discrepancy between transcriptome and proteome 
The degree of connection between transcriptome and proteome has been a 
topic of interest to the research community. 
 
The first attempt at correlating transcriptome and proteome of CHO cells 
indicated that the 6 proteins significantly up-regulated (by a factor of 2.2 to 
6.7) after temperature shift at 33°C and which had matching probes on the 
microarrays, had no linear correlation with their respective transcripts whose 
levels were little or not significantly altered (Baik et al. 2006). Although the 
technical limitation of microarrays and proteomic platforms have contributed 
to some extent to this apparent weak correlation between transcriptome and 
proteome, this lack of correlation continued to persist even when microarray 
and proteomic technologies were improved. In fact, in addition of showing 
differing extent of expression change, some protein expression levels were 
opposite in direction compared to the transcript levels in a combined analysis 
of CHO specific microarrays and proteome data of high producer CHO cells 
(Nissom et al. 2006). The cross analysis of the transcriptome (Doolan et al. 
2008) and proteome (Meleady et al. 2008) of a same PACE-engineered cell 
line showed that for 21 identified proteins which had corresponding probes on 
the microarrays, there were three cases of opposite change direction but no 
quantitative information was provided for the remaining 18. In another 
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analysis, on the effect of butyrate treatment, out of the 7 proteins differentially 
regulated that had corresponding probes on the microarrays, only 3 showed 
similar trend while the other 6 were unchanged at the transcript level (Yee et 
al. 2008a). Similarly, among the 21 genes that were identified differentially 
regulated both at the protein and transcriptome levels through comparison of 
fast and slow growth rate cells, only 14 genes showed common direction 
change between transcriptome and proteome (Doolan et al. 2010). A combined 
analysis of two separate publications that compared the same stable and 
unstable productivity clones at the transcriptome (Doolan et al. 2012) and 
proteome (Meleady et al. 2011) levels, clearly seems to indicate that there is 
not a single identified differentially regulated gene that showed correlation. 
 
These findings imply that a change of a transcript level upon any common 
environmental trigger may not necessarily be accompanied by a similar 
change (direction and amplitude) at the protein level. In fact, it has been 
estimated that only 20 to 40% of the protein concentrations are determined by 
the corresponding transcript level in mammalian cells (Cox et al. 2005; Tian et 
al. 2004) which suggest that not all mRNA are translated with the same 
efficiency. This led to the concept of translation on demand introduced by 
(Brockmann et al. 2007) whereby there is permanently an existing pool of 
mRNA present in the cytoplasm and cells decide what transcript to translate 
based on their needs. Thus, for a more inclusive interpretation of the “-omics” 
landscape in CHO cells, deeper understanding of translational regulation is 
required. The “-omics” that allows investigation of translational regulation is 
known as translatome. 
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2.1.4. Translatome: “What cells need to happen” 
Translatome is the measure of genes translational efficiency on a global scale. 
A reliable measure of translational efficiency of cellular mRNAs is the degree 
of association with ribosomes where actively translated mRNAs are typically 
bound by several ribosomes and referred to as polysomes (Eldad and Arava 
2008). As discussed by Inaki (2011), polysome formation has been shown to 
reflect the translational state of a transcript as examined by Western blot and 
35S-methione incorporation (Beilharz and Preiss 2004; Wang et al. 2010). 
Therefore, translatome information can be obtained via a polysome extraction 
step that allows clustering mRNAs with respect to ribosome loading followed 
by an mRNA quantification step with microarrays for global scale analysis or 
quantitative real time polymerase chain reaction (qRT-PCR) for specific 
mRNAs. 
 
Recently, a few techniques have been developed for polysome extraction 
based on affinity capture of ribosomes or nascent peptides. A protein A-tagged 
version of the ribosomal protein RPL16 was expressed in yeast and 
endogenously formed ribosomes and polysomes were recovered from cellular 
extracts with anti protein A IgG coupled microbeads (Halbeisen et al. 2009). 
On the other hand, heat shock protein HSP70 which binds on nascent peptide 
to assist in protein folding (Hansen et al. 1994), was used as a molecular 
anchor for separating polysome-loaded mRNAs (with nascent peptide) from 
free mRNA (no peptide) by affinity beads capturing HSP70 (Kudo et al. 
2010). However, to date, the gold standard to monitor translational efficiency 
is polysome profiling (Arava et al. 2005; Arava et al. 2003; Mašek et al. 2011) 
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which allows separation of translated mRNA with respect to their ribosome 
loading (density) through a sucrose gradient (Figure 2.3). The separation can 
resolve the free subunits 40 and 60S, the 80S complex (non active ribosomes) 
as well as the consecutive polysomes with increasing number of ribosomes 
(active ribosomes). Polysomes are then fractionated and ribosome bound 
mRNAs are extracted, purified and quantified by microarrays. 
 
 
Figure 2.3: General overview of the polysome profiling approach used to 
generate translatome data. 
Polysomes are first separated by density on a sucrose gradient. Heaviest mRNAs 
(i.g. higher number of ribosome loading) are found at the bottom of the 
centrifugation tube. Then polysomes are profiled to display the distribution of 
ribosome loading where higher translational efficiency corresponds to higher 
level of polysomes. For mRNA quantification, ribosome bound mRNAs are 
extracted from polysome profiles in several fractions of different translational 
efficiency, purified and quantified on microarrays to generate translatome data. 
 
 
The advantage of polysome profiling is that there is no need for pre-expression 
of a protein A-tagged protein and the profiles account for the direct association 
Translatome
mRNAs are probed on 
different microarrays 























between ribosomes and mRNAs as opposed to the binding of chaperone to 
nascent peptides. Consequently, the most established technique of polysome 
profiling was selected for the thesis. 
 
Such translatome approaches with polysome profiling have been successfully 
employed and reported in several areas of research, but never in the context of 
CHO cell cultures. For example, the translatome of normally growing bacteria 
confirmed the high diversity of translational states and showed that mRNAs of 
transcriptional regulators were highly translated (Picard et al. 2012). In a 
cancer cell line, translatome data were generated to identify mRNAs that 
continue to associate with polysomes during hypoxia stress (Thomas and 
Johannes 2007). A similar translatome approach applied on exponentially 
growing yeast showed that majority of mRNAs were highly translated but not 
for 43 genes suggesting that they may be translationally controlled (Arava et 
al. 2003). In another study on yeast, translatome data were used to investigate 
the coordination between transcriptome composition and mRNA translation 
after heat shock or rapamycin treatments (Preiss et al. 2003). The translatome 
of stem cells was also investigated to understand the role of translational 
control during stem cells differentiation (Sampath et al. 2008). Importantly, 
Hendrickson et al. (2009) improved the approach to generate translatome data 
and showed that micoRNAs worked by inhibiting translation initiation or by 
stimulating ribosome drop-off in human embryonic kidney (HEK)-293 cells. 
 




2.2. Translational control 
The following section will describe the significance of sophisticated 
translational control mechanisms, what they are, how they work and their 
relevance to CHO cell cultures. 
 
2.2.1. Reasons for regulating translational activity 
As discussed by Mathews et al. (2007) there are several reasons for 
developing translational control mechanisms, firstly due to energy 
conservation. Translation of mRNA is a highly Adenosine Tri-Phosphate 
(ATP; energy) consuming process for cells, reported to sequester not less than 
20% of total cellular ATP in rat thymocytes (Buttgereit and Brand 1995). 
Through translational control, cells ensure to translate only what they need to 
minimize wastage of precious energy. Secondly, translational control allows 
cells to quickly implement desired change of protein levels as any control step 
prior to translation would require greater response time due to intermediate 
steps like mRNA synthesis, mRNA processing, mRNA transport from nucleus 
to cytoplasm and inevitably entail delay. Thirdly, translational control offers 
the possibility to regulate the site of protein synthesis in the cytoplasm in 
response to spatial requirements (Besse and Ephrussi 2008; St Johnston 2005) 
while transcriptional control is restricted to the nucleus for instance. Fourthly, 
translational control provides cells with flexibility of regulation because there 
are various mechanisms (see section 2.2.4) to fine-tune the level of regulation 
desired. Finally, translational control can easily be switched on and off as 




In order to understand how translational control works, some knowledge on 
the molecular mechanism of translation, its limiting step and the players 
involved is required. 
 
2.2.2. Molecular mechanisms of translation 
As displayed in Figure 2.4, translation can be divided in three general stages: 
(1) initiation, (2) elongation and (3) termination that involve a number 
translation factors called eukaryotic initiation, elongation and release factors 
(Kapp and Lorsch 2004). 
 
 
Figure 2.4: Overview of 5’ CAP translation in eukaryotic cells. 
Translation initiation results in the formation of the 80S ribosomal complex at 
the start codon (AUG) with the help of up to 35 initiation factors (IF; Mathews 
et al. 2007). During the elongation phase the ribosome synthesizes the peptide 
supported by three elongation factors. The terminal codon (UAA) ends the 
process with the release of a new protein involving one release factor and the 
recycling of the ribosomes sub-units for further rounds of translation. Adapted 
from Kapp and Lorsch (2004). 
 
 
During initiation, the 80S ribosomal complex is assembled at the start codon 
(AUG) of mRNA with the help of more than thirty-five initiation factors (IF; 












the mRNA supported by three eukaryotic elongation factors and synthesizes 
the polypeptide chain by translocation (Kapp and Lorsch 2004). For each 
round of translocation, a transfer RNA (tRNA) brings and adds a new amino 
acid to the growing polypeptide chain that is complementary to the codon 
sequence on the mRNA. Termination takes place when a stop codon is 
encountered and the completed protein is released from the ribosome. In this 
final stage, the ribosomal subunits are dissociated with one eukaryotic release 
factor and recycled for another round of translation initiation. At any one time, 
several ribosomes can be actively translating one particular mRNA, thus 
increasing the ratio of protein per mRNA for a specific gene (Eldad and Arava 
2008). 
 
The large majority of the translation factors (35 out of 39) are focused on 
translation initiation while only a few are contributing to elongation and 
termination steps. Such difference in complexity illustrates the particular 
attention that cells bring to properly orchestrate translation initiation, and 
supports the idea that translational control principally takes place at the 
initiation step (Jackson et al. 2010). Furthermore, from a logical standpoint, it 
is more efficient for the decision making process to occur at the beginning 
rather than at the termination of translation where all the energy would be 
consumed and the protein almost synthesized. Initiation was also 
experimentally confirmed as the limiting step of translation by a kinetic study 
of ribosome progression along the mRNA strand (Walden et al. 1981). When 
cycloheximide, an elongation inhibitor, was added to cells in low doses such 
that elongation was effectively slowed down but not completely arrested, the 
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translational efficiency of most mRNA was not altered. This indicated that 
even when the rate of ribosome advancement along mRNAs was intentionally 
decreased; the output of translation was not affected because the limiting step 
was up-stream at the initiation step. Moreover, the average density of 
ribosome on mRNAs is typically observed to be significantly lower than the 
maximal packing capacity of one ribosome to every 30 to 40 nucleotides 
(Wolin and Walter 1988) which further emphasizes initiation of translation as 
the limiting step. The mechanism of translation is described in Section 2.2.2. 
As described and concluded on Page 25, translation initiation rather than 
elongation or termination is widely accepted as the controlling step of 
translation by setting the rate at which ribosomes load on mRNAs 
 
2.2.3. Initiation of translation 
Translation initiation mainly occurs through a cap-dependent procedure 
(Lackner and Bähler 2008) which can be divided in three main stages: (1) 
formation of 43S pre-initiation complex (2) recruitment of 43S pre-initiation 
complex to mRNA, (3) 5’ to 3’ scanning until AUG start codon recognition 
and (4) formation of translation competent 80S subunit (Figure 2.5). 
 
First, the 43S pre-initiation complex is formed (Figure 2.5–A) by association 
of a ternary complex and a 40S small ribosome subunit with the help of 
initiation factors 1 (IF1), 1A (IF1A), 3 (IF3) and 5 (IF5; Van Der Kelen et al. 
2009). The ternary complex consists of the initiation factor 2 (IF2) activated 
with a molecule of guanosine tri-phosphate (GTP) and the methionyl-initiator 
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tRNA. Activation of IF2 is crucial for its binding affinity to the ternary 
complex (Hinnebusch and Lorsch 2012). 
 
 
Figure 2.5: Major molecular events that lead to cap-dependent translation 
initiation. 
(A) Formation of the 43S pre-initiation complex which consists of GTP-activated 
IF2 and the initiator tRNA that will serve to recognize the starting codon. (B) 
Docking of pre-initiation complex to mRNA. (C) 5’ to 3’ scanning and AUG start 
codon recognition. (D) Joining of ribosomal subunits. The content in hairpin 
structure in the 5’UTR is variable from mRNA to mRNA and may hinder the 
scanning step. 
 
In parallel, the initiation factor 4F (IF4F) activates the mRNA (Figure 2.5-B) 






































recognizing and binding to the 5’CAP (Jackson et al. 2010). IF4F is a complex 
consisting of initiation factors 4A (IF4A) and 4E (IF4E) linked together by 
initiation factor 4G (IF4G). IF4A possesses an helicase activity to unwind 
potential hairpin structures along the 5’untranslated region (5’UTR) during the 
scanning step (Rogers et al. 2001), IF4E scans and binds to the 5’cap of the 
mRNA (Sonenberg and Gingras 1998) and IF4G acts as a docking station for 
attachment of the 43S pre-initiation complex (Lamphear et al. 1995) through 
common binding to IF3. 
 
Once the attachment is secured (Figure 2.5-C), the 43S pre-initiation complex 
starts a scanning process in search of the initiation codon AUG (Kozak 2002) 
which is recognized through formation of complementary base pair with the 
anticodon loop of the initiator tRNA (Jackson et al. 2010). Thereafter, 
hydrolysis of the IF2-GTP from the ternary complex into IF2-guanosine di-
phosphate (GDP) promoted by IF5 leads to the displacement of most of the 
initiation factors (Figure 2.5-D) and the subsequent joining of the 60S 
ribosomal subunit mediated by initiation factor 5B (IF5B; Pestova et al. 2000). 
Reunited together, the 60S and the 40S ribosomal sub-units form the 80S 
complex ready to proceed for the elongation phase of translation while IF2-
GDP is regenerated into its active form IF2-GTP by initiation factor 2B (IF2B) 
to initiate another 43S pre-initiation complex. 
 
Based on the understanding of translation initiation basic principles, the major 




2.2.4. Different mechanisms of translational control 
Translational control mechanisms can affect the translational efficiency of a 
specific sub-set or of a large quantity of genes principally by altering the 
interaction between mRNAs and ribosomes during the initiation step. Major 
mechanisms that are conserved across eukaryotes are detailed below. 
 
2.2.4.1. Initiation factor 2 phosphorylation 
Cells have the possibility to regulate translation activity by adjusting the 
availability of active IF2-GTP, which is crucial for the formation of new 
ternary complexes (Figure 2.6). 
 
 
Figure 2.6: IF2 translational control mechanism. 
Upon certain stress conditions, IF2 is phosphorylated and act as a binding 
competitive inhibitor resulting that sequester IF2B and decreases the rate of IF2 
activation required for the formation of the ternary complex. 
 
 
When under environmental stresses such as amino acid starvation, viral 
infection, osmotic shock and oxygen limitation, cells can decide to 






























fold its affinity with IF2B (Rowlands et al. 1988). Thus, phosphorylated IF2 is 
a direct competitive inhibitor of unphosphorylated IF2 that hinders the 
regeneration of IF2-GDP. The consequent lack of active IF2-GTP inhibits 
translation initiation. Based on this fact, Underhill et al. (2003) mutated the 
phosphorylation site serine 51 of the initiation factor IF2 of CHO cells into 
alanine. With the said mutation, phosphorylation of IF2 was not possible and 
led to its constitutive activation by IF2B. Transient co-expression of plasmids 
coding for the mutated IF2 and the reporter gene luciferase in CHO cells 
showed a 3-fold increase in reporter activity. 
 
2.2.4.2. Other initiation factors in the context of CHO cell culture 
Interestingly, two other initiation factors IF4G and IF4A were studied in the 
context of CHO cell cultures. The expression of IF4G was engineered to 
actually create an artificial translational control mechanism (Schlatter et al. 
2003). The authors engineered a system of tetracycline inducible over-
expression and rapamycin-dependent dimerisation of IF4G, a core member of 
the IF4F complex that allows recruitment of the 43S pre-initiation complex 
(Figure 2.5-B). Under induced IF4G over-expression and dimerisation, both 
reporter genes Secreted Alkaline Phosphate (SEAP) and luciferase titres were 
observed to increase by up to 6 and 7 fold respectively. 
 
IF4A was identified as a potential target through proteomic profiling and was 
knocked-down in CHO cells in an attempt to enhance the bioprocess (Kumar 
et al. 2009). Although the authors claimed an increase in specific productivity, 
this approach led to a significant decrease in cell growth. This was expected 
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since IF4A is crucial for the scanning stage of translation initiation and its 
knock down should cause the overall translation activity and therefore cellular 
growth to be negatively affected. 
 
2.2.4.3. microRNA (miRNA) 
miRNA, short RNA of about 22 nucleotides, have more recently been 
discovered as a new mechanism of translational control. For example, it has 
been suggested that around 30% of the animals protein coding genes are 
translationally regulated by miRNA (Krek et al. 2005). Given the fact that 
there are on average one miRNA per ten genes targets, the miRNA mediated 
translational control is rather specific as compared to global. miRNA are 
processed from primary transcripts and then assembled into a RNA-induced 
silencing complex (RISC) which target specific mRNA by base pair annealing 
to 3’UTRs. At present the molecular mechanism is yet to be clearly elucidated 
as there have been different conclusions reported. The current trend seems to 
indicate that how well miRNA are pairing to their target could determine the 
molecular mechanism including endonucleolytic cleavage of the target when 
tightly paired (Gu and Kay 2010) or inhibition by obstruction when loosely 
paired. 
 
2.2.4.4. Interaction of IF4E with 4E binding protein 
Another widely accepted translational control mechanism involves inhibition 
of the binding between IF4E and IF4G during the formation of the IF4F 
complex (Figure 2.7). After recognition of the 5’cap by IF4E, 4E binding 
protein (4EBP) competes with IF4G for a shared binding site on IF4E and as a 
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result inhibits global translation initiation (Marcotrigiano et al. 1999). The 
inhibitory potential of 4EBP is regulated by phosphorylation on five different 
phosphorylation sites Thr 36, Thr 45, Thr 69, Ser 65 and Ser 82 (Mothe-
Satney et al. 2000). 
 
 
Figure 2.7: 4EBP translational control mechanism. 
4EBP hinders the interaction between IF4E and IF4G by binding competitive 
inhibition. 4EBP is inactivated by phosphorylation via the core translational 
control regulator the mTOR pathway. 
 
 
Although sites Thr45 or Ser65 are known to play a greater role, on average 
hyperphosphorylation maintains 4EBP in its inactive form, while 
hypophosphorylation state increases 4EBP affinity for IF4E. A critical kinase 
responsible for the phosphorylation of 4EBP is mTOR, which will be 
described in detailed in section 2.3. The mTOR pathway was engineered in 
CHO cells by overexpression of the human TOR complex (Dreesen and 
Fussenegger 2011). Improvements of bioprocess performances such as growth 
and productivity were claimed but no data were reported regarding 























2.3. mTOR signaling pathway 
The mTOR pathway has been established as one of the core regulators of 
translational control after the discovery in 1975 of the immunosuppressive 
drug rapamycin produced by a strain of Streptomyces on Easter island (Sehgal 
et al. 1975). The mTOR pathway is strongly conserved from yeast to human 
and ensures an appropriate coupling of cell growth and metabolism with 
available resources and environmental conditions (Gibbons et al. 2009). 
 
2.3.1. Organization of mTOR pathway 
The mTOR pathway (Figure 2.8) is divided into an upstream and downstream 
phosphorylation cascades centrally regulated by the TOR protein (Foster and 
Fingar 2010). 
 
Figure 2.8: Simplified overview of the mTOR pathway in mammalian cells. 
mTOR receives signals that indicate whether translational machinery should be 
activated or inhibited and transmits them by way of phosphorylation cascade 
mainly to its main downstream effectors 4EBP and S6K1 to regulate translation 
activity (Ma and Blenis 2009). The complex TORc2 was not included because it 
is more involved in other processes than translation regulation. 



































The upstream part perceives the stress signals generated by environmental 
cues while the downstream part executes the appropriate changes in translation 
activity as a result of these signals. 
 
The TOR protein (Figure 2.9) has a highly conserved structure in mammals 
composed of HEAT repeats structures on its NH2-terminal half that are 
suggested to form large surfaces for protein-protein interaction (Perry and 
Kleckner 2003). The COOH-terminal half contains a kinase domain 
supporting TOR’s phosphotranferase activity and an FRB domain on the side 
which binds rapamycin. 
 
 
Figure 2.9: Structural organization of the mTOR protein. 
The inhibitory effect of rapamycin is highly specific through the complex 




The mTOR protein is found in two different complexes, the TOR complex 1 
(TORc1) also known as FRAP1 and the TOR complex 2 (TORc2) but only 
TORc1 is inhibited by rapamycin (see section 2.3.4 for more details on 
rapamycin treatment of mTOR pathway) and directly control translation while 
TORc2 plays a different role for actin and cytoskeleton organization in 
mammals (Jacinto et al. 2004). TORc1 consists of the TOR protein associated 








2009). RAPTOR enables the interaction between TORc1 and its downstream 
substrates, by direct binding to their TOR signaling (TOS) motifs. The main 
downstream substrates of TORc1 are two proteins involved in the translation 
apparatus including 4EBP and ribosomal protein S6 kinase 1 (S6K1; Thomas 
and Hall 1997). This TORc1-substrate interaction is required to activate and to 
ensure the specificity of the phosphotranferase activity of mTOR kinase 
domain which is stimulated by the GTP-bound form of the protein ras 
homologue enriched in brain (RHEB). RHEB itself is regulated by the 
tuberous sclerosis complex (TSC) containing TSC1 and TSC2 (also known as 
hamartin and tuberin, respectively) (Inoki et al. 2003). TSC1 stabilizes the 
TSC complex while TSC2 exhibits GTPase-activating protein activity that 
inhibits TORc1 by removing one phosphate from the RHEB-GTP form and 
converting it to the inactive GDP-bound (Gibbons et al. 2009). 
 
2.3.2. Upstream signaling of mTOR activity 
In general, under favorable growth conditions, cells sense that there is a 
potential for them to grow via the up-stream signaling cascade and turn on the 
mTOR pathway which stimulates translation activity. At the contrary, under 
adverse conditions, cells perceive the limited potential for growth and inhibit 
the mTOR pathway. There are two major categories of upstream signals 
(Figure 2.8) integrated by the mTOR pathway including (1) growth 
factors/mitogen and (2) nutrients/energy (Hay and Sonenberg 2004). 
 
Growth factors and mitogenic hormones such as insulin activate membrane 
receptors Tyr kinases as well as G protein-coupled receptors, thus propagating 
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PI3K/AKT and Ras-ERK signal transduction pathway towards TORc1 
(Campbell et al. 1999). These signals are suggested to involve phosphorylation 
inhibition of the TSC complex resulting in de-repression of TORc1, though 
the evidence supporting this model remain weak (Huang and Manning 2008). 
 
Availability of key nutrients such as amino acids represents a well-known 
activator of the mTOR pathway although its mechanism remains unclear 
(Foster and Fingar 2010; Kim and Guan 2011). Withdrawal of amino acids, 
particularly leucine and isoleucine, rapidly inhibits the mTOR pathway (Yang 
and Guan 2007). Moreover, energetic stresses leading to an increased ratio of 
adenosine mono-phosphate (AMP) to ATP stimulate the AMP-Activated 
Protein Kinase (AMPK). Stimulated AMPK reduces the consumption of ATP 
for translation by enhancing TSC complex inhibitory activity on TORc1 
through phosphorylation (Foster and Fingar 2010) while turning on the ATP-
generating pathway (Ma and Blenis 2009) to restore the level of ATP. 
 
In addition of the two general categories of signals, various forms of cell stress 
including hypoxia (Brugarolas et al. 2004), genotoxic stress (damage to 
DNA), osmotic stress and mechanical stress, have also been reported to inhibit 
mTOR signaling to some extent (Reiling and Sabatini 2006). 
 
2.3.3. Downstream targets of mTOR pathway 
The two major downstream effectors of TORc1 are 4EBP and S6K1, which 
contain a TOS domain for the specific binding of RAPTOR and TOR proteins. 
These effectors target translation initiation factors important for the 
 36 
 
recruitment of the 43S pre-initiation complex to the 5’cap of mRNA (4EBP) 
or the scanning of the initiation codon (S6K1; Ma and Blenis 2009). 
 
Hypophosphorylated 4EBP binds tightly to IF4E, thereby competing with 
IF4G and preventing the formation of the IF4F complex and translation 
initiation (Figure 2.7). Upon activation of the mTOR pathway, TORc1 
mediated phosphorylation of 4EBP drastically reduces its binding affinity for 
IF4E, therefore releasing sequestered IF4E (Ma and Blenis 2009). With the 
absence of direct competitor, IF4G can then be normally recruited to the 5′ 
cap, thus allowing translation initiation to proceed. Being the most established 
downstream effector, 4EBP and its phosphorylation degree is naturally used as 
the gold standard to assess the activation level of the mTOR pathway 
(Magnuson et al. 2012). 4EBP’s phosphorylation degree is traditionally 
assessed via immuno-detection of phosphorylated site on 4EBP with several 
phospho-specific primary antibodies or of total 4EBP after electrophoresis on 
a high resolution gel that permits the separation of three phosphorylated 
isoforms based on the differential size to electrophoresis mobility (Ikenoue et 
al. 2009). In fact as stated by Ikenoue and co-workers (2009) in their 
methodology article, the phosphorylation of 4EBP is often more clearly and 
conveniently determined by mobility shift with one primary antibody rather 
than by using several phospho-specific antibodies. This is because the primary 
antibody that detect total 4EBP provides the key information of overall 
phosphorylation degree (distribution between the three bands) relative to the 
total 4EBP, in one round of Western-blotting. At the opposite, using different 
phospho-specific antibodies provide limited information only on the 
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phosphorylation at a specific site (out of five on 4EBP) at a time that still need 
to be relative to the total 4EBP present in samples therefore requiring several 
rounds of Western-blotting. For that reason, the total 4EBP approach was 
adapted and used for CHO cells in the context of this thesis. 
 
The second main downstream effector, S6K1 (Figure 2.10), is activated by 
TORc1 mediated phosphorylation at Thr389 under favorable growth 
conditions. Although activated S6K1 has been proposed to govern several 
targets and mechanisms, to date, the target IF4B appears to be most commonly 
identified (Foster and Fingar 2010). 
 
 
Figure 2.10: Activation of IF4B by the downstream effector of mTOR pathway 
S6K1. 
Upon phosphorylation IF4B interacts with the 43S pre-initiation complex and 
increases the binding capacity of eI4A for ATP which results in an increased 
scanning efficiency. 
 
Phosphorylation of IF4B at Ser422 by activated S6K1 enables its recruitment 
to the 43S pre-initiation complex. There, IF4B enhances IF4A’s binding 
affinity for ATP which in turns increases the efficiency of the helicase activity 






















et al. 2001). In addition, S6K1 was suggested to govern the translation of a 
specific subset of mRNAs containing 5’ terminal oligo pyrimidine (5’TOP) 
tracts which encode principally for ribosomal components (Jefferies et al. 
1994; Meyuhas 2000), by regulating the phosphorylation of ribosomal protein 
S6 (RPS6). However, this model based on S6K1 has been recently challenged 
after several studies demonstrated that S6K1 knock-out (Pende et al. 2004) or 
knock-in of non-phosphorylatable RPS6 (Ruvinsky et al. 2005) did not affect 
translation of 5’TOP mRNA (Tang et al. 2001). Consequently, the exact 
mechanism by which TOR controls the translation of 5’TOP mRNAs is 
unclear (Van Der Kelen et al. 2009). Due to this relative degree of uncertainty 
regarding S6K1’s involvements and mechanisms, this thesis focused 
essentially on the TORc1-4EBP branch of the mTOR pathway. 
 
Interestingly, the mTOR pathway was also shown to regulate the transcription 
of various classes of RNAs (rRNA, tRNA and snoRNA) directly involved in 
translation machinery (Hannan et al. 2003; Tsang et al. 2010), by modulating 
polymerases and/or transcription initiation factors activity. For example in 
yeast, TORc1 concomitantly binds to the promoter regions of 5S and 35S 
ribosomal DNA in a nutrient and rapamycin-sensitive manner thereby 
regulating polymerase-I and polymerase-III transcriptional activity (Li et al. 
2006a; Wei et al. 2009). Likewise, in HEK-293 cells, the binding association 
between TORc1 and the promoter regions of 45S and 5S ribosomal DNA 
(rDNA) was observed to depend on the activation status of the mTOR 
pathway (Tsang et al. 2010). Alternatively, TORc1 was shown to 
phosphorylate the transcription initiation factors upstream binding factor 
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(UBF) and TIF-1A both of which are important for the activity of polymerase-
I (Mayer et al. 2004). Together, these observations testify of the various 
emerging downstream targets of the mTOR pathway involving both 
transcriptional and translational regulations (Ma and Blenis 2009). 
 
2.3.4. Rapamycin treatment of mTOR pathway 
Rapamycin is an inhibitor of the mTOR pathway that binds to the FRB 
domain of mTOR protein (Figure 2.9) after forming a complex with 
immunophilin FK-506-binding protein 12 (FKBP12; Choo and Blenis 2009). 
Importantly, the complex rapamycin/FKBP12 is not able to interact with 
TORc2 but is specific to TORc1 (Kim et al. 2002). Upon interaction with the 
complex rapamycin/FKBP12, the mTOR protein is thought to undergo 
conformational changes which could disrupt the mTOR-RAPTOR interaction 
within TORc1 (Oshiro et al. 2004) and thereafter deter the capacity of TORc1 
to bind firmly to its downstream substrates. It should be noted that recent data 
indicated that the inhibitory effect of long term rapamycin treatment on the 
TORc1-4EBP phosphorylation cascade could be transient over time possibly 
due to the development of cell-type specific resistance mechanisms (Choo et 
al. 2008). 
 
It is to be noted that similar system to rapamycin in the form or other chemical 
substances may also be used as alternative to control cellular growth. These 
substances can be classified in three categories based on the physiological 
level they target: (1) cellular growth, (2) mTOR pathway or (3) translation 
activity. For example, substances such as 5-fluorouracil, 5-fluorouridine, 5-
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fluorodeoxyuridine, 5'-deoxy-5-fluorouridine, bleomycin, and cytarabine were 
shown to have various degree of antiproliferative effects in CHO cells 
(Senderoff et al. 1990). Regarding agents affecting the mTOR pathway, the 
rapamycin analogues including CCI-779, RAD001 and AP23576 that directly 
target TORc1 have been engineered for improved potency and are currently 
selected for clinical development in cancer treatment (Vignot et al. 2005). 
Other drugs including wortmannin (Mendez et al. 1996) and S9 (Zhang et al. 
2009) also inhibit the mTOR pathway but at the upstream phosphoinositide-3-
kinases level and were shown to reduce translation activity. Alternatively, 
proteins like calcaelin produced by the mushroom Calvatia caelata inhibit 
translation in general in mouse and breast cancer cells (Ng et al. 2003). While 
most of these systems similar to rapamycin are more generally aimed at cancer 
therapy, the well established rapamycin, owing to its specific inhibitory effect 
on TORc1, has become a standard tool to study mTOR pathway mediated 
translational control over the past decade (Grolleau et al. 2002; Preiss et al. 
2003; Tebaldi et al. 2012), but not such study has been performed in CHO cell 
culture. Therefore rapamycin was used in this study for that purpose. More 
generally, in the context of recombinant protein production cultures, 
rapamycin was shown to reduce death and increase productivity of hybridoma 
cells cultivated in fed-batch (Balcarcel and Stephanopoulos 2001). Lately, the 
first report of rapamycin treatment in CHO cells suggested its implication in 
autophagy mechanisms which delayed cell death (Lee and Lee 2012). 
 
Despite a growing number of studies aimed at deciphering mTOR pathway 
cellular functions through rapamycin treatment, upstream and downstream 
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mechanism of TORc1 remain elusive (Wang and Proud 2006) thus requiring 
further investigations. For example, emerging data revealed a novel 
mechanism by showing that growth arrest upon rapamycin treatment in human 
T-lymphocytes involves the small nucleolar RNA host gene (SNHG) GAS5 
(Smith and Steitz 1998; Williams et al. 2011). This discovery opens new and 
exciting perspectives towards a complete understanding of mTOR pathway 
molecular mechanisms in cells. 
 
2.4. Small Nucleolar RNAs (snoRNAs) 
Small nucleolar RNAs are a group of non-coding RNAs of 60 to 300 
nucleotides in length largely involved in posttranscriptional modification of 
ribosomal RNAs (Ganot et al. 1997). There are two types of snoRNAs, based 
on conserved nucleotides motif, box C/D and box H/ACA which guides 2’-O-
ribose methylation and pseudouridylation respectively of ribosomal and 
transfer RNA (Bratkovič and Rogelj 2011). The human genome is estimated to 
contain approximately 1,000 snoRNAs (Rearick et al. 2011) and 
pseudouridylation (H/ACA box snoRNAs), the most common and 
evolutionary conserved modification of rRNA (Jack et al. 2011) has attracted 
great attention in the past years. Insertion of pseudouridines (Figure 2.11) 
introduces more hydrogen bond donors in the rRNA structure therefore 
provides the potential to form new intramolecular interactions between partner 






Figure 2.11: Chemical structure difference between uridine and pseudouridine. 
Isomerisation results in a 180° rotation of the uracil base through the N3-C6 axis 
denoted by the circular arrow. The base in uridine possesses one hydrogen-bond 
(a) acceptor and one (d) donor while pseudouridine gains a second hydrogen-
bond donor after isomerisation. Adapted from Charette and Gray (2000). 
 
 
2.4.1. Biogenesis and mode of action of snoRNAs 
In mammalian cells, most of the snoRNAs are encoded in the intron regions of 
genes coding for proteins involved in the translation machinery (Maxwell and 
Fournier 1995). Interestingly, a few snoRNAs are found in introns of non 
protein-coding genes whose mRNAs harbor several early stop codons in their 
three reading frames (Bortolin and Kiss 1998). It is postulated that these host 
genes are actually expressed only for the purpose of generating the snoRNAs 
they contain (Jack et al. 2011). Nonetheless, independently of their coding 
capacity, all genes hosting intronic snoRNAs appear to belong to the family of 





Upon transcription of the host genes (Figure 2.12), the intronic snoRNAs are 
spliced out from the pre-mRNA and are further matured by exonucleolytic 
cleavage (Kiss and Filipowicz 1995). 
 
 
Figure 2.12: Biogenesis of snoRNAs. 
The introns containing snoRNAs are first removed from the exon during splicing 
of the primary RNA transcripts. Then snoRNAs are further processed by 
exonucleolytic cleavage and are used as guides for RNA modifications. 
 
 
Mature H/ACA box snoRNAs recruit a set of effector proteins to form 
snoRNA-ribonucleoprotein complexes (snoRNP; Figure 2.13) comprising 
dyskerin which catalyzes pseudouridylation, GAR1 that supports dyskerin 
activity as well as NHP2 and NOP10 which act as core protein to stabilize the 
snoRNP complex (Reichow et al. 2007). 
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Figure 2.13: H/ACA snoRNPs and mode of action. 
H/ACA box snoRNAs form a characteristic twin hairpin structure that contains 
the pseudouridylation pockets which specifically recognize the uraciles to be 
isomerized by base-pairing. Isomerisation “Ψ” is catalyzed by the protein 
dyskerin that binds to the snoRNA hairpin with three other proteins including 
GAR1, NHP2 and NOP10 and form a snoRNP. 
 
 
Within snoRNPs, the snoRNA adopts an hairpin-like secondary structure 
consisting of two “stem-bulge-stem” domains separated by a hinge region 
which contains the H box characterized by its consensus motif ANANNA, 
where N is for any nucleotide (Reichow et al. 2007). The second conserved 
motif known as ACA box is located after the second hairpin structure, 3 
nucleotides before the 3’ end of the snoRNA (Kiss et al. 2010). The snoRNA 
regions enclosed within the hairpin structures contain 9 to 13-nucleotides anti-
sense elements on each side that specifically base-pair with the substrate 
rRNA to form the pseudouridylation pocket (Ganot et al. 1997). This specific 
base-pairing between snoRNA and rRNA target identifies the uridine to be 


















Although their full physiological implication is unclear, pseudouridylation 
modifications, are thought to be important mostly because (1) they are found 
in functionally core regions of mature ribosomes (Brimacombe et al. 1992; 
Decatur and Fournier 2002) and (2) the number of pseudouridylated bases 
increases considerably from prokaryotes to eukaryotes (Ofengand 2002). 
 
2.4.2. Function of H/ACA box snoRNAs 
The hypothesis that pseudouridylation is an essential component of proper 
rRNA folding and ribosome function has been supported by several evidences. 
Mutation of the pseudouridylation synthetase dyskerin is known to cause X-
linked dyskeratosis congenita referred to Hoyeraal-Hreidarsson syndrome in 
human (Walne and Dokal 2009). This syndrome is a severe multisystem 
disorder associated with premature mortality, due to bone marrow failure 
(Mason and Bessler 2011). Similar dyskerin mutation in yeast resulted in 
pseudouridylation defects of rRNAs which reduced ribosome translational 
fidelity and efficiency thereby impairing cellular growth (Jack et al. 2011). In 
the same line, complete ablation of dyskerin in mouse liver cells was observed 
to induce a global decrease in H/ACA box snoRNA abundance (Ge et al. 
2010). 
 
Arguably, a number of studies on cells lacking individual snoRNA indicated 
that several single pseudouridylation could be dispensable for cells viability 
and growth in prokaryote and yeast (Parker et al. 1988; Samarsky et al. 1995). 
However, none of these studies performed a competition assay against the 
parental cell lines unlike Badis et al. (2003) who observed a growth advantage 
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for the parental yeast against cells lacking snoRNA U19. snoRNA U19 is a 
member of the H/ACA box family and guides pseudouridylation of the two 
most conserved pseudouridines in 28S rRNA from bacteria to human (Badis et 
al. 2003). In parallel, overexpression in bronchial epitheliums cells of another 
snoRNA, snoRNA-42; a snoRNA found in high levels in lung tumors, was 
reported to increase cell growth and colony formation (Mei et al. 2012). 
 
Interestingly, in CHO cell cultures, snoRNA U14 encoded within the introns 
5, 6 and 8 of the heat shock protein 70 gene was reported to participate in heat 
resistance phenotype after heat shock treatment (Chen et al. 1996). 
 
Together these emerging evidences support the importance of rRNA 
pseudouridylation evolutionarily conserved from yeast to human cells. 
Deciphering snoRNAs implications in gene regulation in CHO cell cultures in 
line with mTOR pathway translational control of 5’TOP mRNAs is of interest 





Chapter 3: Materials and Methods 
 
 
3.1. Cell culture 
3.1.1. Cell lines 
3.1.1.1. CHO M250-9 
The cell line CHO M250-9 used in this thesis was previously generated in the 
laboratory of the Bioprocessing Technology Institute of Singapore by 
Chusainow and co-workers (2009). CHO M250-9 originates from a CHO-
DG44 cell line whose both DHFR alleles were mutagenized (Urlaub et al. 
1983). To obtain CHO M250-9, the CHO-DG44 cell lines were co-transfected 
with vectors phCMV-VHRhD-g1C-neo (Figure 3.1-A) and phCMV-VLRhD-
KR-dhfr (Figure 3.1-B). respectively, encoding for the heavy chain (HC) and 
light chain (LC) of a recombinant monoclonal immunoglobulin G against 
human rhesus-D antigen (Chusainow et al. 2009). 
 
 
Figure 3.1: Map of the expression vectors co-transfected in CHO M250-9 cell 
line. 
(A) Vector coding for the heavy chain (VH RhD) of the monoclonal antibody. (B) 
vector coding for the light chain (VL RhD) of the monoclonal antibody as well as 




















3.1.1.2. CHO U19 
The cell line CHO U19 was generated in this study as a pool stably 
overexpressing the snoRNA U19 under the selection pressure of hygromycin 
as detailed in section 3.6. CHO U19 was used to investigate the potential role 
of the snoRNA U19 in the mTOR pathway upon rapamycin treatment 
(Chapter 6). 
 
3.1.2. Cell maintenance 
3.1.2.1. Cell line banking 
CHO M250-9 and CHO U19 cell lines were conserved as working cell banks 
by cryo-preservation at −180°C in liquid nitrogen. High viability (>95%) cells 
were collected during the mid-exponential growth phase and pelleted by 
centrifugation at 1000 rpm for 5 min. The cells were resuspended at a 
concentration of 1 x 107 cells.mL-1 into a solution containing 10% (v/v) 
DMSO (Sigma-Aldrich), 10% (v/v) spent medium and 80% (v/v) fresh 
medium and were stored in 1 mL CryoTubeTM vials (Nunc). The vials were 
transferred into a cryogenic freezing tube holder (Nalgene) containing 
isopropanol and were placed in a –80°C freezer for the first 24 hours in order 
to ensure a controlled freezing rate of −1°C.min-1. After 24 hours, the vials 
were transferred into liquid nitrogen holding tank for long-term storage. 
 
3.1.2.2. Cell line revival 
When required, cell bank vials were thawed completely and rapidly in a water 
bath at 37°C and the contents were transferred in a 15 mL falcon tube 
containing 5 mL of fresh medium and centrifuged at 1000 rpm for 5 min. The 
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supernatant containing the cryo-protective agent DMSO was discarded and 
cells were resuspended and maintained in an in-house protein free and 
chemically defined medium (see section 3.1.3) All the cell lines used were 
routinely sub-cultured every 3-5 days at a seeding density of 3x105cells.mL-1 
in shake flasks. Cell lines were maintained no longer than 4 to 6 weeks in 
order to avoid potential instability of phenotype due to long term sub-
culturing. 
 
3.1.3. Batch cultures 
All cultures were seeded at 3 × 105 cell.mL-1 and grown in suspension in 1L 
(working volume 300 ~ 330mL) or 3L (working volume 1000mL) disposable 
Erlenmeyer shake-flasks (Corning), at 37°C, under an 8% CO2 atmosphere 
and shaker platform set at 110 rpm in a humidified incubator (Kühner).The 
basal media used in batch control cultures was an in-house proprietary protein 
free and chemically defined medium supplemented with 5 g.L-1 glucose, 8 
mM L-glutamine (Sigma-Aldrich), with 600 μg.mL-1 G418 (Sigma-Aldrich), 
250 nM methotrexate (Sigma-Aldrich) and 0.1% (v/v) Pluronic® F68 
(Invitrogen).  
 
3.1.4. Feeding of batch cultures 
In fed-batch cultures the basal media’s starting glucose and glutamine 
concentrations were reduced to 1 g.L-1 and 0.8 mM respectively. Feeding of 
batch cultures was performed once a day with a proprietary feed-solution in 
order to maintain a glutamine concentration above a threshold of 0.3 mM. The 
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volume of feed-solution to be added at time t was determined based on 
projected consumption of glutamine by the cells till the next feeding at time 
(t+1 day). Projected consumption was calculated according to a constant 
glutamine consumption rate of 2.68x10-1mmol.cell-1.hrs-1 (specific maximal 
consumption rate during exponential growth phase for CHO M250-9 which 
was experimentally measured) and projected cell density at time (t+1 day). 
Viable cell density was projected based on growth rate and cell density at time 
t as well as duration to next feeding. 
 
3.1.5. Rapamycin treatment of batch cultures 
For rapamycin treatment of batch cultures, 20 ng.mL-1 of rapamycin (Sigma-
Aldrich) was added to batch basal medium on day 0 of cultures. The 
supplemented batch basal medium was stirred for 1 hour before use, to ensure 
homogeneous and complete dissolution of rapamycin. 
 
3.1.6. Determination of cell viability 
Cell densities and viabilities were determined by the trypan blue exclusion 
method (Strober 2001) using a Cedex automated cell counter (Innovatis). 
 
3.1.7. Determination of monoclonal antibody titers 
Titers of secreted monoclonal antibody were measured every 24 hours by 
IMMAGE® 800 immunochemistry system (Beckman Coulter) according to 
the manufacturer’s instructions. Samples for day 0 and 1 of cultures contained 
insufficient amount of monoclonal antibodies and could not be quantified 
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since they were below the detection limit of the instrument. Hence, 
monoclonal antibody titers are reported from day 2 of cultures onwards. 
 
3.1.8. Measurement of residual glutamine and glucose 
concentrations 
Residual glutamine and glucose were quantified in technical triplicates every 
24 hours by the bioanalyzer, YSI-7100 (Life Sciences). 
 
3.2. Translation activity 
3.2.1. Sucrose solutions and gradient preparation 
Ten and 50% sucrose solutions were prepared by heat-dissolving sucrose 
(Sigma-Aldrich) in RNase free water supplemented with 75 mM KCl 
(Ambion), 1.5 mM MgCl (Ambion), 10 mM Tris-HCl (First base) and were 
passed through 0.45 µm filters (Satorius) before being stored at 4°C until 
further use. On the day of polysome profiling, 11.5 mL linear gradients were 
prepared by mixing room-temperature 10% and 50% sucrose solutions in 
centrifuge tubes (Seton) using an automated gradient machine (Gradient 
Master Ip, Biocomp) under the program “long sucrose 10-50%”. Four hundred 
microliters of the 10% sucrose solution were then gently deposited on top of 
the sucrose gradients to act as a buffering layer. The tubes were precisely 
balanced using a micro-scale (Mettler Toledo) by adding 10% sucrose solution 




3.2.2. Polysome extraction 
Culture volumes containing 20 × 106 cells were directly incubated with 100 
µg.mL-1 of cycloheximide (Sigma-Aldrich) for 10 minutes at 37°C with no 
agitation to arrest ribosome progression on mRNAs. After incubation, cells 
were subjected to cold shock by addition of ice-cold PBS solution (1st BASE) 
containing 100 µg.mL-1 of cycloheximide (Sigma-Aldrich) in 50 mL falcon 
tubes maintained on ice. Cells were then harvested by centrifugation at 1500 
rpm for 5 minutes at 4°C and washed 2 times with 1 mL of the ice-cold PBS 
solution containing cycloheximide and transferred to 1.5 mL Eppendorf tubes. 
Washed cell pellets were resuspended in 240 μL of resuspension buffer (20 
mM Tris-HCl pH 7.4 (1st BASE), 20 mM NaCl (Ambion), 30 mM MgCl2 
(Ambion), RNasin (Promega), 100 µg.mL-1 Heparin (Merck-Calbiochem), and 
5 µg.mL-1 cycloheximide (Sigma-Aldrich) and lysed for 10 minutes on ice 
after addition of an equal volume of lysis buffer (1.2% (v/v) Triton X-100 
(Promega), 1.2% (v/v) deoxycholate (Thermo Scientific)). Upon lysis, nuclei 
and cell debris were removed by centrifugation at 12,000 rpm for 10 min at 
4°C and the cell-free supernatant was transferred into a new 1.5 mL Eppendorf 
tube on ice. Nucleic acid content was quantified by absorbance reading at 260 
nm (Ultrospec 2100 Pro, Amersham Biosciences) through 1 cm light-path 
quartz micro-cuvette (18UV10, Precision Cells Inc) Thereafter, samples (up to 
400 µl) of equal optical density (A260) units were loaded onto 10% to 50% 
linear sucrose gradients and centrifuged at 34,000 rpm for 2 hours at 8°C 





3.2.3. Polysome profiling and fractionation 
After ultra-centrifugation, sucrose gradients were submitted to a piston 
fractionator (Piston Gradient Fractionator, Biocomp Instruments) and 
polysome profiles were monitored at 260 nm with an EM-1 UV Monitor 
(Biorad) and processed by the software Gradient Profiler (Version 1.58, 
Biocomp Instruments). Before each run, the system was washed with DEPC 
water to eliminate any potential contamination with RNase and to serve as 
reference baseline for UV absorbance. The polysome profiles indicated the 
distribution of ribosome between monosomes (non active ribosomes) and 
polysomes (active ribosomes; Figure 3.2-A), providing a snapshot of the 
global translation activity. This was further numerically calculated as the ratio 
of the areas under the curve of polysomes to monosomes (Mašek et al. 2011) 
using the trapezium rule (Figure 3.2-B). 
 
 
Figure 3.2: Polysome profiling and global translation. 
(A) Schematic view of polysome profile displaying the monosome and the 
polysome area that correspond to not-translated or translated mRNA 
respectively. (B) The standard trapezium rule with its formula was used to 
calculate the area under the curve. The ratio of the area of polysome to 















Area under the curve =
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At the same time, 20 fractions of the sucrose gradient (0.5 mL each) over the 
full polysome profile range were collected with the following parameters 
(speed: 0.3, distance: 3.75 and number of fractions: 20) on the piston gradient 
fractionator. The fractions were incubated in 10% (v/v) sodium dodecyl 
sulfate (1st BASE) and 5 U.mL-1 proteinase K (Invitrogen) at 42°C for 30 min 
to rapidly inactivate endogenous nucleases such as RNases and DNases and 
were stored at -80°C before fraction pooling. 
 
3.2.4. Fraction pooling 
Thirteen fractions (actual fractions 7-19) that covered from the 80S to the last 
polysome peaks (Figure 3.3-A) were pooled in monosome (pool B) and 
polysome (pool A) enriched pools according to an adaptation of the strategy 
previously established by Hendrickson et al. (2009). 
 
 
Figure 3.3: Polysome profile fractionation and pooling. 
(A) Example of polysome profile fractionation. The alternation of vertical 
grey/white bars locates the 13 fractions used for the pooling. The sigmoidal 
curves display the trends of volume distribution from each fraction that was 
added in pool A (¡ ) enriched in polysome and in pool B (l) enriched in 
monosome. (B) Volumes of fractions to generate pools A and B. 
Fraction Volume (uL)
# (actual #) Pool A Pool B
1 (7) 1.5 168.5
2 (8) 2.9 167.1
3 (9) 5.7 164.3
4 (10) 11.8 158.2
5 (11) 24.3 145.7
6 (12) 48.2 121.8
7 (13) 85.0 85.0
8 (14) 121.8 48.2
9 (15) 145.7 24.3
10 (16) 158.2 11.8
11 (17) 164.3 5.7
12 (18) 167.1 2.9






















The volumes of each fraction to be added in pool A and pool B (Figure 3.3-B) 
followed two inverse sigmoidal trends with a crossing point, corresponding to 
the fraction from which equal volumes were added to pool A and pool B, 
between polysome peaks 3 and 4 as in the original published strategy 
(Hendrickson et al. 2009). Pools A and pools B were kept at −80°C until 
further use. 
 
3.2.5. RNA extraction from pools and purification 
RNA was extracted from 900 µL of each pool A and pool B and an equal 
volume of poly-A RNA controls from the GeneChip® eukaryotic poly-A 
RNA control kit (Affymetrix) coding for the prokaryotic gene thrB of B. 
subtilis was then spiked in each pool. This exogenous RNA was used for 
normalization to account for potential loss during extraction and purification 
of RNA. RNA extraction was allowed by addition of 1 volume of 
phenol:chloroform:isoamyl (Sigma-Aldrich) and vigorous mixing. Samples 
were centrifuged at 10,000 rpm for 10 min at room temperature and equal 
volumes of the upper aqueous phase were collected and mixed with 1 volume 
of chloroform:isoamyl to remove residual traces of phenol. After further 
centrifugation at 10,000 rpm for 10 min at room temperature, equal volumes 
of the aqueous phase were collected and the RNA were precipitated 0.1 
volume of 5M sodium acetate (Ambion) and 1 volume of isopropanol 





For purification, the precipitated RNA were pelleted by centrifugation at 
13,000 rpm for 30 min at 4°C and pellets were then washed with 75% (v/v) 
ethanol (Sigma-Aldrich) and re-dissolved in 30 µL of RNase free water. A 
second round of precipitation was performed on the RNA samples with a final 
concentration of 0.6 M lithium chloride (Ambion) and incubated overnight at -
80°C. Lithium chloride precipitation was used to remove residual heparin in 
the RNA samples. On the next day, RNA precipitates were pelleted at 13,000 
rpm for 45 min at 4°C and washed with ice-cold 70% ethanol before re-
dissolution in RNase free water. RNA was then subjected to a final round of 
precipitation with addition of 0.1 volume of 5M sodium acetate (Ambion), 2 
µL of glycogen (Invitrogen) and 2 volumes of 100% ethanol (Sigma-Aldrich) 
before overnight incubation at −80°C. Finally, the precipitated RNA pellets 
were washed in 75% ethanol and resuspended in 30 µL of RNase-free water. 
RNA concentration was determined using NanoDrop (Thermo Scientific) and 
RNA samples were stored at -80°C until further usage for microarrays or qRT-
PCR. 
 
3.3. Translatome profiling and transcriptome 
profiling 
Translatome profiling and transcriptome profiling were performed in three 
general consecutive steps: (1) preparation of the labeled cDNA libraries from 
the RNA samples; (2) microarray hybridization; and (3) data analysis and 









3.3.1. Preparation of labeled cDNA library for microarrays 
For transcriptome, total RNA was isolated from 5 × 106 cells using RNeasy 
Mini Kit (Qiagen) as per the manufacturer instructions. For translatome 
samples, total RNA was isolated and pooled in pool A and B as described in 
section 3.2. RNA samples were subjected to quality control to verify the 
integrity of RNA via Bioanalyser 2100 (Agilent Technology) under the assay 
class “Eukaryote total RNA nano”, as prescribed by the manufacturer 
(Bioanalyzer chromatograms are found in Appendix B). The RNA integrity 
numbers were all ranging from 8.6 to 10, indicating that samples conserved a 
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Fifty nanograms of total RNAs with validated integrity were reverse 
transcribed and amplified using TransPlex Whole Transcriptome 
Amplification Kit #WTA1 (Sigma-Aldrich) as indicated in the manufacturer 
protocol. The size of the amplified cDNA was assessed using the Bioanalyzer 
(Agilent Technology) under the assay class “mRNA nano” (Bioanalyzer 
chromatograms are found in Appendix C). 
 
One microgram of cDNA for each sample were then labeled using NimbleGen 
One-Colour DNA Labeling Kit (Roche) and purified by overnight ethanol 
precipitation. Unique sample tracking controls from NimbleGen Sample 
Tracking Control Kit (Roche) were added to each labeled cDNA sample to 
track the sample locations after hybridization, and to monitor for any cross-
contamination during loading and hybridization of target to array. 
 
3.3.2. Microarrays procedure 
All microarrays procedures including hybridization, washing and scanning 
were based on the NimbleGen Arrays User’s Guide Gene Expression Arrays 
protocol. Prior to hybridization, arrays were prepared by applying 12-plex 
mixers on the slides that presented the proprietary 12 x 135K CHO specific 
probes (Consortium for Chinese Hamster Ovary Cells Genomic Research) on 
their surface (Figure 3.5-A). Mixers are pieces of plastic that create 
hybridization chambers with fill and vent ports on top of each of the 12 arrays. 
For hybridization of the targets to the probes, 6 uL of samples were injected 
through the fills ports of the CHO NimbleGen arrays. Importantly, due to the 
close proximity of the fill and vent ports on the 12 plex-array configuration 
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(Figure 3.5-B), particular precautions were taken to not overfill the arrays and 
to avoid samples to come to the surface at the vent port which could lead to 
sample cross-contamination. Moreover, after loading the array, a plastic cover 
was used to seal the ports. Arrays were mixed and incubated at 42°C for 16 
hours to allow hybridization. 
 
 
Figure 3.5: Mixer and glass slide assembly of the 12-plex microarrays. 
(A) Vertical section view of the mixer and glass side assembly showing the 
hybridization chambers. (B) Position of fill and vent ports that were used to 




For washing, the mixer part was removed from the glass slide and the arrays 
were subsequently soaked into three different washing solutions with vigorous 












GenePix 4000B Scanner (Axon) with the parameters reported in Table 3.1 and 
a 2-µm resolution. 
 
Table 3.1: Parameters for microarrays scanning with GenePix 4000B scanner 
Parameter Setting 
Slide type Roche NimbleGen 
Speed/Sensitivity High Speed 
Channel 1 532 
Channel 2 635 
Laser Intensity 1 100% 
Laser Intensity 2 100% 
Autogain Selected 
Apply to slide 1/cycle 1 Selected 
 
 
3.3.3. Microarray data analysis 
Scanned data were extracted and background corrected using NimbleScan 
v2.6 software (Roche). The sample tracking report indicated that there was no 
cross-contamination of the samples. On each array, there were exactly 135,883 
probes covering a total of 13,514 CHO genes and other control genes with 2 to 
4 probes per gene. For each gene, the corresponding probes intensities were 
first averaged. Quantile normalization was then performed on the 
transcriptome, pool A and pool B samples separately using the R package 
AffyPLM (http://svitsrv25.epfl.ch/R-doc/library/affyPLM/html/normalize-
exprSet.html). The normalized microarray intensity values were validated by 
qRT-PCR (see section 3.4.3 for experimental details) performed on a selection 
of 15 genes (Table 3.3) that covered the range of microarray-normalized 
values for transcriptome and translatome (ratio pool A over pool B). 
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For determining translational efficiency of each gene, intensity value 
measured in pool A was divided by its counterpart intensity value measured in 
pool B. A 1.5 ratio fold change was considered as a significant differential 
enrichment between pool A and pool B. For functional clustering, the online 
program DAVID (Huang et al. 2009) was utilized, to enrich genes in GO 
terms based on the existing functional annotation between gene identifiers and 
GO terms. GO terms were themselves clustered in annotation clusters that 
grouped GO terms of similar biological meaning. Input list of selected genes 
were clustered under the GOTERM_BP_FAT gene ontology system (Huang et 
al. 2009). Only GO terms with a P-value lower than 0.05 were accepted as 
significantly enriched. In brief, P-values were calculated according to a 
modified Fisher exact P-value that tested the random chance for genes to be 
enriched in GO terms. Thereafter, the P-values of accepted GO terms 
pertaining to one annotation cluster were averaged. 
 
 
3.4. Targeted relative quantification of specific 
RNA level 
3.4.1. Primers 
3.4.1.1. Primer design 
All primers used for qRT-PCR purpose were designed using the online 
software primer 3 (http://seqtool.sdsc.edu/CGI/BW.cgi), based on different 
input proprietary CHO-EST DNA sequences and according the parameters in 
Table 3.2 while other parameters remained default. Primers were synthesized 
as 100 µM desalted liquid form (AIT biotech; Table 3.3). 
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Table 3.2: Parameters for qRT-PCR primer design 
Parameter Value 
Primer length min (bp) 18 
Primer length max (bp) 22 
Optimal length (bp) 20 
Tm min (°C) 55 
Tm max (°C) 70 
GC content min (%) 40 
GC content max (%) 60 
Product size min (bp) 100 
Product size max (bp) 200 
 
 
Table 3.3: qRT-PCR primer sequences 
Target 
gene Forward (5' > 3') Reverse (5' > 3') (E)
a 
CLPP CAGAAGGAGACTCCCACAGC  AGAGCAGCCTCAATCGACAT  0.99 
HIST1H3G CCAAAAGTCCACCGAGCTAC  CACAGGTTGGTGTCCTCAAA  1.01 
NFAT5 GGGTCAAACGACGAGATTGT  TCCAGCTTTTGAGTTGCCTT  0.95 
MRG2 ACACTCACACTCCCACGTCA  TGCTGCTGTCTCATGGTTTC  1.01 
PRRX1 TAAAAACGCTTCCCTCCTCA  AGAGTGGGCCATTCATTCAC  0.99 
RBMX2 CTGGAAGCAGGGCAGTAAAG  TCTTCCTCCCCTCTCTGGAT  0.94 
MAP3K15 TTAAGGCAGGTGAACAAGGG  CTGCTGCTGCACATAAGCTC  1.04 
GRINA CGCCATACTCTGCATCTTCA  TGTGTACAGGTTCAGAGCCG  0.93 
CRIP1 ACTCGTGCAGGACCAAGTTC  GTAGCAGGGATGGTTGCAGT  1.05 
ITGB5 CATCCAGATGACACCACAGG  CATCCTTCATGGAGAGGGAA  0.92 
TTYH2 ACAGAACACACTGAAGCCCC  GGCTCACAGTATTCACGGGT  0.91 
SLC19A1 CTTCACAATCGAGCAGGTGA  CAGGATCAGGATTGGCTTGT  0.95 
ALG3 ATAAAGGTGGTGGTTGCTCG  ACCAGGCTGGCCTTAAACTT  0.91 
PSMC3IP ATTTTGCAGACCAGGACCAG  TGCATCTCAGGAGTGGTCAG  0.93 
DOCK8 CTCATGATGGCTGGGAATCT  AATTGTCCCCTGGGTAAAGG  0.97 
U19 GTGGTGCCTGTGATTGTGTT  ACCAGGACCAACTCCACAAG  1.06 
β-actinb AGCTGAGAGGGAAATTGTGCG GCAACGGAACCGCTCATT 0.95 
LCb CTTCCACCCTGTCTGCATCTG GATCCTTGATGGGACCCC 0.98 
HCb AAGGGCCGATTCACCATCTC CGGCCTCTCGCACAGTAATAC 0.98 
ThrBb CTCGCTCAAGCTGTCATGTAC CGGTGATTTCTCACAGATGG 0.97 
a  E: Primer amplification efficiency (see section 3.4.1.3 and Appendix D) 
b Primers for HC, LC, ThrB and β-actin were kindly provided by co-workers 
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Primer pairs were aligned against the database “nucleotide collection (nr/nt)” 
in the Basic Local Alignment Search Tool (BLAST; National Center for 
Biotechnology Information version 2.2.23; Altschul et al. 1990) to check if the 
top alignment matches corresponded well to the expected target, thus serving 
as a first indication of primers specificity.  
 
3.4.1.2. Primer validation using PCR 
Primers designed for qRT-PCR were first validated by PCR amplification on a 
control cDNA template (exponentially growing CHO 250-9 in batch; see 
section 3.4.2.1. for details on RNA extraction and section 3.4.2.4. for cDNA 
synthesis). The assessment was based on whether the expected size of 
amplified product was obtained and with no other unspecific band. At least 
three sets of primers were assessed per gene target. The PCR reaction was 
driven by Taq polymerase (Fermentas) in a 25 µL working volume for 40 
cycles at 95°C for 0.5 min, 60°C for 0.5 min and 72°C for 2 min. Other 
components of the reaction mixture can be found in Table 3.4. 
 
Table 3.4: Composition of reaction mixture for PCR with Taq polymerase 
(Fermentas) 
 
Reagent Concentration Volume (µL) 
DNAse free water - 18 
PCR buffer with KCl 10 X 2.5 
MgCl2 25 mM 1.5 
dNTP 10 mM 0.5 
TAQ polymerase 5 U. µL-1 0.5 
Primer pair 10 µM 1 
Template (cDNA) Dilution 1:20 of reverse transcription from 1 µg of total RNA 1 
Total  25 
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Amplified products were analyzed using DNA gel electrophoresis. The set of 
primers, which resulted in a single band of correct molecular size, were chosen 
for further evaluation. 
 
3.4.1.3. Assessment of primer efficiency by qRT-PCR 
The amplification efficiencies of shortlisted primer pairs were assessed by 
qRT-PCR on serially diluted control cDNA sample (by a factor of 10 or 4) 
comprising a total of six to eight different concentrations. These qRT-PCR 
reactions (see section 3.4.3 for details) were performed using the same 
conditions as for actual qRT-PCR reactions to quantify the targeted genes. The 
quantified CT values were plotted against the log10 of their respective dilution 
factors, and primer efficiency (E) was obtained by the formula: E=10 !!!! ; 
where a is the slope of the straight line correlating the measured CT values and 
their corresponding log10(dilution factor). The amplification efficiency plots 
for each primer pair used in this study for qRT-PCR purpose are presented in 
Appendix D. Only primer pairs whose efficiency was between 0.9 and 1.1 
were used. 
 
3.4.2. Template DNA 
Depending on the type of RNA to be quantified, either mRNA (with polyA 
tail) or snoRNA (without polyA tail), the methods to prepare the template 
DNA for qRT-PCR reaction differed by the addition of a gDNA digestion (see 
section 3.4.2.2) and a polyadenylation (see section 3.4.2.3) steps as described 
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in Figure 3.6-A. This experimental strategy (detailed in Figure 3.6-B) was 




Figure 3.6: Workflow overview for the synthesis of cDNA template. 
(A) Due to their lack of polyA tail, snoRNA were submitted to an additional 
polyadenylation step based on the strategy reported by Ro et al. (2006). (B) 
Detailed description of the polyadenylation strategy. 	  	  
3.4.2.1. Total RNA extraction 
Five millions cells were collected by centrifugation at 1,000 rpm for 5 min and 
used for total RNA extraction. For mRNA quantification, total RNA was 
extracted from the cells using the RNeasy kit (Qiagen) as per the manufacturer 
instructions. For snoRNA quantification, total RNA was extracted with Trizol 
(Invitrogen). Cells were first homogenised in 1 mL Trizol with a 26-gauge 
needle connected to a 1 mL syringe and 200 µL of chloroform was added 
before vigorous shaking and centrifugation at 12,000 rpm for 15 min at 4°C 







Total RNA extraction 
(Rneasy kit)








snoRNA5’ – (N100-200) – 3’
5’ – (N100-200) – AAAAAAAAAAAA(n) 3’ 






5’ – (N100-200) – AAAAAAAAAAAA(n) 3’ 





containing RNA was collected and supplemented with 1.5 µL of glycogen 
(Invitrogen) and 750 µL of 100% ethanol and incubated overnight at −20°C 
for precipitation. Centrifugation at 12,000 rpm for 20 min at 4°C was used to 
pellet the precipitated RNAs which were then washed with 1 mL of 75% 
ethanol, resuspended in 50 µL of RNase free water and quantified by 
Nanodrop (Thermo Scientific). Extracted total RNA for either mRNA or 
snoRNA quantification were stored at −80°C until further use. 
 
3.4.2.2. gDNA digestion 
Total RNA extracted for quantification of snoRNA had to undergo an 
additional step of gDNA digestion in order to ensure quasi-removal of 
potential residual gDNA contamination which could affect the quantification 
of snoRNA U19. gDNA digestion was performed in PCR microtubes with the 
RQ1 RNase-Free DNase (Promega) in 100 µL working volume including the 
reagents as listed in Table 3.5. The reaction mix was incubated at 37°C for 30 
min. 
 
Table 3.5: Standard master mix composition for gDNA digestion. 
 
Reagent Concentration Volume (µL) 
Dnase buffer 10X 10 
Rnase free water - Top up to 100 µL 
Total RNA - 25 (µg) 
Rnasin 20-40 U.µL-1 3 
Dnase 1 U.µL-1 25 





After gDNA digestion, samples were supplemented with 10 µL of the 
prokaryotic gene thrB of B. Subtilis (dilution 1:2000; Affymetrix) that served 
as an internal control accounting for possible RNA loss along the various steps 
prior to qRT-PCR measurement and were scaled up to 700 µL with RNase 
free water (Ambion). One volume of phenol:chloroform:isoamyl (Sigma-
Aldrich) was added, samples were vigorously mixed and centrifuged at 12,000 
rpm for 15 min at room temperature, 600 µL of the upper aqueous phase was 
collected and one volume of chlorofom:isoamyl (Sigma-Aldrich) was added. 
Samples were centrifuged and equal volumes of RNA contained in the upper 
phase were collected and precipitated with 0.1 volume of sodium acetate 
(Ambion) and 2.5 volumes of 100% ethanol (Sigma-Aldrich), overnight at 
−20°C. RNAs were pelleted at 12,000 rpm for 20 min at 4°C, washed with 
75% ethanol (Sigma-Aldrich) and resuspended in 50 µL of RNase free water 
(Ambion). Total RNA concentration was determined with Nanodrop reading 
(Thermo Scientific). 
 
3.4.2.3. Polyadenylation of snoRNA 
Polyadenylation reaction was performed on total RNA samples that were used 
for the quantification of snoRNA U19 since they lack the poly A tail. This 
approach was derived from the method developed by Ro and co-workers 
(2006) to quantify short RNA such as miRNA and snoRNA. Polyadenylation 
was driven by polyA polymerase (Ambion) and was allowed to take place in 
100 uL of working volume in PCR microtubes with the reagents as indicated 




Table 3.6: Standard master mix composition for polyadenylation reaction. 
 
Reagent Concentration Volume (µL) 
Water - 12 
Total RNA (gDNA free) - 45 
Polyadenylase buffer 5X 20 
MnCl2 25 mM 10 
dATP 10 mM 10 
Polyadenylase 2 U.µL-1 3 
Total  100 
 
 
The reaction was stopped and the total RNA extracted through a 
phenol:chloroform:isoamyl purification (see section 3.4.2.2. for details) which 
was necessary to remove the MnCl2 that can affect the reverse transcription 
reaction that followed. 
 
3.4.2.4. Reverse transcription 
Independently of the type of RNA to be measured (mRNA or snoRNA), the 
same experimental procedure was used for the reverse transcription reactions. 
For a group of RNA samples from the same day (snoRNA U19 study) or for a 
pair of samples poolA/poolB (polysome profiles), reverse transcription was 
performed on same volume. This volume was calculated for 1 or 0.5 µg of 
total RNA based on the most concentrated sample. First, oligo dT primers 
(Promega) were added to RNA (Table 3.7), denatured at 65°C for 5 min and 





Table 3.7: Oligo dT priming mixture for reverse transcription 
 
Reagent Concentration Volume (µL) 
RNase free water - Top up to 5 uL 
RNA - equal volume 
oligo dT primers 0.5 ug.µL-1 1 
Total  5.0 
 
 
The reverse transcriptase (Promega) was then added with other components 
(Table 3.8) to a final working volume of 20 µL. The annealing step was 
performed at 25°C for 5 min, then the reverse transcription took place at 42°C 
for 60 min and the reaction was terminated by incubation at 70°C for 10 min. 
Synthesized cDNA were thereafter diluted by a factor 20 in DNase free water 
and stored at −20°C until quantification via qRT-PCR. 
 
 
Table 3.8: Reaction mixture for reverse transcription 
 
Reagent Concentration Volume (µL) 
Rnase free water - 4.5 
Reverse transcriptase buffer 5X 4 
MgCl2 25 mM 4 
dNTP 10 mM 1 
RNA + primers - 5 
RNA-sin 20-40 U.µL-1 0.5 
Reverse transcriptase - 1 





3.4.3. Quantitative-RT PCR 
For both types of RNA to be quantified (mRNA and snoRNA), qRT-PCR 
experimental conditions were the same. Each qRT-PCR reaction was 
performed in at least technical duplicates in a 96-well iQ real-time PCR plate 
(Biorad) for 40 cycles at 95°C for 30 seconds and 60°C for 10 seconds. 
Reactions were driven by the supermix SsoFastTMEvaGreen® (Biorad) in 10 
µL working volume for each technical duplicate. Reaction mixtures were 
prepared as master mixes (Table 3.9). 
 
Table 3.9: Master mix for qRT-PCR reaction 
 
Reagent Concentration Volume (µL) 
Primer 10 uM 1.0 
cDNA diluted 1:20 4.0 
SsoFastTM EvaGreen® supermix - 5.0 
Total  10.0 
 
 
Amplification signals were acquired with the iQ5 system (Biorad) and 
processed with the software Bio-rad iQ5 2.1 (Standard Edition Optical System 
Software 2.1.97.1001). CT values were determined at the point where the 
fluorescence (amplification signals) began to exponentially increase and 
crossed the threshold cycle when there is 200 arbitrarily units of fluorescence 
intensity. Measured CT values were processed as averages from technical 
replicates and samples with relative standard deviation greater than 1% of the 





3.5. mTOR pathway activity 
3.5.1. Total protein extraction 
The activity of the mTOR pathway was determined by the standard approach 
based on the relative phosphorylation degree of eukaryotic initiation factor 4E 
binding protein (4EBP; Ikenoue et al. 2009). Immunobloting on total proteins 
was used to assess the phosphorylation degree of 4EBP. Total protein was 
extracted from 10 million cells for 45 minutes with of ice-cold RIPA buffer 
(Pierce) supplemented with 1X HaltTM phophatase inhibitor cocktail (Thermo 
scientific) and 1X HaltTM protease inhibitor (Thermo scientific). Supernatants 
were collected and stored at -20°C after centrifugation at 18,000 rpm for 15 
min at 4°C (Beckman Coulter Microfuge 22R). 
 
3.5.2. Total protein quantification 
The total protein concentration in the supernatant was quantified using BCA 
assay (Thermo Scientific) according to manufacturer’s instructions. Each 
sample was diluted by a factor 10, allowed to react with the BCA reagent as 
technical duplicates and their respective absorbance was measured at 562 nm 
within 10 min. Total protein concentrations were determined against a 
standard curve of Bovine Serum Albumin (BSA). 
 
3.5.3. Immunobloting 
For immunoblotting, 20 to 25 µg of protein extract from each sample was 
separated in a 12% Bis-Tris gel (Invitrogen) and transferred to a PVDF 
membrane using the iBlot® dry blotting system (Invitrogen). The membrane 
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was blocked in bovine serum albumin blocking solution (Sigma). Total 4EBP 
was probed with an antibody raised in rabbit against total-4EBP (Cell 
Signaling Technology, #9452, dilution 1:1,000) and detected by using an anti-
rabbit HRP conjugated secondary antibody (Cell Signaling Technology, 
#7074, 1:2,000). Antigen bands were visualized using the ECL or ECL+ kits 
(Amersham Bioscience) and recorded onto chemiluminescent film (Roche 
Diagnostics). Consecutively, the membrane was restored using Western blot 
stripping buffer (Thermo Scientific) and reprobed with an anti-actin antibody 
(Abcam, ab8226, dilution 1:5,000 - secondary antibody Abcam, ab6728, 
dilution 1:8,000) as a loading control. 
 
3.6. Generation of stable CHO U19 pools 
3.6.1. Construction of expression vector pcDNA3.1/hygro-U19 
The general process for the construction of the expression vector pcDNA3.1-
hygro-U19 is displayed in the diagram below (Figure 3.7) and the 
experimental procedures are detailed in the following sections. 
 
 
Figure 3.7: Schematic overview of the cloning procedure for the construction of 
pcDNA3.1-hygro-U19 expression vector. 



























3.6.1.1. gDNA extraction from CHO M250-9 
gDNA was used as a template to amplify snoRNA U19 because it carries the 
intron coding for snoRNA U19 as well as its flanking exons. The gDNA was 
extracted from 5×106 control cells (exponentially growing CHO M250-9 cells) 
with the GenElute™ Mammalian Genomic DNA Miniprep Kit (Sigma-
Aldrich) as per the manufacturer instruction. 
 
3.6.1.2. Preparation of insert-U19 for cloning 
Primers for PCR-amplification of the snoRNA U19 insert were designed 
manually to include the full intron coding for the snoRNA U19 as well as 30 
nucleotides of each flanking exon based on the vector design elaborated by 
Kiss and co-workers for expression of snoRNA (Kiss and Filipowicz 1995). 
Each primer was 30 nucleotides long with (a) 3 nucleotides (GGC) extension 
to leave sufficient space for restriction enzyme to bind, (b) 6 nucleotides 
corresponding to restriction sites for restriction enzyme to cut and (c) 21 




Figure 3.8: Primer design for PCR amplification of the insert-U19. 
The size in number of nucleotides is indicated on top of the primers. A 3-
nucleotide extension was added at the 5’ end to allow sufficient space for 
restriction enzyme to be active. 
 
5’ – GGC TAACTTACAATCAGGCAAGTG – 3’









The restriction site NehI was introduced on the left of the amplified insert and 
BamHI was on the right to ensure correct orientation into the multiple cloning 
site (MCS) after the CMV promoter on the pcDNA3.1/hygro backbone 
(Invitrogen; Figure 6.6) and the corresponding restriction enzyme had no 
other cutting site within the amplified insert. 
 
PCR amplification was performed with the high fidelity enzyme Platinum Taq 
polymerase (Invitrogen), in order to ensure minimum copying error. PCR was 
performed in a working volume of 50 µL (reagents in Table 3.10) and reaction 
conditions were 30 amplification cycles at 94°C for 30 sec, 60°C for 30 sec 
and 68°C for 2 min. 
 
Table 3.10: Composition of reaction mixture for PCR with high fidelity 
Platinum Taq polymerase (Invitrogen) 
 
Reagent Concentration Volume (µL) 
DNase free water - 38.8 
PCR buffer 10X 5 
MgSO4 50 mM 2 
dNTP 10 mM 1 
Primer 10 µM 2 
gDNA template - 1 
Platinum Taq polymerase 5 U.µL-1 0.2 
Total  50 
 
 
The amplified DNA fragment were extracted and purified from the gel with 
the QIAquick PCR Purification Kit (Qiagen) as per the manufacturer 
instructions and were kept at −20°C until digestion of 5’ and 3’ extremities 
with restriction enzymes. 
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3.6.1.3. Cloning of insert-U19 into vector backbone pcDNA3.1/hygro 
First a digestion step was performed with restriction-enzyme in order to 
generate the cohesive ends needed for the directional incorporation of the 
insert-U19 into the vector backbone pcDNA3.1/hygro. The insert and 
backbone were separately digested with both restriction enzymes NheI-HF™ 
and BamHI-HF™ (New England Biolabs) at the same time in NEBuffer 4 
(New England Biolabs) and other reagents (Table 3.11). The double digestion 
took place in 50 µL working volume and was incubated at 37°C for 60 min. 
 
 
Table 3.11: Composition of reaction mixture for digestion with NheI and BamHI 
restriction enzymes 
 
Reagent Concentration Volume (µL) 
Nuclease free water - Top up to 50 µL 
Buffer 4 10X 5.0 
BSA solution 100X 0.5 
Insert-U19 or backbone pcDNA3.1/hygro - 1 (µg) 
NheI enzyme 50 U.µL-1 0.2 
BamHI enzyme 20 U.µL-1 0.5 
Total  50 
 
 
The digested backbone was submitted to an additional dephosphorylation step 
in order to remove potential 5´ phosphates from DNA which could hinder 
proper ligation of the insert. For that, the enzyme Antartic phosphatase (New 
England Biolabs) was directly added in the digestion reaction mixture with 
other components as listed in Table 3.12 and was further incubated at 37°C 
for 60 min. 
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Table 3.12: Composition of reaction mixture for phosphatase treatment 
 
Reagent Concentration Volume (µL) 
Digestion reaction - 50.0 
Phosphatase buffer 10X 6.0 
Nuclease free water - 2.0 
Phosphatase enzyme 5 U. µL-1 2.0 
Total  60 
 
Digested insert-U19 were purified with the QIAquick PCR Purification Kit 
(Qiagen) as per the manufacturer instructions while digested backbones were 
submitted to electrophoresis in order to check on the correct linearization of 
the vector, and were purified from the agarose gel as described in section 
3.6.1.2. 
 
Ligation of the insert to the backbone was catalyzed by the T4 DNA ligase 
(New England Biolabs) in a 20 µL working volume (reagents in Table 3.13). 
 
Table 3.13: Composition of reaction mixture for ligation of insert U19 in 
backbone pcDNA3.1/Hygro 
 
Reagent Concentration Volume (µL) 
Nuclease free water - Top up to 20 µL 
T4 ligase buffer 10X 2.0 
Digested vector - 50 ng 
Digested insert - Molar ratios 1, 3, 5 or 10 
T4 ligase 400 U.µL-1 3.0 
Total  20 
 
Different molar ratios insert:vector (calculation details in Equation 1) were 
used to increase the chances to obtain a positive ligation product. The mixes 
were incubated overnight at 16°C before transformation into E.coli cells. 
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Equation 1: Equation for the calculation of the quantity of insert or vector 





3.6.1.4. Selection and production of positive construct pcDNA3.1/hygro-
U19 
Five microliters of the ligation products were added to 50 µL of chemically 
competent E.coli (Invitrogen) and incubated on ice for 30 min. Ligation 
products were then allowed to penetrate E.coli cells via heat shock at 42°C for 
30 sec directly followed by cooling on ice for 10 min. Transformed E.coli 
were complemented with 250 uL of SOC medium (Invitrogen), vigorously 
mixed at > 200 rpm on a vertical shaker at 37°C for 60 min and were later 
plated on LB-agar plates (LB Miller, First Base) containing 100 µg.mL-1 of 
ampicillin (Calbiochem), for overnight incubation at 37°C. 
 
On the following day, a number of cells that expanded into single colonies 
were hand-picked, diluted in 10 µL of sterile nuclease free water and 5 µL was 
used for colony PCR assessment with the same primers that were used for 
amplification of the insert-U19 (Figure 3.8). Colony PCR was performed with 
the standard Taq polymerase from Fermentas, as per section 3.4.1.2, but with a 
longer initial incubation at 95°C up to 5 min to break E.coli membranes and 
release the DNA. Colonies which had positive results i.e. showing a single 
band of the expected size of the insert-U19 (~800 bp) after colony PCR were 
shortlisted for sequencing validation. The remaining 5 µL was inoculated in 5 
ng of vector × size of insert (kb)
× molar ratio
size of vector (kb)
Insert
vector
= ng of insert required
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mL of liquid LB broth containing 100 µg.mL-1 of ampicillin (Calbiochem) and 
incubated for 14 hours at 37°C and 150 rpm. 
 
Exponentially growing E.coli were harvested by centrifugation at 5,000 rpm 
for 5 min at room temperature and plasmid DNA were extracted and purified 
with the Wizard® Plus SV Minipreps DNA Purification kit (Promega) as per 
the manufacturer instructions. Purified plasmid DNA were quantified using 
NanoDrop (Thermo Scientific), stored at −20°C and sent for sequencing 
(AITbiotech) with T7 and BGH pre-existing priming site on pcDNA3.1/hygro 
backbone. 
 
The plasmid DNA with the correct sequence of the insert-U19 (no mutation or 
missing nucleotides) was selected for large-scale production. The colony stock 
was inoculated in 100 mL of liquid LB broth containing 100 µg.mL-1 of 
ampicillin (Calbiochem) and incubated for 14 hours at 37°C and 150 rpm. 
Large scale plasmid DNA extraction was performed using NucleoBond Xtra 
Maxi EF (Macherey Nagel) according to manufacturer’s instructions. The 
extracted plasmid DNA was verified to contain the insert-U19 via PCR 
(Figure 3.8). The expression vector pcDNA3.1/hygro-U19 was used for 
transfection in CHO M250-9 cell line. 
 
3.6.2. Transfection of CHO M250-9 cell line 
Exponentially growing CHO M250-9 cells were transfected using the Amaxa® 
Cell Line Nucleofector® Kit V (Lonza) in the Nucleofector™ 2b device 
(Lonza) under the program U-030, as per the manufacturer instructions. For 
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each transfection reaction, ten million cells were transfected with 5 µg of the 
expression vector pcDNA3.1/hygro-U19 or the blank backbone 
pcDNA3.1/hygro (Invitrogen) to generate the CHO U19 and control pools 
respectively. Each transfection was performed in biological triplicates and 
after transfection, cells were incubated in 20 mL of pre-conditioned PF 
medium without antibiotics in shake-flask (Corning) for 24 hours at 37°C 
under an 8% CO2 atmosphere and 110 rpm agitation (Kühner incubator). 
 
Transfection efficiency was assessed separately by co-transfecting the 
pmaxGFP® Vector (Lonza) along with the U19 or blank vector respectively. 
Upon successful integration in cells, the pmaxGFP® vector expressed GFP 
whose fluorescence level was quantified by fluorescence-activated cell sorting 
(FACS) analysis. For FACS, 1 mL of overnight co-transfected cells was 
passed through a Becton Dickenson FACS Analyser with the parameters 
indicated in Table 3.14 and normalized against untransfected cells. 
Alternatively, GFP fluorescence was also semi-quantitatively evaluated under 
fluorescent microscope (Olympus). 
 
Table 3.14: Parameter settings used for FACS 
Detector Voltage Amp gain Mode 
FSC E-1 6.06 Linear 
SSC 420 1.00 Linear 
FL1 512 1.00 Log 
FL2 461 1.00 Log 
FL3 691 1.00 Log 
FL1-A - 1.00 Linear 
FL1-W - 1.00 Linear 
FL4 590 1.00 Log 
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3.6.3. Selection of stable CHO U19 pool 
After 24 hours of incubation transfected cells were pelleted for 5 min at 1000 
rpm and re-suspended in fresh PF medium complemented with 600 µg.mL-1 
G418 (Sigma-Aldrich), 250 nM methotrexate (Sigma-Aldrich) and 300 
µg.mL-1 hygromycin (Clontech). These selection pressures were maintained as 
long as necessary to obtain stable pool CHO-U19 while untransfected control 
cells which were not able to survive hygromycin selection pressure were 
observed to die or not grow. The appropriate concentrations of hygromycin to 
be used was experimentally determined through a kill curve whereby CHO 
M250-9 cells were seeded at different concentration including 0, 150, 300, 500 
and 1000 µg.mL-1 (Figure 6.8) with the same culture condition as for the 
selection of the stable pools. Stable pools were banked (see section 3.1.2.1. for 
experimental details on cell banking) and experimental cultures were 
performed after 3 days of scaling up, to conserve the same overall genotype 
and phenotype as much as possible. 
 
3.7. Quantification of pseudouridine in 28S 
rRNA 
The rRNA pseudouridylation measurement was performed in collaboration 
with the Dedon Laboratory (http://dedon.mit.edu/). Receipt of RNA sample 
shipment is found in Appendix E. 
 
The different RNA species were resolved on a Agilent 1100 series HPLC 
using the Agilent SEC-5 column (5 µm particle size, 1000 Angstrom pore size, 
7.8 × 300 mm) with 100 mM ammonium acetate as the mobile phase at a flow 
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rate of 0.5 mL.min-1, 65°C. Fractions corresponding to the 28S rRNA were 
collected and the RNA was concentrated using a 10kD filter (Pall, YM-10). 
 
CHO 28S rRNA was hydrolyzed and dephosphorylated into single nucleosides 
as described previously (Chan et al. 2010). After a second filtration by a 10kD 
filter (Pall, YM-10), the digested nucleosides were separated on a Thermo 
Scientific Hypercarb reversed-phase column (100 × 2.1 mm, 3 µm particle 
size) with a gradient of acetonitrile in water containing 0.1% formic acid at a 
flow rate of 0.2 mL.min-1 at 65°C: 0 - 5 min, 5%; 15 – 25 min, 5 - 28%; 25 – 
75 min, 28 - 75%; 25 -30 min, 75%. This particular porous graphite column 
was chosen for its superior resolution of highly polar molecules. The LC 
system was directly coupled to an Agilent 6410 QqQ LC/MS mass 
spectrometer with an ESI source operating in positive ion mode: gas 
temperature, 350°C; N2 gas flow, 10 L.min-1; nebulizer pressure, 20psi; and 
capillary voltage, 3500V. To detect the ion of pseudouridine, the first 
quadruple Q1 was set at unit resolution to monitor the m/z = 245 species and 
the third quadruple Q3 monitor the m/z = 191 and 125 species, two of the 
fragment ions that form as previously described in literature after 
bombardment at the Collision Chamber (q2) with a collision energy of 10 eV 
and a fragmentor voltage at 80V (Dudley et al. 2005). The dwell time for each 
transition was 200 msec. The abundance of pseudouridine was quantified by 
integrating the MS peak due to the 245 à 191 MRM transition at 12.7 min, a 
retention time of the molecule that was pre-determined by the MS study of the 
chemical standard (Berry & Associates) and also validated by the 245 à 125 
MRM transition. To adjust for the variation in RNA concentration between 
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different samples, total ion count of pseudouridine was normalized by the total 
quantity of canonical nucleosides C present in the sample, as determined by 
the integral of the peak at 9.7 min in the UV A260 signal which was pre-




3.8. Design of experiment and calculation of 
variables effect 
In the design of experiment, the effect of the variable (X) on the output (Y) 
was determined as the slope of the line connecting the 2 averaged output 
values obtained for the levels “0” and “+1” of the variable (X; Figure 3.9). 
 
 
Figure 3.9: Determining the effect of the variable (X) on the output (Y) for an 























Y2+Y4Y value for “0” level =
2
Y1+Y3Y value for “+1” level =
Calculation for variable X1:
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Chapter 4: Developing a Strategy for 
the Translatomic Analysis of CHO Cells 
 
4.1. Introduction 
CHO cells, a predominant cell line utilized for the production of recombinant 
therapeutic proteins, have recently been subjected to several “-omic” 
technologies, in attempts to decipher the fundamental molecular mechanisms 
underlying investigated phenotypes (Kuystermans et al. 2007; O'Callaghan 
and James 2008). It is anticipated that such systems biology information will 
greatly contribute to the development of knowledge-based strategies for 
optimizing culture yield. For example, with more than twenty publications, 
transcriptomic and proteomic platforms were employed to assess the state of 
transcriptome and proteome of CHO cells presenting various phenotypes of 
interest. The main outcome for the vast majority of these studies was a list of 
genes or proteins suggested as significantly involved in the cellular 
phenotypes investigated. However, discrepancies were observed between the 
transcriptome and proteome datasets even if obtained from the same culture. 
For instance, some genes were measured as up-regulated at the transcript level 
but their respective proteins were down-regulated (Nissom et al. 2006). This 
discrepancy implied that the translational efficiency of mRNAs actively 
contributes to regulate gene expression by adjusting the flow of information 
between mRNA and proteins. In fact, such regulation of translational 
efficiency seems to be quite conserved across eukaryotic organisms such as 
yeast and human (Gygi et al. 1999; Pradet-Balade et al. 2001) suggesting that 
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it plays a central role. Hence there is a need to develop a translatomics strategy 
to profile the translational efficiency of every gene in CHO cells. 
 
In this chapter a translatomics platform combining polysome profiling and 
CHO-specific microarrays technologies was implemented to unravel the first 
translatome of CHO cells. Each experiment was analyzed once on microarray 
due to limitation in the number of microarray chips. The exponential growth 
phase characterized by a constant maximal growth over 4 days was analyzed 
to identify highly translated genes using translatomics. Additionally, 
transcriptome data were also generated at the same time points to investigate 
the correlation between transcript level and translational efficiency. 
 
 
4.2. Results and discussion 
4.2.1.  Generation of first translatome data in CHO cells 
4.2.1.1. A translatome which combines high resolution and streamlined 
data processing 
To our best knowledge, this is the first set of translatome data generated for 
CHO cell cultures. The translatomic platform was the main technique of this 
thesis and the underlying principles are explained in the following section (see 
section 3.2 and 3.3 for more technical details). Total RNA was first separated 
according to ribosome loading density on a sucrose gradient by centrifugal 
force, where higher ribosome density RNAs (more ribosomes attached) were 






Figure 4.1: Schematic overview of the translatomic platform. 
Ribosome bound RNAs were separated on 10-50% sucrose gradient and the 
polysome profile was fractionated in thirteen different fractions to allow high 
resolution of the translatome data. The fractions were reduced to pool A 
(enriched in polysome) and pool B (enriched in monosome) according to the 
sigmoidal-trend repartition of volumes devised by Hendrickson et al. (2009). 
Translatome was defined as the measurement of translational efficiency of every 
gene and was calculated as the ratio of microarray intensity obtained for pool A 






















In this thesis, thirteen fractions were collected from the sucrose gradient via 
polysome profiling, thereby providing a very high resolution of the 
translatome information. The thirteen different fractions ranged from the 80S 
monosome peak (fraction 1) to the highest polysome degree (fraction 13). 
Note that higher number of fractions increases the resolution and quality of 
translatome information. Figure 4.2 exemplifies the case by comparing the 




Figure 4.2: Polysome fractionation and resolution of translatome data. 
The horizontal sucrose gradient depicts the various layers of ribosome loading 
up to nine ribosomes attached to mRNA for the purpose of the example. The 
lines display the level of information after collecting two (green), four (red) or 
twelve (blue) different fractions. For two fractions there are only two steps or 
two level of information which cannot distinguish between nine or four 
ribosome-bound mRNAs therefore drastically reduces the resolution of the 
information as compared to 4 or 12 fractions. 
 
 
Twelve fractions provide twelve distinct sets of information (although the first 
three fractions are not translationally active) while there are only four levels of 
Sucrose 





































information for four fractions. Thus RNA translated by six ribosomes will 
appear in the same information level as those translated by 4 ribosomes even 
though they are actually significantly differentially translated. The loss of 
information is even greater for the case of two fractions where no distinction is 
possible between RNA bound by nine and four ribosomes. Ultimately, as an 
extreme case, a single fraction would not allow any translational efficiency 
distinction between RNA, which is the equivalent of the transcriptome (total 
RNA). In this regard, thirteen fraction collected in the current work can 
provide a very high resolution of the translatome information as compared to 
other previous translatome studies based on two (Tebaldi et al. 2012), four 
(Sampath et al. 2008) and twelve (Thomas and Johannes 2007) fractions. 
 
It is to be noted that separation of the polysome profile could be qualitatively 
assessed by assaying the 28S (large ribosome subunit) and 18S (small 
ribosome subunit) rRNA distribution in the various fractions. However, this 
control assay is performed only in a few reported studies mainly where 
polysome profiles are likely not or poorly recorded possibly due to limited 
equipment (Ventoso et al. 2012). Indeed, tracing the polysome profile is not a 
pre-requisite and is independent to collecting sucrose gradient fractions; hence 
some translatome data are reported without polysome profiles. On the other 
hand, most of the translatomic studies ignore such control assay because 
polysome profiles are a good and sufficient visual indicator of the resolution 
and separation of different peaks representing monosomes and polysomes 
(Melamed and Arava 2007). In this work, the polysome profiles were 
performed on a standard 10-50% sucrose gradient which is known to be 
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particularly well adapted for resolving eukaryotic 40S, 60S subunits, 80S 
ribosome and polysomes (Mašek et al. 2011). Furthermore the polysome 
profile traces of the biological triplicates were highly super-imposable with 
well-defined peaks and a net separation between monosomes and polysomes 
reaching the lowest point close the baseline (Figure 4.6). As a result the 
qualitative assay for 28S and 18S rRNA was omitted in this study. 
 
Across the fractions collected, monosomes were enriched in mRNAs with low 
translation activity while polysomes represented mRNAs that were being 
actively translated. As a result, each fraction contained mRNA of different 
translational efficiencies, which were then pooled together in two pools based 
on sigmoidal trend repartition of fractions adapted from the pooling approach 
developed by Hendrickson et al. (2009) for human HEK-293T cells. The two 
pools were enriched in polysomes (pool A – highly translated mRNAs) or 
monosomes (pool B – poorly translated mRNAs). Each pool was then probed 
on separate proprietary NimbleGen CHO microarray chip containing 13,514 
unique annotated CHO genes. For each gene, translatome data were processed 
as microarray intensity ratios of polysome-enriched pool (pool A) to 
monosome-enriched pool (pool B), noted as A/B. Measurement of 
translational efficiencies on a global scale was then termed translatome. 
 
Processing translatome data with large number of fractions is one of main 
challenges since it is not straightforward to weigh the microarray intensities of 
mRNAs found in the different fractions towards one translational efficiency 
value per gene. Interestingly, Preiss et al. (2003) collected twelve fractions and 
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pooled a selection of them in two pools with no weightage of their respective 
contribution to the overall translational efficiency. By doing so, they could 
determine translational efficiency as the ratio of the two pools, but the benefit 
of the twelve fractions resolution was actually reduced to two fractions. 
Alternatively, translational efficiency can also be assessed by graphical 
visualization showing the microarray intensity of mRNAs in each fraction 
(Thomas and Johannes 2007) however this representation remains semi-
quantitative and tedious for global scale analysis. Recently, Sampath et al. 
(2008) suggested a mathematical approach that could process the microarray 
intensities from four fractions into one numerical value per gene which could 
then conveniently be used for further computational analysis. However, this 
mathematical approach was designed only for four fractions and it is not 
readily applicable to a higher number of fractions. Unlike other translatome 
data processing, the sigmoidal pooling strategy utilized in this study weighted 
the contribution of every single fraction, thus ensuring the maintenance of the 
high resolution information even after reduction to the two pools (pool A and 
B). This advantage allowed us to achieve high resolution with streamlined data 
processing. 
 
4.2.1.2. Processing polysome profiles with microarrays  
The single channel NimbleGen microarrays used in this thesis measured 
absolute RNA level. Therefore the three different types of sample input: 
transcriptome, pool A and pool B were ran on separate microarrays. 
Transcriptome and translatome were performed as single biological replicates 
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so that several days of culture could be covered with the same number of 
microarrays in an effort to optimize the ratio cost/information. 
 
All transcriptome and translatome data were normalized according to the 
quantile technique, which is one of the most widely used methods for the 
processing of microarray data (Grewal et al. 2007). Normalization of the 
microarray data was required in order to minimize any variability of the data 
that could arise from non-biological factors thereby ensuring a reliable 
comparison between samples based on unbiased biological phenomenon. 
Figure 4.3 displays the distribution of pre-normalized intensity in form of box 
plots, and indicates that the intensity distribution was relatively stable across 




Figure 4.3: Box plot of pre-normalized microarray data. 
The box plots indicated the median values, upper quartile (Q3; dark box), lower 
quartile (Q1; light box) as well as the lower fence and the upper fence of the pool 
A (green), pool B (red) and transcriptome (blue) data. The box plots were 









































































The median appeared between 7 and 7.5 log2 intensity with little dispersion of 
lower and upper quartile (25 and 75 percentile) visualized at approximately 6 
and 10 log2 intensity respectively. Indeed transcriptome and translatome 
samples were taken over the exponential growth phase during which the 
physiological steady state was not expected to significantly change the 
distribution of global gene expression. Furthermore, the large number of probe 
sets on the microarrays surface that probed for 13,514 genes tend to stabilize 
the distribution of intensity across samples by reducing the overall dispersion. 
 
This diagnosis of pre-normalized data distribution was in good agreement with 
the quantile normalization methods which assumes that distribution of 
intensities is the same across samples (Bolstad et al. 2003). This is if the 
expression of one gene increases, the expression of another gene decreases 
(Mar et al. 2009). 
 
Moreover, as can be seen in the heat map (Figure 4.4) that compares the 
correlation degree between every samples, the pre-normalized microarray data 
displayed a high degree of correlation with respect to time (green; day 1-4) but 
a lower correlation between sample types (red; transcriptome, pool A and pool 
B). This difference is likely due to the nature of the mRNA content of each 
sample since pool A and pool B were artificially enriched whereas 
transcriptome was based on total RNA. Consequently, the data of these three 




Figure 4.4: Correlation inter pre-normalized microarray data sets. 
High degrees of correlation are displayed in green while relatively low degrees of 
correlation are in red. 
 
 
Finally, the reliability of the normalized data was validated by qRT-PCR 
which is considered as a more accurate reference measurement (Morey et al. 
2006). The qRT-PCR targeted a set of fifteen genes (Table 3.3) selected to 
cover the range of normalized intensities for adequate validation of the entire 
data sets. Also since the translatome was analyzed as the ratio of pool A to 
pool B intensities, the validation was processed by correlating the ratio values 
obtained through microarrays and qRT-PCR respectively. Linear regression 
between microarrays and qRT-PCR values indicated R2 coefficient close or 
greater than 0.7 (Figure 4.5) which were comparable to the correlation 
obtained for reported translatome data measured with Affymetrix arrays 
(Sampath et al. 2008). 
Pool A Pool B Transcriptome























Figure 4.5: Validation of the microarray data by qRT-PCR 
Samples from day 1 were used to validate the transcriptome and translatome 
data. Pool A and pool B were directly validated as A/B ratio because it was the 
value that was used for further analysis of translatome data. 
 
These high resolution translatome data were further investigated via (1) 
functional enrichment analysis to identify key growth genes as potential cell 
engineering targets as well as (2) via correlation analysis with transcriptome 
data to explore translational control mechanisms in CHO cell cultures. 
 
4.2.2. Global translation activity during exponential growth 
phase 
Cellular growth rate is known to reach its maximum during the exponential 
growth phase. Assuming that cellular growth is essentially driven by protein 
accumulation via translation throughout the G1 phase of the cell cycle 
(Jorgensen and Tyers 2004), global translation activity was assessed by 
polysome profiling on exponentially growing CHO M250-9 cells. Figure 4.6 
(left panel) displays the growth performance of the cells in batch culture; as 
indicated by the logarithmic-scale plot, the linearity range corresponding to 














































constant growth rate µmax of 0.64 day-1. Samples for translatome were 
collected on days 1, 2, 3 and 4 of the batch culture as well as for the 
transcriptome samples in order to investigate the correlation between 





Figure 4.6: Framework of translatome analysis for the identification of key 
growth genes. 
Left panel: Cellular growth performance of CHO cells in batch culture. The 
logarithmic scale was used to determine the linearity range of the exponential 
growth phase characterized by maximum and constant growth rate. Right 
panel: Global translation activity measured from polysome profiling. Only the 
polysome profile of day 1 is shown as an example. Monosomes (M) and 
polysomes (P) area under the curve were determined with the trapezium rule 
and presented in the bar chart. The ratio of P/M (blue bars × 10 for presentation 
purpose) was an indicator of global translation which appeared to be relatively 




Global translation activity supported the constant and maximal growth rate 
(μmax) during the exponential growth phase as shown by the distribution of 
monosomes and polysomes via polysome profiling (right panel in Figure 4.6). 
The bar chart depicts the area under the curves in green for polysome (P) and 
in red for monosome (M) which were utilized to calculate global translation 
(Blue bars) as the ratio of polysome to monosome via polysome profile 
analysis (Mašek et al. 2011). Global translation was relatively constant at an 
average of P/M = 1.6 ± 0.1 over the four days and corresponded to the 
maximum global translation value that was observed over a full-length culture 
(see Figure 5.7 for polysome profile on day 5 to 8 of a similar batch culture). 
 
This maximum and relatively constant ratio was in good agreement with the 
expected physiological state of exponentially growing CHO cells during the 
exponential growth phase where there was neither limitation of nutrients, nor 
accumulation of toxic molecules which could have affected maximal growth 
rate μmax. In summary, global translation supported maximum growth rate via 
high production level of cellular proteins. Thus, the identity and biological 
function of mRNAs specifically enriched in polysomes (highly translated) can 
be further analyzed via the translatome data. 
 
4.2.3. Translatome for identifying key growth genes 
Specific growth rate and global translation trends in the left and right panels of 
Figure 4.6, respectively, were observed to be constant during the exponential 
growth phase. Hence only genes with constant translational efficiency (relative 
standard deviation < 10% over the four days) were regarded as potentially 
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related to growth, thereby identifying 4,003 genes (30% of the total 13,514 
annotated genes on the microarray chip) with annotated functions (Figure 
4.7). These genes were statistically analyzed based on both the average and 
standard deviation of their respective translational efficiencies from day 1 to 
day 4. The highest translational efficiency was A/B = 4.38 ± 0.35, the lowest 
was A/B = 0.09 ± 0.01 and their average was 1.24 (greater than 1). Such 
distribution indicated that there were more genes enriched in polysome 
fractions in good agreement with the observed global translation trend (right 
panel Figure 4.6). 
 
Based on a typical fold change of 1.5, A/B > 1.5 and A/B < 0.66 were used to 
define highly and poorly translated genes respectively. Amongst the 4,003 
genes, 1,079 (26.9%) genes were classified into the highly translated region 
while there were 475 (11.9%) stably and poorly translated genes. Since 
cellular growth is understandably the result of an active expression rather than 
a consequence of passive non-expression of genes, the 1,079 stably and highly 
translated genes were selected for further functional enrichment analysis using 
the program DAVID (Huang et al. 2009). As a result, from significantly 
enriched 15 clusters (enrichment Pvalue < 0.05), the genes with the top four 
translational efficiencies (ratio A/B) in each cluster were shortlisted, giving 
rise to a total of 55 unique genes (Table 4.1). Note that 5 genes were enriched 
in two or more different clusters. This new translatome information was then 





Figure 4.7: Workflow of translatome data processing towards the identification 
of key growth genes in CHO cells. 
Shortlisted genes in the translatome data (current study) and overlap 
comparison with the genes previously identified by transcriptome and proteome 
analysis are summarized. 
 
 
Previously, twenty-one and thirteen key growth genes were identified by a 
comparison of transcriptome and proteome data between fast and slow 
growing CHO cells (Doolan et al. 2010) and by coexpression network analysis 
of 295 transcriptome profiles of CHO cells (Clarke et al. 2011) respectively. 
However, none of these genes (21+13) overlapped with each other, but 
interestingly, four genes including Pcna, Phgdh, Atic and Idh3a were found 
among the 55 shortlisted genes via our translatome analysis (Figure 4.7). Thus 
the current analysis clearly demonstrated that translatome data could be used 
to identify potential cell engineering targets. It should be noted that 
 98 
 
translatome data represent an ideal complement but does not replace the 
importance of transcriptome and proteome data. In fact, correspondingly high 
translatome and proteome level are expected to confirm the importance of cell 
engineering targets. 
 
As can be seen in Table 4.1, other high potential cell engineering targets 
identified through the translatome data included two heterogeneous nuclear 
ribonucleoprotein genes including Hnrnpc (A/B = 2.88 ± 0.22) and 
Hnrnpa2b1 (A/B = 2.67 ± 0.09) from the most significantly enriched 
annotation cluster (lowest Pvalue), RNA processing. These genes are known 
to play a positive role on cellular proliferation (Krecic and Swanson 1999). 
For example, Hnrnpc was shown to be crucial for maintaining cellular 
homeostasis (Hossain et al. 2007) and to modulate translation of c-myc in 
human cell lines by binding to the 5’UTR of c-myc (Kim et al. 2003). In the 
same cluster, the gene Utp6 coding for UTP6 small subunit processome 
component had the highest translational efficiency (A/B = 3.36 ± 0.25) and 
was also enriched in the ribosome biogenesis annotation cluster. Mutation of 
the gene Utp6 in yeast was shown to have deleterious consequences 
suggesting that it plays an essential role in the nucleolar processing of pre-18S 
ribosomal RNA and cellular growth (Champion et al. 2008). 
 
The second most actively translated annotation cluster was enriched in genes 
involved in cell cycle including the gene Prc1 coding for protein regulator of 
cytokinesis 1 which had the highest translational efficiency (A/B = 3.17 ± 
0.23). During cytokinesis, the terminal stage of cell division, protein regulator 
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of cytokinesis 1 plays a crucial role by binding to and regulating the 
microtubules responsible for the correct splitting of the chromosomes 
(Subramanian et al. 2010) ensuring that chromosome number is maintained 
from one generation to the next. The gene Ruvbl1 with the second highest 
translational efficiency (A/B = 3.02 ± 0.28) in that annotation cluster coded for 
RuvB-like protein 1. This protein possesses ATPase and helicase activities 
implicated in several cellular processes including cell cycle checkpoint 
activation, DNA repair and replication, snoRNP assembly, telomere 
regulation, centromere stability and chromosome segregation (Jha and Dutta 
2009; Niewiarowski et al. 2010). The presence of Ruvbl1 in three different 
annotation clusters namely cell cycle, chromosome organization and DNA 
repair (Table 4.1) seemed to indicate an important involvement in cells 
homeostasis. 
 
Other noteworthy annotation clusters included carbohydrate metabolic 
processes and cofactor metabolism. The gene G6pdh coding for the glucose-6-
phosphate dehydrogenase had the highest translational efficiency (A/B = 3.44 
± 0.32) in both annotation clusters. This enzyme is the rate limiting enzyme 
involved in the pentose phosphate pathway and generates a major source of 
NADPH coenzyme (Stanton 2012). This source of NADPH has been shown to 
be essential for cell survival by fueling critical cellular pathways such as the 
antioxidant pathways, nitric oxide synthase, NADPH oxidase, and others 
(Stanton 2012). The effort of the cells to recycle and balance their pools of 




Table 4.1: Functional enrichment of genes with constant and high translational 
efficiency during the exponential growth phase. 
 
Annotation 
cluster Pvalue Gene ID Details A/B 
RNA 
processing 1.0E-03 
Utp6 UTP6, small subunit (SSU) processome component 3.36 ±0.25 
Hnrnpc heterogeneous nuclear ribonucleoprotein C 2.88 ±0.22 
App amyloid beta (A4) precursor protein 2.69 ±0.26 
Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 2.68 ±0.09 
Cell cycle 1.8E-03 
Prc1 protein regulator of cytokinesis 1 3.18 ±0.23 
Ruvbl1 RuvB-like protein 1 3.02 ±0.28 
Vps4b vacuolar protein sorting 4b (yeast) 2.76 ±0.27 
App amyloid beta (A4) precursor protein 2.69 ±0.26 
tRNA 
aminoacylation 5.3E-03 
Wars tryptophanyl-tRNA synthetase 3.26 ±0.31 
Yars tyrosyl-tRNA synthetase 2.34 ±0.13 
Dars aspartyl-tRNA synthetase 2.27 ±0.19 





Pcna proliferating cell nuclear antigen 3.22 ±0.31 
Snx14 sorting nexin 14 3.09 ±0.22 
Ipo8 importin 8 2.81 ±0.16 
Sec31a Sec31 homolog A (S. cerevisiae) 2.77 ±0.26 
Catabolic 
processes 9.0E-03 
Rnpep arginyl aminopeptidase (aminopeptidase B) 3.29 ±0.27 
Lgmn legumain 3.18 ±0.29 
Hltf helicase-like transcription factor 2.81 ±0.13 






Ruvbl1 RuvB-like protein 1 3.02 ±0.28 
Actl6a actin-like 6A 2.89 ±0.27 
Hltf helicase-like transcription factor 2.81 ±0.13 






Thnsl1 threonine synthase-like 1 (bacterial) 3.25 ±0.26 
Asns asparagine synthetase 2.96 ±0.14 
Phgdh 3-phosphoglycerate dehydrogenase 1.91 ±0.09 
Got1 glutamate oxaloacetate transaminase 1, soluble 1.89 ±0.07 
Copper ion 
homeostasis 1.6E-02 
App  amyloid beta (A4) precursor protein  2.69 ±0.26  
Aplp2 amyloid beta (A4) precursor-like protein  2.37 ±0.12  
Atp7b 2ATPase, Cu++ transporting, beta polypeptide 1.96 ±0.19 





Top2b topoisomerase (DNA) II beta 3.55 ±0.33 
Pcna proliferating cell nuclear antigen 3.22 ±0.31 
Ruvbl1 RuvB-like protein 1 3.02 ±0.28 






Anxa5 annexin A5 3.05 ±0.21 
Atl3 atlastin GTPase 3 2.91 ±0.23 
Ipo8 importin 8 2.81 ±0.16 





G6pdh glucose-6-phosphate dehydrogenase 3.44 ±0.32 
Gbe1 glucan (1,4-alpha-), branching enzyme 1 2.66 ±0.25 
Pgm2l1 phosphoglucomutase 2-like 1 2.40 ±0.24 






Atic 5-aminoimidazole-4-carboxamide ribonucleotide 2.18 ±0.20 
Paics phosphoribosylaminoimidazole carboxylase 2.10 ±0.13 
Ampd2 adenosine monophosphate deaminase 2 1.66 ±0.09 




Table 4.1 continued 
Annotation 
cluster Pvalue Gene ID Details A/B 
Cofactor 
metabolism 2.8E-02 
G6pdh glucose-6-phosphate dehydrogenase 3.44 ±0.32 
Gstt2 glutathione S-transferase, theta 2 2.86 ±0.25 
Idh3a isocitrate dehydrogenase 3 (NAD+) alpha 2.34 ±0.12 
Aco1 aconitase 1 2.33 ±0.22 
RNA 
localization 3.3E-02 
Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 2.68 ±0.09 
Nup35 nucleoporin 35 2.47 ±0.22 
G3bp2 GTPase activating protein (SH3 domain) binding protein 2 2.27 ±0.16 
Stau1 staufen (RNA binding protein) homolog 1 2.11 ±0.16 
Ribosome 
biogenesis 3.4E-02 
Utp6 UTP6, small subunit (SSU) processome component 3.36 ±0.25 
Rrn3 RRN3 RNA polymerase I transcription factor 2.02 ±0.12 
Rsl24d1 ribosomal L24 domain containing 1 2.02 ±0.19 
Pes1 pescadillo homolog 1, containing BRCT domain 1.96±0.13 
 
In summary, these genes translated with high priority during the exponential 
growth phase are postulated to represent new potential cell engineering target 
to enhance cellular growth. Engineering most relevant targets Hnrnpc, Hnrnpa 
2b1, Utp6 and Ruvbl1 was suggested as future work (section 7.2.3.) since it 
was out of the scope in the present study, which was focused on translational 
control mechanisms in CHO cells. 
 
4.2.4. Translational control mechanisms in CHO cells 
The relationship between transcriptome and translatome data was studied in 
order to assess if high translational efficiency corresponded to high transcript 
level of the same respective genes in CHO cells. 
 
Similarly to the previous statistical analysis of translatome data, the 
correlation between transcript level and translational efficiency was 
investigated by selecting the genes whose transcript level showed a steady 
trend over the four days of the exponential growth phase (relative standard 
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deviation < 10% over the four days). There were 6,198 genes with a constant 
level of transcript across the exponential growth phase (Error! Reference 
source not found.-A). The overlap of these 6,198 (transcriptome) and 4,003 
(translatome) genes resulted in 1,353 genes that displayed constant trends for 
both their transcript level and translational efficiency (Error! Reference 
source not found.-A). Each gene was then characterized according to an 
average value of both transcriptome (absolute value) and translational 
efficiency (ratio A/B; Error! Reference source not found.-B). 
 
 
Figure 4.8: Correlation between transcript level and translational efficiency. 
Genes with both stable transcript level and translational efficiency over the 
exponential growth phase (B). Correlation plot of transcriptome vs translatome. 
Thresholds for high and low transcript levels were defined by the average TCav 
plus and minus the standard deviation (σ), respectively while a 1.5 fold change 
was used for the translatome data. Green and yellow regions correspond to 
uncoupled transcript level and translational efficiency. Blue region marks the 
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genes for which there is homodirectional coupling while genes in the red region 
have antidirectional relationship. 
Arguably, there was no strong correlation between transcript level and 
translational efficiency as indicated by the Pearson coefficient, which was -
0.057. This correlation was further characterized by classifying genes in nine 
different regions based on threshold of high and low transcriptome and 
translatome (Error! Reference source not found.-B). High and low 
transcriptome were commonly defined (Bilban et al. 2002) as the average TCav 
plus or minus one standard deviation (σ) calculated for the 1,353 genes (TCav 
+ σ) and (TCav - σ) while high and low translatome were defined upon a 1.5 
fold change. Based on these criteria, genes were classified in coupled or 
uncoupled groups (Error! Reference source not found.-B). Transcript level 
and translational efficiency were considered as coupled if both were 
significantly high or low in a homodirectional manner (blue). They were 
instead regarded as uncoupled if (a) both were significantly high or low but in 
antidirectional way (red), (b) only translational efficiency was significantly 
high or low (green) and (c) only transcript level was significantly high or low 
(yellow). The overall degree of uncoupling (94% - green, yellow and red 
regions) between transcript level and translational efficiency was higher than 
the degree of coupling (6% - blue region). This correlation analysis was based 
on a subset of genes (1,353 genes) representing 10% of the total number of 
annotated genes on the microarrays, that ranged within the upper and lower 
limits including 90% of all translatome (A/B) and transcriptome values, thus 
presumably representing the characteristics of the whole CHO cell gene 
expression. Arguably, a recent proteomic analysis of CHO cells claimed that 
transcript and protein levels were correlated but this study was also performed 
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on a subset of genes (6,164 genes) and the correlation calculated on a log2 
scale was rather low 0.46 thereby rendering such strong claim potentially 
questionable (Baycin-Hizal et al. 2012). On the other hand, the state of 
correlation that we observed was consistent with other studies (Halbeisen and 
Gerber 2009; Preiss et al. 2003; Tebaldi et al. 2012). Although generating and 
correlating the full transcriptome and translatome data could further uncover 
the state of correlation, the current result illustrated the complex regulation of 
gene expression and the involvement of translational control (Pradet-Balade et 
al. 2001). 
 
Comparison of transcriptome and translatome data could help devise adequate 
cell engineering strategies in future. For example, the previously discussed key 
growth genes, Hnrnpc, Utp6, Pcna and Atic with a high and constant 
translational efficiency (A/B > 1.5) were present in the green region (green 
marker with black line; Error! Reference source not found.-B) in which 
transcripts level and translational efficiency were uncoupled. In this case, 
translational efficiency was high and therefore unlikely to represent a 
bottleneck along the gene expression process. Instead, moderate transcript 
level could be limiting the flow of genetic information available for 
translation. We speculated that overexpression of such genes leading to 
increased level of mRNA (shift towards the blue region) could be an 
appropriate strategy for cell engineering where the increase in mRNA level 
would allow for the synthesis of more proteins with the high translational 
efficiency. 
 
Interestingly, the correlation analysis also implied the involvement of the 
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mTOR pathway on translational control in CHO cells. The yellow region of 
high transcript level and average translational efficiency (ratio A/B ~ 1) 
appeared to be enriched with 20 different ribosomal proteins (yellow marker 
with black line; Error! Reference source not found.-B). This observation 
may appear intriguing because ribosomal proteins are supposed to be 
important for the cell growth mainly through the biogenesis of ribosomes 
(Boisvert et al. 2007), and therefore they would be expected to be highly 
translated in order to form more ribosomes and support the exponential 
growth. The particular enrichment could indicate that this subset of ribosomal 
protein was not highly required by cells or even some might have been 
dispensable for ribosomes canonical function as reported elsewhere (Baronas-
Lowell and Warner 1990; Chaudhuri et al. 2007). Furthermore, ribosomal 
proteins have been shown to regulate their own expression by their 
extraribosomal functions (Warner and McIntosh 2009). For example, RPS13 
is known to negatively control splicing of its own pre-mRNA (Malygin et al. 
2007) and several ribosomal proteins have been shown to prime apoptosis 
amongst other activities, when over-expressed (Lindström 2009; Naora 1999). 
Therefore, more than a simplistic relationship between ribosome proteins and 
growth might be taken into account by cells to regulate their translational 
efficiency during the exponential growth phase. It should be highlighted that 
ribosomal proteins are known to be 5’TOP mRNA which are translationally 
regulated by the mTOR pathway (Meyuhas 2000). This pathway is known as a 
master regulator of gene expression in cells mainly by regulating translation 





A translatomic strategy was successfully developed and applied within the 
bioprocessing context of CHO cultures. High resolution polysome profiling 
technique and commercial CHO-specific NimbleGen microarray were used to 
study the translational efficiency of CHO cells during the exponential growth 
phase. This translatome data delivered a novel insight in the gene expression 
pathway right at the point at which cells had to make a crucial decision on 
which mRNA they would translate. In this case of exponential growth, genes 
whose mRNAs were highly translated were likely to contribute to maximal 
growth rate, thus suggested as engineering targets. Furthermore, our 
translatome data revealed the existence of translational control mechanisms 
causing major uncoupling between transcript level and translational efficiency, 
which seemed to involve the mTOR pathway. Understanding the implications 
of the mTOR pathway on translational efficiency regulation in producer CHO 
cells could pave the way for further enhancement of CHO cells cultures.  
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Chapter 5: Understanding 
Translational Control Mechanisms of 




In the previous chapter, a number of genes coding for ribosomal proteins 
known as members of the 5’TOP family (Meyuhas 2000) appeared to be 
present in high mRNA level in the cytoplasm of CHO cells but translated with 
low priority. This observation prompted the hypothesis that the mTOR 
pathway, which is a master translational controller known to regulate the 
expression of 5’TOP mRNA (Gibbons et al. 2009), was involved in the 
regulation of gene expression in CHO cell during the course of cultures. 
 
Recently, engineering of the mTOR pathway in CHO cells was shown to 
increase growth and productivity phenotypes (Dreesen and Fussenegger 
2011), but the underlying mechanisms of action employed by the mTOR 
pathway remained unclear. The first investigation of mTOR pathway 
mechanism in CHO cells was based on rapamycin treatment (Lee and Lee 
2012), a specific inhibitor of the mTOR pathway typically used as an 
experimental tool for that purpose (Ballou and Lin 2008). Upon rapamycin 
treatment, autophagy extended cellular growth of CHO cells thereby was 
suggested as one mechanism of action of the mTOR pathway. However, no 
data were reported on translation activity generally known as a major effector 
of the mTOR pathway. Hence, it was interesting to establish the relationship 
 108 
 
between translation and mTOR pathway and its influence on growth and 
productivity of CHO cell cultures. 
 
Apart from rapamycin treatment, more natural environmental stresses such as 
limiting levels of amino-acids (Hara et al. 1998; Wang et al. 1998) or low 
energy levels (Chong et al. 2009; Patel et al. 2001), are known to alter the 
activation of the mTOR pathway and its downstream effector 4EBP in CHO 
cell cultures. It was thus postulated that depletion of nutrients in batch 
cultures, will deactivate the mTOR pathway, whereas maintenance of nutrient 
levels in fed-batch cultures will extend the activation of the mTOR pathway 
and translation activity. 
 
In this chapter, we attempted to understand the action mechanisms of the 
mTOR pathway from a translation activity perspective in the context of CHO 
cells producing monoclonal antibodies (mAb) cultures. We started by 
specifically inhibiting the mTOR pathway with rapamycin in order to establish 
a reference effect on translation activity. Then batch and fed-batch cultures 
were compared to study how these two modes of supplying nutrients to the 
cells would affect the mTOR pathway and translation activity. Global 
translation as well as targeted specific translational activities of the heavy and 
light chains of the monoclonal antibody were evaluated via the translatomics 
platform established in chapter 4. The activity of the mTOR pathway was 




5.2. Results and discussion 
5.2.1. Targeted inhibition of the mTOR pathway by rapamycin  
Rapamycin is known to be a specific inhibitor of the mTOR pathway and this 
was experimentally confirmed in CHO DG44 cells by Lee and Lee (2012). 
Consequently, rapamycin was used as a well established inhibitory signal to 
artificially impede the mTOR pathway and to assess the resulting effect on 
translation activity. 
 
5.2.1.1. Experimental conditions for rapamycin treatment 
A kill-curve was established to determine the amount of rapamycin which 
should be used in the CHO-mAb experiments. Six different concentrations 
ranging from 20 to 1,000 ng.mL-1 of culture medium were added to culture on 
day 0 (single replicate per concentration) and their effect on growth and 
viability were qualitatively assayed. DMSO, the solvent of rapamycin stock 
solution, was also included as a control in a separate culture. Figure 5.1-A 
shows that all rapamycin concentrations provoked a similar slowing of growth 
but also prolonged growth with maintenance of viability above 80% beyond 
the time when the viability of the batch control culture dropped (Figure 5.1-
B). The specific effects of rapamycin are discussed in details in the following 
paragraphs. Although 1.5% v/v DMSO was shown to possibly affect CHO 
cells (Li et al. 2006b), it had no noticeable effect in this experiment, which 





Figure 5.1: Kill curve for rapamycin in CHO-mAb cultures. 
The effect of six different rapamycin concentrations was assessed with respect to 
(A) cellular growth and (B) cellular viability. A DMSO carrier control was also 
included to ensure that the effects observed were due to rapamycin. 
 
Several strategies of rapamycin treatment on different organisms were 
previously reported. CHO cells underwent rapamycin treatment with 
concentrations as low as 9.14 ng.mL-1 (10 nM; Schlatter et al. 2003) and up to 
182.84 ng.mL-1 (200 nM; Lee and Lee 2012). In stem cells, Sampath et al. 
(2008) carried out rapamycin treatment at 20 ng.mL-1 over three days before 
sampling for analysis. Hybridoma cells producing recombinant proteins were 
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treated with 45.71 ng.mL-1 of rapamycin (50 nM; Balcarcel and 
Stephanopoulos 2001) and yeast cells were subjected to 200 ng.mL-1 
rapamycin treatment for 90 minutes before sampling (Preiss et al. 2003). The 
rapamycin kill curve experiments included these reported concentrations (10 
to 200 ng.mL-1) and appeared to have no qualitative differences in effect on 
growth and viability as also observed by Lee and Lee (2012). Based on these 
preliminary observations, 20 ng.mL-1 rapamycin was used for further 
experiments. 
 
5.2.1.2. Rapamycin treatment effect on growth and translational activity 
of CHO cells 
Rapamycin was added on day 0 of batch cultures to specifically inhibit the 
mTOR pathway in CHO M250-9 cell line. The inhibitory effect was 
monitored over the five days following the rapamycin treatment by assessing 
4EBP phosphorylation degree via the gel shift approach that resolved three 
phosphorylated forms (gamma -γ, beta -β and alpha -α) of 4EBP via Western-
blotting. The gamma band is the most phosphorylated 4EBP while the alpha 
band is the least phosphorylated (Ikenoue et al. 2009). As can be seen on the 
immunoblot results in Figure 5.2, there was a strong shift of total 4EBP in its 
alpha-form upon rapamycin treatment, which confirmed inhibition of the 
mTOR pathway as compared to the control culture where there was higher 
phosphorylation degree in the gamma and beta bands. Nonetheless, as 
previously noted by Thoreen and co-workers (2009), although largely 
inhibited, the mTOR pathway was not completely inhibited by the rapamycin 




Figure 5.2: Effect of rapamycin of mTOR pathway activation level. 
The activity level of the mTOR pathway was assessed through the 
phosphorylation degree of the downstream protein eukaryotic initiation factor 
4E-binding protein (4EBP). The more phosphorylated the 4EBP, the higher the 
activity of the mTOR pathway. The gel shift approach utilized in this study 
resolved the three phosphorylated isoforms alpha (α), beta (β) and gamma (γ) of 
4EBP around 20 kDa on immunoblotting. The alpha band was the least 
phosphorylated, while the gamma band was the most phosphorylated according 
to Ikenoue et al. (2009). Rapamycin treated and control cultures were compared 
from day 1 to day 5 with β-actin as loading control. 
 
 
However, unlike Choo et al. (2008) who reported that 4EBP phosphorylation 
increased over time after rapamycin treatment in HEK-293 and HeLa cells; the 
least phosphorylated alpha-form appeared to be persistent in this experiment, 
which could be due to the cell type and treatment conditions. 
 
The inhibition of the mTOR pathway resulted in a significant diminution of 
cellular growth (Figure 5.3-A) with a 30% decrease in the maximal growth 
rate µmax from 0.648±0.007 to 0.457±0.001 day-1 (means ± SD, n = 3; Pvalue 
< 0.05) in the rapamycin treated culture. Moreover, there was a 1.5 fold 
decrease of the maximal viable cell density from 6.15×106 to 4.26×106 
cells.mL-1. However, the culture was extended for 3 additional days compared 
to the control culture and the viability remained high up to day 9 (87% versus 
47% for control culture). This prolonged culture led to a 16% increase of final 
recombinant mAb titer from 357.5±0.71 to 415±11.31 mg.L-1 (means ± SD, n 




Figure 5.3: Effect of rapamycin treatment on CHO-mAb cell culture. 
(A) Cellular growth performances. (B) Product accumulation of recombinant 
protein. (C) Residual concentration of glucose and glutamine metabolites. 
Rapamycin treated cells (orange) and control batch cultures (dark blue). Error 

















































































































In parallel, upon rapamycin treatment, consumption rates of glutamine and 
glucose (slope of curves) were also markedly slower on average from day 0 to 
day 4 and day 5 respectively (Figure 5.3-C). However, glutamine and glucose 
reached depletion on the same days for both culture conditions (day 6 for 
glutamine and day 9 for glucose respectively) since control cultures 
progressively entered death phase (µ < 0) after day 5 while rapamycin treated 
cells continued to grow. 
 
Differences were observed concerning cellular growth and metabolites 
consumption as compared to the recently reported data by Lee and Lee (2012). 
The authors saw no significant change in growth while in this experiment, a 
30% decrease in growth rate as well as a slowing of glucose and glutamine 
metabolism were observed. This is likely due to the difference in day of 
rapamycin treatment, since Lee and co-workers added rapamycin on the third 
day of cultures, when cells had already achieved most of their growth during 
the exponential growth phase. In this experiment, rapamycin was added on 
day 0 and the early treatment impaired cellular growth right from the start. 
 
On the other hand, rapamycin treatment effects on productivity and viability 
were similar in both studies. The 16% increase in final titer upon rapamycin 
treatment was comparable to the 21% increase observed by Lee and Lee 
(2012). The viability extension upon rapamycin treatment was previously 
reported in hybridoma cells (Balcarcel and Stephanopoulos 2001) and could 
be related to autophagy (Lee and Lee 2012). Autophagy recycled unnecessary 
cellular components to support growth and extend cellular viability towards 
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the end of the culture when nutrients such as glutamine became limiting 
(Figure 5.3-C) but other molecular mechanisms of the mTOR pathway were 
responsible for the decrease in growth rate at the earlier stage of the culture 
(day 1 to day 5) when there was no nutrient limitation. 
 
Since the mTOR pathway is known to regulate cellular growth principally by 
leveraging on translation activity (Gibbons et al. 2009), the interplay between 
mTOR pathway inhibition and cellular growth decrease was studied from a 
translational perspective. Figure 5.4 compares the polysome profiles from day 
1 to day 5 of both the control and rapamycin treated cultures. 
 
 
Figure 5.4: Effect of rapamycin treatment on global translation. 
For each polysome profile, the first three peaks detected before the dashed 
vertical line, represented non-actively translating ribosomes referred as the 
monosome (Mašek et al. 2011) whereas the subsequent series of peaks after the 
vertical line, represented the polysomes with increasing numbers of ribosomes 
attached to the mRNA. Rapamycin treated cells (orange) and control batch 
culture (dark blue). Arrows locate 80S peak increase. 
Density (arbitrary units)




















The rapamycin inhibition of the mTOR pathway resulted in a shift in 
proportion of polysomes to monosomes, with a clear increase of the 80S peak. 
This resulted in a 23% decrease of the ratio of polysome over monosome area 
under the curve from 2.15±0.03 to 1.64±0.09 arbitrary units (means ± SD, n = 
3; Pvalue < 0.05) on day 1. This percentage of decrease reflected the impact of 
mTOR pathway translational control on global translation recently 
demonstrated to be mostly limited to mRNAs with 5’TOP and TOP-like 
motifs. These proteins are associated with the proliferative response, involved 
in the translation machinery and the transition from G1 to S phase in the cell 
cycle (Thoreen et al. 2012). After rapamycin treatment, 4EBP inhibits 
translation initiation by hindering the interaction between the cap-binding 
protein IF4E and IF4G1. Loss of this interaction diminishes the capacity of 
IF4E to bind TOP and TOP-like mRNAs much more than other mRNAs, 
therefore mTOR inhibition selectively suppresses their translation (Thoreen et 
al. 2012). Similar changes of ribosome distribution were also observed in 
other cell lines treated with rapamycin (Van Dyke et al. 2006; Wall et al. 
2008). This polysome run-off concomitant to an increase in the amount of 
monosomes indicated a slowdown in translation initiation rate (Mašek et al. 
2011) upon rapamycin treatment which was a likely element causing the 
decrease of growth rate. In parallel, monoclonal antibody productivity was 
only reduced but maintained because heavy and light chains mRNAs may not 
be members of the 5’TOP mRNA family (Yamashita et al. 2008) therefore not 
directly translationally regulated by the mTOR pathway but as a whole after 
reduction of translation machinery expression.  
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Surprisingly, on day 5, the 80S peak content of the control culture exceeded 
the rapamycin treated culture, indicating a drop of translation activity as well. 
We postulated that such a sudden and strong increase of the 80S peak on day 5 
of control culture could arise after inhibition of the mTOR pathway due to a 
nutrient limitation such as glutamine (Figure 5.3-C). 
 
5.2.2. Maintenance of mTOR pathway activation through 
nutrient supply 
We investigated the response of the mTOR pathway to nutrient 
supplementation by comparing control batch to fed-batch cultures. Batch 
cultures were characterized by a fixed initial amount of nutrients which 
depleted as the culture progressed whereas additional nutrients were 
supplemented daily in fed-batch cultures. These cultures were performed in 
shake-flasks because the limiting nutrient availability in the batch cultures has 
a greater impact compared to minor fluctuations of pH and oxygen which 
could have been overcome using bioreactor control. 
 
Fed-batch cultures exhibited a 1.5-fold higher maximum viable cell density 
and a 5 days extension of culture viability (above 50%) as compared to batch 
cultures (Figure 5.5-A). Peak cell densities of 6.4 and 9.4 × 106 cell.mL-1 
were achieved on days 5 and 8 for the batch and fed-batch cultures 
respectively. In addition, final recombinant mAb titer was increased by 4-fold 
in the fed-batch as compared to the batch culture from 243 to 976 mg.L-1 




In parallel, residual glutamine, the key metabolite observed to be depleted in 
the rapamycin experiment (Figure 5.3-C), was similarly depleted and dropped 
below the 0.044 g.L-1 (0.3 mM) threshold from day 5 onwards in batch while 
it was steadily maintained above 0.044 g.L-1 through feeding in fed-batch 
cultures (Figure 5.5-C). This 0.044 g.L-1 threshold defined the glutamine 
limitation state in our feeding strategy. 
 
Both increases of maximal viable cell density (1.5 fold) and productivity (4 
fold) were much greater than those observed in similar comparison of batch 
and fed-batch cultures by Han et al. (2011) who reported a 1.2 (viable cell 
concentration) and 1.5 (final recombinant protein titer) fold increase after 
addition of feed solutions. The amplitude of change could be cell and process 
specific. However, the authors also found that there was a glutamine 
consumption phase (day 1- 5) followed by a starvation phase (day 5-8) in 
batch cultures and that supplementation of glutamine in feed solution allowed 
to extend growth. Glutamine, a key source of energy in CHO cell cultures 
(Sanfeliu and Stephanopoulos 1999), was the controlling nutrient in our cell 
culture platform and dictated the feeding strategy of fed-batch cultures (see 
section 3.1.4). The continuous supply of nutrient in fed-batch cultures was 
expected to stimulate the phosphorylation cascade upstream of the mTOR 




Figure 5.5: Feeding nutrients enhances growth performances of batch cultures. 
(A) Cellular growth performances. (B) Product accumulation of recombinant 
protein. (C) Residual concentration of glutamine. Fed-batch cultures (red) and 
control batch cultures (dark blue). Error bars show ± standard deviation of 





















































































Phosphorylation events on 4EBP served to assess the mTOR pathway 
responses to nutrient supplementation. Immunoblots on Figure 5.6 shows that 
the phosphorylation state of 4EBP was maintained after day 5 of the fed-batch, 
with the presence of the three phospho-isoforms of 4EBP as compared to 
batch cultures for which 4EBP largely accumulated in the least phosphorylated 
alpha-band during the same period of time. These phosphorylation patterns 
indicated that supplementation of glutamine amongst other nutrients in the 
feed solution was able to extend the activation of the mTOR pathway in fed-
batch cultures relative to batch cultures. 
 
 
Figure 5.6: Extension of mTOR pathway activation by nutrient 
supplementation. 
Gel shift analysis of 4EBP phosphorylation degree for batch (day 1 - day 8) and 
for fed-batch (day 1- day 12) cultures. Results are shown only up to day 8 for the 
batch culture, when the culture ended. β-actin served as a loading control. 
Lysate of cells treated with rapamycin, served as a negative control. 
 
 
The extension of mTOR pathway’s activation in fed-batch culture kept 4EBP 
inactivated by phosphorylation (Gingras et al. 1999; Mothe-Satney et al. 2000) 
which allowed the binding between IF4G and IF4E required for efficient 
 121 
 
translation initiation activity (Sonenberg and Hinnebusch 2009). The effect of 
the mTOR pathway on translation activity was assessed via polysome 
profiling on day 4 to day 8 because it was during this time period that the 
enhancement of the mTOR pathway activity in fed-batch cultures was most 
obvious as compared to batch cultures. 
 
 
5.2.3. Control of translation activity by the mTOR pathway in 
CHO cell cultures 
5.2.3.1. mTOR pathway and global translation activity 
 
Figure 5.7-A compares the polysome profiles from day 4 to day 8 of the batch 
and fed-batch cultures. There was an increase of polysome content upon 
nutrients supplementation while the monosome content was lower than in 
batch cultures. This shift of ribosomes from monosomes towards polysomes 
indicated a relative increase of translation initiation rate in fed-batch cultures 
as compared to batch cultures. 
 
The ratio of area under the curve of the polysomes and monosomes was used 
as the indicator of global translation (Foiani et al. 1991; Smirnova et al. 2005). 
Although the overall trend indicated a slowdown of global translation activity 
in both batch and fed-batch cultures (Figure 5.7-B), there was nonetheless a 
consistent 1.2- to 2-fold higher translation activity upon nutrient addition as 





Figure 5.7: Effect of mTOR pathway on global translation activity upon nutrient 
supplementation. 
(A) Daily comparison of fed-batch (red) and batch (dark blue) cultures polysome 
profiles from day 4 to day 8. The vertical dashed line marked the separation 
between monosomes and polysomes. (B) Global translation was derived from the 
ratio of polysome to monosome area under the curve of polysome profiles. Error 
bars show ± standard deviation on three biological replicates. 
 
It is to be noted that there was no strict correlation between mTOR pathway 
activity and global translation trends. For example, the deactivation of the 
mTOR pathway activity in batch cultures seemed to occur gradually over days 
5 to 8 (Figure 5.6) while most of the shift in polysomes to monosomes took 
place on day 5 (Figure 5.7-B). This could due to the semi-quantitative nature 
of the gel shift assay utilized to assess mTOR pathway activation levels in the 











































current study. Furthermore, other parameters than the mTOR pathway may 
also have slightly contributed to the overall control of translation activity such 
as the initiation factor IF2 (Underhill et al. 2005) or miRNAs (Druz et al. 
2011) which were reported to potentially affect translation activity under 
nutrient depletion stress. Nonetheless, the relative increase of global 
translation in fed-batch as compared to batch cultures seemed to correspond 
with the observed extended activation of the mTOR pathway (Figure 5.6). 
This observation supports the involvement of the mTOR pathway in the 
overall translational control mechanisms. Furthermore, it seemed clear that the 
mTOR pathway’s response to nutrient depletion/supplementation signals as 
well as its corresponding impact on translation activity was analogous to that 
of rapamycin inhibition as both led to a shift of ribosomes between 80S peak 
and polysomes altering cellular growth. To our best knowledge, this is the first 
evidence on the role of the mTOR pathway on translation activity in CHO cell 
cultures. 
 
In CHO cell cultures, the two most desirable phenotypes are high cellular 
growth and specific productivity which are primarily the consequence of 
proteins biosynthesis via translation (Thomas and Hall 1997). The next two 
sections investigate the impact of mTOR translational control on cellular 
growth and productivity. 
 
5.2.3.2. mTOR pathway and cellular growth 
Extension of cellular growth after day 5 in fed-batch as compared to batch 
cultures appeared to be driven by the sustained translation activity supported 
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at least in part by the mTOR pathway activation. Day 5 of batch cultures 
(Figure 5.5-A) was a transition from active cellular growth to cell death where 
kd (death) was greater than µ (growth) as conceptualized in Figure 5.8. 
 
 
Figure 5.8: Viable cell density: a balance between cellular growth and death. 
Translation is one of the main parameter fueling cellular growth. kd: death rate. 
µ: growth rate 
 
This shift happened on the same day as the drop of translation activity 
following mTOR pathway deactivation by glutamine starvation. In this 
context, it was then established whether this growth transition was a 
consequence of a significant decrease of the growth input or if it was more due 
to a considerable increase of death output that outcompeted growth. 
 
Actually, at the same time as growth was reduced (decrease of µ) due to the 
deactivation of the mTOR pathway in the batch cultures, cell death 
phenomenon (increase of kd) also took place after day 5 and caused the viable 
cell density to drop. However since feeding fresh nutrients sustained cells 
growth (maintenance of µ) at high viability (Figure 5.5-A) it appeared that 
cell death in batch cultures was a consequence which could be minimized. In 
fact, in addition to not driving cellular growth, inhibition of the mTOR 









et al. 2002). On the other hand, death in fed-batch was likely to be also 
influenced by accumulation of toxic by-products at the later stage of cultures 
such as ammonium or lactate (Chaplen 1998). As a result, higher global 
translation driven by the mTOR pathway appeared to be a determinant factor 
for cellular growth in CHO cell cultures. 
 
5.2.3.3. mTOR pathway and productivity 
We then investigated how the translational control affected the monoclonal 
antibody productivity of CHO cells. While the production of cell mass 
(growth) encompassed the translation of all mRNA (global translation), the 
production of the monoclonal antibody involved the mRNA of its heavy (HC) 
and light chains (LC). Targeted quantification of these two mRNAs from 
fractionated polysome profiles with qRT-PCR enabled the determination of 
specific translational efficiencies which were measured as the ratio of values 
quantified in pool A (polysome enriched) over pool B (monosome enriched) 
respectively. Both HC (Figure 5.9-A) and LC (Figure 5.9-B) mRNAs 
translational efficiencies showed similar trends. The HC and LC translational 
efficiencies were maintained at relatively stable and high levels in fed-batch 
while they decreased in batch cultures. 
 
It was noticed that the stable trend of specific translational efficiencies of HC 
and LC in fed-batch did not appear to follow the exact same trend as the 
global translation (Figure 5.7-B), which progressively decreased over the 
same period of time. This could be because the expression HC and LC mRNA 
which are present in the vicinity of genes dfhr and neo (Figure 3.1) were 
 126 
 
coupled to the expression of these two resistance genes required for cells to 
survive selection pressure. 
 
 
Figure 5.9: HC and LC mRNAs translational efficiency upon nutrient 
supplementation and mTOR pathway activation. 
Specific translational efficiencies reflected the extent of ribosome loading on 
selected mRNA. (A) Specific translational efficiency of the HC of the monoclonal 
antibody. (B) Specific translational efficiency of the LC of the monoclonal 
antibody. Fed-batch (red) and batch (dark blue) cultures. There was insufficient 
mRNA for day 8 of batch culture to assess translational efficiency. Error bars 
show ± standard deviation on three biological replicates. 
 
 
Nonetheless, HC and LC specific translational efficiency trends were in 
agreement with the product accumulation profiles (Figure 5.5-B); therefore 
translation activity seemed to support the increase in final titer upon nutrient 
supplementation. Targeted specific translational efficiency can be regarded as 
a rate constant in a chemical reaction where the substrate is mRNA and the 
product is monoclonal antibody. Agreement in trends between specific 
translational efficiency (Figure 5.9) and product accumulation (Figure 5.5-B) 




































































The structured kinetic model developed by Bibila and Flickinger (1992) 
showed analogous findings where translation of the HC and LC of a 
monoclonal antibody in hybridoma cell was suggested to be rate-limiting step 
during the stationary growth phase. 
 
These results represent the first evidence that higher translation activity in fed-
batch cultures relative to batch cultures supports the greater production of 
recombinant protein in CHO cells. 
 
5.3. Summary 
In this chapter, we provided the first comprehensive evaluation of the mTOR 
pathway’s role on translation activity and its impact on growth and 
productivity in CHO-mAb cultures. The translatomic platform developed in 
chapter 4 was applied to analyze translation activity after altering the mTOR 
pathway’s signaling cascade via rapamycin treatment and nutrient 
supplementation. Feeding additional nutrients was shown to be an effective 
strategy to maintain the mTOR pathway activation and to increase translation 
activity as compared to batch cultures. The data generated represent a 
complementary knowledge to the work reported by (Dreesen and Fussenegger 
2011), in which they affected the mTOR pathway by modifying the quantity 
of TORc1 complex. Translation activity as characterized by the activation of 
the mTOR pathway affected both growth (global translation) and productivity 
(specific translation) phenotypes. It is acknowledged that the mTOR pathway 
may not be the only parameter that controls translation but our data show that 
it does contribute to the overall control of translation in CHO cells by 4EBP 
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inhibition of translation initiation. These results highlight translational control 
as a parameter that has the potential to influence the fate of bioprocess 
relevant features in CHO cell cultures. Therefore in the following chapter, it 
was established how the mTOR pathway affected gene expression on a global 





Chapter 6: Characterizing the Interplay 




In the previous chapter, the mTOR pathway was shown to affect the overall 
translation activity in CHO cell cultures, which appeared to be important for 
cellular growth and productivity. The mTOR pathway is a master regulator of 
translational control that ensures appropriate coupling between growth and 
available energy yet many of its molecular mechanisms remain largely 
unknown (Foster and Fingar 2010). It is crucial to understand these 
mechanisms clearly since translation is one of the main driving forces of 
cellular growth in cultures. 
 
Treatment of cells with rapamycin, a specific inhibitor of the mTOR pathway, 
induced a shift in polysome distribution towards monosome (Figure 5.4) as 
measured by our translatomic platform. Therefore, it was postulated that the 
genes involved in this shift, played a role in the growth inhibition. 
 
A comparative analysis of the translatome data between rapamycin treated and 
control cultures was used to shortlist genes showing the most significant shift 
from polysomes to monosomes. A selected target (snoRNA U19) was 
overexpressed in CHO cells and its potential role in the mTOR pathway was 
characterized via a simple design of experiment approach with two variables 
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characterization led to the proposal of a model describing a new potential 
effector mechanism of the mTOR pathway. 
 
6.2. Results and discussion 
6.2.1. Regulation of snoRNA U19 expression by mTOR 
pathway 
mTOR pathway regulatory mechanisms have often been investigated by 
means of rapamycin treatment (Grolleau et al. 2002) which was also used in 
this study to identify potential players on the mTOR pathway in CHO cells. 
 
6.2.1.1. snoRNA host gene 4 significantly shifted from polysomes to 
monosomes distribution upon rapamycin treatment 
The translatome of rapamycin treated and control cultures were compared on 
days 1, 2 and 3 (three days following the rapamycin treatment) because most 
of the shift in ribosomes was observed on these three days (Figure 5.4). Two 
stringent conditions were applied to define specific genes whose binding to 
polysomes was significantly reduced by rapamycin treatment: (1) at least 2-
fold decrease in translatome as well as (2) consistently decreased level over 
the three days. The comparative translatome (Figure 6.1-A) showed that there 
were 695 genes below log2 fold change −1 (2-fold decrease; red markers) one 
day after rapamycin treatment (day 1). In order to fulfill the second condition 
of consistency, these genes were identified in days 2 and 3 and only the ones 
conserving the 2-fold decrease over time were considered. In the end, there 
were 16 genes complying with the two stringent conditions of which 4 with 
unknown functions were disregarded (Figure 6.1-B). It was noted that 
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rapamycin treatment appeared to increase the translational efficiency of a 
number of genes which was also observed in yeast and HEK293 cells (Genolet 
et al. 2011; Preiss et al. 2003) but a greater number of genes were down-
translated on a global scale. The translatome data of the rapamycin treated 
cultures were validated by qRT-PCR as the ratio of A over B (Figure 6.1-C). 
 
 
Figure 6.1: Identification of genes significantly affected by polysome shift upon 
rapamycin treatment. 
(A) Comparative translatome analysis between rapamycin treated and control 
cultures over the three days following treatment. Red square markers represent 
genes with log2 fold change < -1 and consistent decrease overtime. (B) 
Shortlisting of the 12 genes with consistent decrease of their translatome after 
rapamycin treatment having a known function. (C) qRT-PCR validation of the 


















































































Despite fulfilling the fold change requirement, the twelve shortlisted genes 
showed divergence in terms of intensity and direction of translatome change 
after rapamycin treatment, which could be classified in two groups. The genes 
Hsd17B6, Ryr1, Ppp3r2, Ctrb1, Msmb, Cp and Jazf1 with translatome 
decrease relatively higher or lower on day2 than on day1 and day3, while, the 
other genes (Snhg4, Ddx25, Kcnj11, Tbx19 and Gm13814) followed similar 
trend as the polysome profiles (Figure 5.4) with a shift from polysome to 
monosome decreasing from day 1 to day 3, likely due to a transient inhibitory 
effect of rapamycin. Furthermore, SNHG4 appeared to undergo the overall 
highest shift from polysome to monosome with at least a 4-fold decrease (log2 
= -2) on the three days. 
 
In terms of functional relevance to the mTOR pathway, the twelve shortlisted 
genes covered various functions such as catabolism of androgen hormones and 
embryogenesis/spermatogenesis for ddx25, hsd17b6 and msmb genes (Tsai-
Morris et al. 2010) as well as potassium and calcium channels for kcnj11 and 
ryr1 genes respectively, which were shown to relate to diabetes and insulin 
regulation (Tkáč 2012) or such as proopiomelanocortin expression for tbx19 
gene that is known to stimulate cortisol release (Whitfeld et al. 1982). It was 
surprising that these twelve shortlisted genes were not particularly enriched in 
5’TOP mRNA which would be expected to be affected by the mTOR pathway 
inhibition. This could be because 5’TOP mRNAs were globally affected but 
not identified due the high stringency criteria. Nonetheless, it was also normal 
that the translational efficiencies of other non 5’TOP mRNAs were changed 
after rapamycin treatment as shown in yeast (Preiss et al. 2003). Interestingly, 
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the gene most significantly and consistently affected by rapamycin treatment 
appeared to be the snoRNA host gene 4 (SNHG4), which belongs to the 
family of 5’TOP genes (Smith and Steitz 1998). Hence because of its down-
regulation values and its biological relevance to the mTOR pathway, SNHG4 
was selected for further investigation. 
 
An initial nucleotide BLAST of the available CHO-EST sequence 
corresponding to SNHG4 in our database against the nucleotide collection 
“nr/nt” (Altschul et al. 1990) had no relevant match indicating that SNHG4 
sequence was poorly conserved and rather unique as previously observed for 
several snoRNA host genes (Smith and Steitz 1998; Tycowski et al. 1996). 
Furthermore, the presence of only short open reading frames and numerous 
stop codons in the CHO-EST sequence (Figure 6.2), suggested that SNHG4 
had low potential for protein coding. This is also the case for several other 
snoRNA host genes including U17HG, gas5, U19HG, UHG and U87HG 
(Bortolin and Kiss 1998; Makarova and Kramerov 2005; Pelczar and 
Filipowicz 1998). Surprisingly, despite the fact that these host genes do not 
translate proteins, they were still found to associate with ribosomes and also to 
shift from polysomes towards monosomes after rapamycin treatment 
(Makarova and Kramerov 2005; Smith and Steitz 1998) as we also observed 
for SNHG4 with our comparative translatomic approach. 
 
These non-protein coding host genes encode for snoRNAs in their introns. The 
identity of the snoRNA hosted in SNHG4 and its role on cellular physiology 




Figure 6.2: SNHG4 is a non protein coding host gene. 
SNHG4 had no protein coding potential due to the presence of numerous stop 
codons as highlighted in red, independently of the reading frames. 
 
6.2.1.2. snoRNA host gene 4 of CHO cells hosted the equivalent of human 
snoRNA U19 in its intron 
In order to access the intronic region containing the snoRNA, the genomic 
DNA (gDNA) sequence was retrieved through a BLAST search of the CHO-
EST of SNHG4 against BTI’s gDNA database. SNHG4 EST actually 
separated in two different pieces of exon at the gDNA level (Figure 6.3-A) 
TAC CCA TGT TCA TTT GCT GAT ACA TTG TCT GAC TTT CAT ACA GTT ACG AAA ACA 
AAG ACA GTA TTA ACA ATA TTT ACT ATG TAG GCT GTT CTA AGA ACT TAA TAG GCC 
TTT GCT TTT AAA AAC CAA TGT CAC ACA CTT TCT GGA ATG TTC TGA GCT GTC CTA 
AGA TGA CTA CTA TCC AAA TAA AAC CTG AAA ACC ACT AAC AAG TAA CCA GCC ATA 
TGT GGT ACC CAG CCA CCA TCT AGG ACC TCA AGA AAT TAT AAC AGG GGA GTG GAG 
AGA TGG CTC AGA GGT TAA GAA GTC CTG AAT TCA ATT TCC AGC AAC CAC ATT GGT 
GGC TCA CAA CCA CCT ATA ATG AGA TCT GGT GCC CTC TTC TGG CCT GCA GGG ACA 
CAT AGA GGC AGA ACA CTG CAT AAC TGG GTG TGA GCT CCA TCA CTG GAT TCT GCA 
TTC TCT GGA ATT GTG TCA CAG CTC TTT AGC AAT TTA GCT TTC TCT CCA CAT CTG 
AGT ATT CTA ATC ATG ACC TAG AGA CAT TTC AGG GAC CAC ATA CAT TAC TCA AAA 
CAT GGT GTC AGA AAC CTG AAG TCC TGA TGG AGT CAG TTT TCT CAT TCA GAT CTG 
ATA ACC ACA CTT GCC TGA TTG TAA GTT ACT ACT TCC TTT AAG GAG GTG AAG ACC 
ACT TTT ACT TCC AAG TTA TCC TAA AGG AAA ATA AAC AAC CAT GCT TAG TAA TTC 
ATA ATA GTG AGG TAA TAA CAA TGC ACT ATA TAT TTA TAA TTG TAA ACA ACC TAG
TTC AGT CCT TCC CTG GGA AGC AGA GAA ATG CCC CCT GGC AAG CTA ATC CT
ACC CAT GTT CAT TTG CTG ATA CAT TGT CTG ACT TTC ATA CAG TTA CGA AAA CAA 
AGA CAG TAT TAA CAA TAT TTA CTA TGT AGG CTG TTC TAA GAA CTT AAT AGG CCT 
TTG CTT TTA AAA ACC AAT GTC ACA CAC TTT CTG GAA TGT TCT GAG CTG TCC TAA
GAT GAC TAC TAT CCA AAT AAA ACC TGA AAA CCA CTA ACA AGT AAC CAG CCA TAT 
GTG GTA CCC AGC CAC CAT CTA GGA CCT CAA GAA ATT ATA ACA GGG GAG TGG AGA 
GAT GGC TCA GAG GTT AAG AAG TCC TGA ATT CAA TTT CCA GCA ACC ACA TTG GTG 
GCT CAC AAC CAC CTA TAA TGA GAT CTG GTG CCC TCT TCT GGC CTG CAG GGA CAC 
ATA GAG GCA GAA CAC TGC ATA ACT GGG TGT GAG CTC CAT CAC TGG ATT CTG CAT 
TCT CTG GAA TTG TGT CAC AGC TCT TTA GCA ATT TAG CTT TCT CTC CAC ATC TGA
GTA TTC TAA TCA TGA CCT AGA GAC ATT TCA GGG ACC ACA TAC ATT ACT CAA AAC 
ATG GTG TCA GAA ACC TGA AGT CCT GAT GGA GTC AGT TTT CTC ATT CAG ATC TGA
TAA CCA CAC TTG CCT GAT TGT AAG TTA CTA CTT CCT TTA AGG AGG TGA AGA CCA 
CTT TTA CTT CCA AGT TAT CCT AAA GGA AAA TAA ACA ACC ATG CTT AGT AAT TCA 
TAA TAG TGA GGT AAT AAC AAT GCA CTA TAT ATT TAT AAT TGT AAA CAA CCT AGT 
TCA GTC CTT CCC TGG GAA GCA GAG AAA TGC CCC CTG GCA AGC TAA TCC T
Reading frame 1:
Reading frame 2:
CCC ATG TTC ATT TGC TGA TAC ATT GTC TGA CTT TCA TAC AGT TAC GAA AAC AAA 
GAC AGT ATT AAC AAT ATT TAC TAT GTA GGC TGT TCT AAG AAC TTA ATA GGC CTT 
TGC TTT TAA AAA CCA ATG TCA CAC ACT TTC TGG AAT GTT CTG AGC TGT CCT AAG 
ATG ACT ACT ATC CAA ATA AAA CCT GAA AAC CAC TAA CAA GTA ACC AGC CAT ATG 
TGG TAC CCA GCC ACC ATC TAG GAC CTC AAG AAA TTA TAA CAG GGG AGT GGA GAG 
ATG GCT CAG AGG TTA AGA AGT CCT GAA TTC AAT TTC CAG CAA CCA CAT TGG TGG
CTC ACA ACC ACC TAT AAT GAG ATC TGG TGC CCT CTT CTG GCC TGC AGG GAC ACA 
TAG AGG CAG AAC ACT GCA TAA CTG GGT GTG AGC TCC ATC ACT GGA TTC TGC ATT 
CTC TGG AAT TGT GTC ACA GCT CTT TAG CAA TTT AGC TTT CTC TCC ACA TCT GAG 
TAT TCT AAT CAT GAC CTA GAG ACA TTT CAG GGA CCA CAT ACA TTA CTC AAA ACA 
TGG TGT CAG AAA CCT GAA GTC CTG ATG GAG TCA GTT TTC TCA TTC AGA TCT GAT 
AAC CAC ACT TGC CTG ATT GTA AGT TAC TAC TTC CTT TAA GGA GGT GAA GAC CAC 
TTT TAC TTC CAA GTT ATC CTA AAG GAA AAT AAA CAA CCA TGC TTA GTA ATT CAT 
AAT AGT GAG GTA ATA ACA ATG CAC TAT ATA TTT ATA ATT GTA AAC AAC CTA GTT 




thus overlapping an exon junction. Accordingly, DNA primers were designed 
based on the two flanking exons sequences for amplifying the intron from 
gDNA template extracted from CHO cells. The amplified intron were cloned 
in TOPO vectors for further sequencing validation and identification of the 
hosted snoRNA identity (Figure 6.3-B). 
 
 
Figure 6.3: Characterization of the intron region in SNHG4. 
(A) Localization of the intron sequence within the CHO gDNA based on the 
available CHO-EST seuqence. (B) Sequence of the intron (italic font) flanked by 
pieces of 5’ and 3’ exons (grey highlight) containing the snoRNA U19 (red font) 
in CHO cells. Alignment of forward (>>) and reverse primers (<<) used for 
cloning (section 6.2.2.1). Alignment of the two 60-mer DNA probes (^^ and **) 























>> > > > > > > >> > > > > > > > > > > >
>> >>>>> > >> >> >>>>>>>>>
* ** * ** * * * * * * * * ** * * * * * * * * * * ** * * * * * * * * **
^
** * ** * * * * * ** * * * * * * * * *
^
^ ^ ^ ^ ^ ^ ^ ^^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^^ ^^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^
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The intronic snoRNA was identified by BLAST search against the snoRNA 
database (www-snorna.biotoul.fr; Lestrade and Weber 2006) and was found to 
be equivalent to the human snoRNA U19 with 87% homology as further 
assessed via ClustalW (version2.0.12; Larkin et al. 2007) alignment (Figure 
6.4-A). SnoRNA U19 was shown to guide pseudouridylation of the two most 
conserved pseudouridines from bacteria to human in 28S rRNA (Bortolin and 
Kiss 1998; Ofengand 2002). Although the CHO 28S rRNA sequence was not 
available, Figure 6.4-B confirms that the three closest species human, mouse 
and rat harbor the conserved pseudouridylation sites. 
 
 
Figure 6.4: Identification of snoRNA U19 hosted in SNHG4 of CHO cells. 
(A) ClustalW alignment between human and CHO snoRNA U19. Alignment 
legend: “*”: identical, “:”: conserved substitution and “.”: semi-conserved 
substitution. Key conserved regions of snoRNA U19 included the characteristic 
H/ACA boxes (blue box) as well as the guiding sequences A/A’ (green box) and 
B/B’ (orange box) which guide the two pseudouridylation sites “Ψ” by specific 
base pairing on each side. (B) Human, mouse and rat 28S rRNA sequences 
(GenBank; Benson et al. 2013) had conserved pseudouridylation sites flanked by 
A/A’ and B/B’ regions specific to snoRNA U19 guide. 
28S











































































Non protein-coding host genes are strongly believed to be expressed for the 
sole purpose of generating snoRNAs which perform essential RNA 
modifications for ribosome synthesis and functioning (Bachellerie et al. 2002). 
Hence we next assessed how the apparent shift from polysomes to monosomes 
of SNHG4 upon rapamycin treatment in CHO cells affected its hosted 
snoRNA U19. 
 
Figure 6.5 indicates that there was on average 2-fold decrease of the snoRNA 
U19 quantity in CHO cells upon rapamycin treatment from day 1 to day 3, 
relative to the respective untreated control level as quantified by qRT-PCR 
(see section 3.4 for technical details on snoRNA quantification). This decrease 
seemed to imply that rapamycin not only affected the ribosome association of 
SNHG4, but also down-regulated the expression level of the snoRNA U19. 
 
 
Figure 6.5: snoRNA U19 level was reduced upon rapamycin treatment in CHO 
cells. 
Levels of snoRNA U19 in rapamycin treated CHO cells are normalized to the 
respective untreated controls quantified by qRT-PCR. Standard deviations were 









































The two most conserved sites pseudouridylated by snoRNA U19 are located in 
the loop of helix H69 of the big ribosomal subunits (Yusupov et al. 2001). 
This loop was demonstrated to undergo conformational changes in order to 
probe the association with the small subunits as well as to contact the acceptor 
t-RNAs (Decatur and Fournier 2002; Noller et al. 2001). The strategic and 
highly conserved position of the two pseudouridylation sites at the heart of the 
interface between two ribosomal subunits underscores the strong potential of 
snoRNA U19 to play a key role in ribosome biogenesis and functioning. The 
relevance of snoRNA U19 was further demonstrated at the phenotype level via 
a growth competition assay in yeast which indicated that snoRNA U19 
endogenous presence conferred a growth advantage against its knockout 
mutant (Badis et al. 2003). Therefore snoRNA U19 appeared as a potential 
effector of the mTOR pathway and we formulated the hypothesis that the 
growth inhibition of the CHO cells due to mTOR pathway (upon rapamycin 
treatment) was mediated in part through a mechanism involving snoRNA U19. 
To test this hypothesis, the snoRNA U19 was over-expressed in CHO cells. 
 
6.2.2. Model for inducible pseudouridylation in CHO cell 
cultures 
6.2.2.1. Functional cell engineering of snoRNA U19 
The expression vector for over-expression of snoRNA U19 was designed 
based on the model developed by Kiss and Filipowicz (1995) for snoRNA 
U19 and U17 expression. This design included the entire intron region as well 
as 30 bp fragments of 5’ and 3’ flanking exons, which were amplified by PCR 
(Figure 6.6-A; see primer details in Figure 3.8) directly from CHO gDNA 
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template. The 789 bp long amplified product was inserted in pcDNA3.1/hygro 
vector backbone between NheI and BamHI restriction sites downstream of 
PCMV promoter and upstream of the poly-A tail signal (Figure 6.6-B). The 
correct orientation and absence of mutation of the insert in the vector were 
confirmed by sequencing (Figure 6.3-B). 
 
 
Figure 6.6: Design of the snoRNA U19 expression vector. 
(A) PCR amplification product of snoRNA U19 from gDNA. A single band 
including full intron and 30 bp of each flanking exon, of 789 bp expected size 
was generated. (B) Directional integration of U19 insert in pcDNA3.1/hygro 
vector MCS between restriction sites Nhe I and Hind III, according to the design 
developed for U17 and U19 expression (Kiss and Filipowicz 1995). The vector 
cartoon was adapted from Invitrogen pcDNA3.1/hygro guidebook. 
 
 
The vector pcDNA3.1/hygro-U19 as well as the empty backbone 
pcDNA3.1/hygro were then stably transfected in CHO cells in biological 
triplicates. In parallel, each vector was co-transfected with the control 





































































































hours after transfection, a qualitative assessment of transfection efficiency was 
visualized under UV microscope (Figure 6.7-A) and was complemented with 
quantification by FACS (Figure 6.7-B). The FACS analysis indicated that 
more than 80% of the cells were successfully transfected. This high number of 
positive transfectants was appropriate for stable pool selection under 
hygromycin selective pressure. 
 
  
Figure 6.7: Transfection efficiency of stably transfected CHO cells. 
(A) Qualitative visualization with UV microscope under white light and UV 
conditions respectively. (B) Quantitative measurement by FACS. The FL1-H 
range (x axis) was set to allow a distinctive visualization of the control 
untransfected cells in order to accurately position the signal threshold that 
distinguished between transfected and untransfected cells. However, due to their 
wide range of GFP fluorescence intensity, high intensity signals for 




Prior to the stable pool selection, a hygromycin kill curve was performed with 
five different hygromycin concentration including 50, 150, 300, 500 and 1000 
µg.mL-1, in order to determine the appropriate concentration to be used. After 
five days of culture, cells stopped growing from 150 µg.mL-1 (Figure 6.8-A) 
and most of the cells were dead after day 8 at 300, 500 and 1000 µg.mL-1 of 
hygromycin (Figure 6.8-B). As a result, 300 µg.mL-1 appeared to be the 
minimum concentration that efficiently killed all cells and thus was used to 
select stable pools. 
 
 
Figure 6.8: Hygromycin kill curve. 
A range of five different hygromycin concentrations (50, 150, 300, 500 and 1000 
µg.mL-1) were tested for their effect on viable cell density (A) and viability (B). 






















































































































































Stable U19 (pcDNA3.1/hygro-U19) and blank (pcDNA3.1/hygro) pools were 
selected in parallel to non-transfected controls serving as a reference for cell 
death. After a period of minimal cell accumulation from day 0 to day 11 of 
hygromycin selection pressure (Figure 6.9-A), due to a concomitant cell death 
which counteracted growth (Figure 6.9-B), positive transfectants started to 
recover and reached about 100% viability on day 18 while control 
untransfected cells completely died. Transfectant U19-2 was observed to not 
resist the antibiotic selection pressure which was likely due to a failed 
transfection. Thereafter two U19 pools were utilized for characterization. 
 
 
Figure 6.9: Selection of stable CHO U19 pool at 300 µg.mL-1 hygromycin. 
(A) Viable cell density (B) Viability. Cells were diluted through passage on the 






















































































































































































































































The generated CHO-U19 and blank pools were immediately scaled up and 
characterized to avoid significant change of overall pool phenotype. It is to be 
noted that in this case, selection of single cell clones was not necessary 
because the overexpressed snoRNAs U19 remain as RNAs in cells and are not 
translated into proteins, therefore requiring less overexpression stringency. 
Furthermore, stable pools already went through a stable selection of highly 
transfected cells (Figure 6.7-B). 
 
6.2.2.2. Role of snoRNA U19 in CHO cells 
The effective increase in snoRNA U19 expression level in CHO-U19 pools as 
compared to CHO M250-9 blank pools was first measured (Figure 6.10). 
There was a 25-fold increase on average from day 1 to day 5 of cultures which 
confirmed the success of the overexpression. 
 
 
Figure 6.10: Overexpression of snoRNA U19 in CHO-U19 pool. 
















































The characterization of the interplay between mTOR pathway and snoRNA 
U19 in CHO cells was then studied via a DOE approach. The DOE offered a 
systematic method that considered all factors simultaneously instead of the 
trial and error technique of changing one parameter at a time (Anderson 1997). 
In this DOE, there were two categorical variables (Figure 6.11-A), which 
were assigned a 0 and +1 values, including the engineering of snoRNA U19 
(0: no cell engineering; +1: overexpression) as well as rapamycin inhibition 
(0: no treatment; +1: treatment). On the other hand, there were two output 
readouts comprising cellular growth quantified as µmax and overall 
pseudouridylation content of 28S rRNA quantified by mass spectrometry in 
Arbitrary Units (AU; see technical details in section 3.7). 
 
The two variables with two levels each defined four different culture 
conditions (Figure 6.11-B), which were performed in biological triplicates. 
Corresponding readouts values measured for the four conditions are also 
displayed in Figure 6.11-B. The DOE analysis was focused on day 1 because 
it was the nearest sample after rapamycin treatment in which the mTOR 
pathway was significantly inhibited (Figure 5.4). With such DOE design, 
determination of the main effects as well as the interaction effects of 
experimental variables on readout outputs could be effective. The effects were 
determined as the slope of the curve between levels 0 and +1 (see section 3.8). 
 
As can be seen in Figure 6.11-C, rapamycin inhibition of the mTOR pathway 
appeared to have the most contribution effect to the growth rate variability 
with - 0.163 ± 0.002 day-1 which was 8 fold greater than the effect of snoRNA 
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U19 overexpression (0.028 ± 0.004 day-1). Nonetheless, overexpression of 
snoRNA U19 itself seemed to be partially contributing towards an increase in 
maximal growth rate. It was noted that rapamycin inhibition and snoRNA U19 
had no interaction effect. 
 
 
Figure 6.11: Design of experiment to determine the effects of snoRNA U19 and 
rapamycin treatment on cellular growth and pseudouridylation. 
(A) Selection of variables and definition of binary levels (0/+1). (B) DOE table 
containing the readout values. µmax values were calculated from day 1 to day 4 of 
the exponential growth phase as the slope of the straight trend-line on 
logarithmic scale. Pseudouridylation values were obtained from mass 
spectrometry peak area normalized to the cytidine content. (C) Pareto chart 
displaying the effects of variables on growth (µmax). (D) Pareto chart displaying 
the effects of variables and pseudouridylation (Ψ). 
 
 
X1 X2 X1× X2 µmax Ψ
+1 +1 +1 0.46 ± 0.01 366.24 ± 5.58
0 +1 0 0.45 ± 0.01 355.25 ± 7.58
+1 0 0 0.62 ± 0.02 338.75 ± 8.72




























































































For pseudouridylation readout (Figure 6.11-D), rapamycin treatment appeared 
to have a 31.32 ± 2.37 AU increase effect and overexpression of snoRNA U19 
induced a 20.43 ± 1.75 AU increase. The interaction effect of both variables 
was observed to be negative. Importantly, since the technique used to measure 
pseudouridylation of 28S rRNA was global (i.e. no distinction between 
specific pseudouridylation sites) the increased pseudouridylation by the two 
variables was not contradictory. In other words, overexpressed snoRNA U19 
most likely increased the pseudouridylation at its two specific sites (Bortolin 
and Kiss 1998) whereas rapamycin treatment could increase the 
pseudouridylation elsewhere amongst the close to 100 sites in mammalian 
cells rRNAs (Ofengand and Fournier 1998). 
 
6.2.2.3. A model of mTOR pathway and snoRNA mechanism 
In the multi-variable analysis of the interplay between mTOR pathway and 
snoRNA U19 in CHO cells, it appeared that the decreased effect of rapamycin 
treatment on cellular growth outcompeted the potential positive effect of 
snoRNA U19. However both variables contributed to the increase of global 
pseudouridylation of 28S ribosomal RNA which likely indicated the existence 
of regulatory mechanisms inducing positive and/or negative 
pseudouridylations. The mTOR complex, as a master regulator, seemed to act 
on several fronts at the same time upon rapamycin inhibition, by reducing the 
expression of positive effectors such as snoRNA U19 and inducing “negative” 
pseudouridylation in parallel. In fact it was recently demonstrated that 
extracellular stimuli such as starvation and heat shock triggered the 
introduction of additional pseudouridines in yeast spliceosomal snRNA U2 
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(Wu et al. 2011). These additional pseudouridines negatively impacted pre-
mRNA splicing causing a growth defect. In the latter, the starvation trigger 
was likely to inhibit the mTOR pathway which was comparable to the effect 
of rapamycin treatment in this work. Moreover, the mTOR pathway was also 
shown to regulate the expression of the snoRNA host gene GAS5 which has a 
negative effect on cell growth upon rapamycin treatment (Mourtada-
Maarabouni et al. 2010; Williams et al. 2011). In the same light, the host gene 
ZFAS1 was observed to have an inhibitory effect on growth (Askarian-Amiri 
et al. 2011). All together, these findings seemed to imply that snoRNAs as 
well as snoRNA host genes might have important functions in regulating 
cellular growth and homeostasis. 
 
To summarize our data, a model has been suggested describing the potential 
interplay between mTOR pathway and snoRNA U19 in CHO cells (Figure 
6.12). Amongst its various ranges of mechanisms to regulate growth, the 
mTOR pathway seemed to involve pseudouridylation modification of RNAs 
by orchestrating the expression level of snoRNAs. When under adverse 
growth conditions (mimicked by rapamycin treatment), the mTOR pathway is 
inhibited and possibly up-regulates snoRNAs which guide pseudouridylations 
that have a negative impact on cellular growth. At the same time, it seems that 
the mTOR pathway down-regulates the expression of snoRNAs such as U19 
whose pseudouridylation activity enhances ribosome structure and function 




Figure 6.12: Model for mTOR pathway control of growth via inducible 
pseudouridylation. 
The mTOR pathway is proposed to differentially activate pseudouridylation 
sites that may have positive or negative impact on cellular growth depending on 
the stress conditions. Such regulatory mechanism based on RNA modification is 
novel to the mTOR pathway. 
 
On the other hand, under favorable growth conditions, the mTOR pathway 
would inverse its regulation and foster positive pseudouridylation to take 
place. It should be noted that since the mTOR has been known to be a master 
regulator (Ma and Blenis 2009), other mechanisms unidentified in this work 




In this chapter, our translatomic platform was successfully applied and 
identified snoRNA U19 as a potential downstream effector of the mTOR 
pathway regulatory mechanisms. Additionally, a simple yet powerful DOE 
was developed for the multi-variable analysis of snoRNA U19 overexpression 
in CHO cells. 
 
While DOE strategies have been mainly applied in CHO cells for optimization 
of transfection conditions (Bollin et al. 2011) as well as culture medium 
development (Kim and Lee 2009), the DOE resulted in the proposition of a 
model which described how the mTOR pathway could adjust RNA 
modifications as a new regulatory mechanism of cellular growth. This 
preliminary discovery of “inducible” pseudouridylation in CHO cell cultures 
has added another level of complexity to the cellular processes regulation 
which will certainly pave the way towards new exciting research areas for 










In this thesis, a high resolution translatomic platform was developed and 
successfully applied for the first time in the context of CHO cell cultures thus 
identifying genes with selected translation patterns to investigate translational 
control mechanisms. 
 
We started by using our translatomic platform to profile the translatome of 
exponentially growing CHO cells, where translatomics was a previously un-
accessed dimension of the “-omics” family. To our knowledge, the resolution 
of our translatomic platform was one of the highest reported based on 
sigmoidal repartition of thirteen different fractions in polysome and 
monosome enriched pools. Unlike traditional transcriptomic and proteomic 
profilings which are based on static information of transcript and protein 
levels, this high resolution and novel translatomic knowledge allowed us to 
identify cell engineering targets based on the dynamic need of cells at any 
time of cell cultures. Genes with high and stable translational efficiency over 
the exponential growth phase of cell cultures were identified as specific key 
growth proteins for cell engineering based on the premise that cells do not 
waste resources in the costly translation of un-necessary genes. Genes such as 
heterogeneous nuclear ribonucleoprotein Hnrnpc and Hnrnpa2b1 as well as 
the Utp6 small subunit processome component and RuvB-like protein 1 
(Ruvbl1) were suggested as key growth targets for cell engineering. Moreover, 
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combined analysis of this first translatome with transcriptome data revealed 
the existence of major uncoupling between transcript level and translational 
efficiency in CHO cells, which was caused by translational control 
mechanisms likely involving the mTOR pathway. 
 
The mTOR pathway is known to be a master regulator of translation in many 
organisms; therefore this prompted us to evaluate its role on translation 
activity in CHO cells and its impact on growth and productivity. CHO cells in 
batch cultures were subjected to rapamycin treatment (inhibition) and nutrient 
supplementation (induction). Rapamycin, a typical specific mTOR pathway 
inhibitor, induced a ribosomal shift from polysomes towards monosomes and 
reduced maximum cellular growth rate by 30%. Starvation state in batch 
culture led to similar inhibitory effects as rapamycin but feeding additional 
nutrients was found to restore mTOR pathway activity which contributed to an 
increase in global translation activity by up to 2-fold, and to a higher specific 
translation of the recombinant monoclonal antibody heavy and light chains. 
These increases in translation activity corroborated with a 5-days extension in 
cellular growth and a 4-fold higher final product titer observed upon nutrient 
feeding. Therefore, although there might have been other mechanisms 
affecting the overall translational control, the mTOR pathway appeared to be a 
major regulator of translation activity, which had the potential to significantly 
influence the fate of CHO cell cultures. Thus, there was a need to understand 
how the mTOR pathway impacted the specific translational efficiency of 
genes that were involved in growth and productivity of CHO cells. 
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To address this question, we considered the case of rapamycin inhibition of 
the mTOR pathway which reduced cellular growth with a concurrent shift of a 
number of genes from polysome to monosomes. These genes were postulated 
to mediate in part the growth inhibition and were identified with our 
translatomic platform. The snoRNA equivalent of human U19, hosted in one 
intron of the CHO snoRNA host gene 4, was shortlisted and overexpressed in 
CHO cells for functional characterization. The design of experiment strategy 
used for the multi-variable analysis revealed that both overexpression of 
snoRNA U19 and rapamycin treatment increased the overall 
pseudouridylation of 28S rRNA but the rapamycin effect on growth was much 
greater than snoRNA U19. This implied that different pseudouridylation sites 
along the 28S rRNA might have different effects on the cellular phenotype. 
This discovery offers the first insight into how the mTOR pathway could 
regulate translation activity by means of inducible ribosomal RNA 
modifications and a model was suggested which incorporated the findings in 
this work. 
 
In conclusion, these results demonstrated that translatomics analysis of CHO 
cells was an invaluable tool to generate a deeper understanding of translational 
control in mammalian cell cultures. With the knowledge gained, snoRNA U19 
was identified and its modulation led to the discovery of a new possible 
mechanism of the crucial mTOR pathway. In addition, a number of potential 





7.2. Recommendations for future work 
The following recommendations are suggested for future research: 
 
7.2.1. Inclusion of proteome data 
In chapter 4, translatome data were analyzed either alone or in correlation with 
the transcriptome and both proved to be effective in providing valuable 
information. Nonetheless, it would be interesting to also generate proteome 
data under the same experimental conditions together with transcriptome and 
translatome. Under such circumstances it would be possible to more 
accurately bridge the gap between transcriptome and proteome. Integrating 
these multiple “-omics” datasets will lead to a more complete understanding of 
the associations between genotype and phenotype (Figure 2.1); thereby 
helping to define new strategies for improving CHO cells cultures. However, 
it is to be noted that although the three “-omics” data can be technically 
generated; there are some limitations to consider at the level of functional 
annotation database available (see section 7.2.2). Meaningful analysis of the “-
omics” data at the transcriptome, translatome and proteome level will require 
accurate annotation of the shortlisted genes and proteins. 
 
7.2.2. Updated functional annotation of CHO genes 
At the point of microarray analyses (chapter 4 and 6), only 13,514 genes on 
the microarrays had a known functional annotation based on sequence 
homology with the mouse annotation database. This reflected the lack of a 
robust CHO specific annotation database. Therefore whenever functional 
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analysis was performed, only about half of the information could be used. 
However, as the sequencing technology is progressing, the CHO functional 
annotation databases for transcripts (Xu et al. 2011) as well as peptides 
(Baycin-Hizal et al. 2012) are gradually improving. In future, making use of 
the full potential offered by more comprehensive annotation databases will 
potentially provide more information that will further improve our 
understanding of biological systems. 
 
7.2.3. Cell engineering on suggested key growth targets 
We suggested a number of key growth genes in chapter 4, after analyzing the 
first translatome data in CHO cells. As discussed in chapter 4, all these genes 
have also been shown to positively impact growth in other organisms. It is 
recommended that cell engineering of Hnrnpc, Hnrnpa2b1, Utp6 and Ruvbl1 
be performed as a possible means to improve growth and productivity of CHO 
cultures. 
 
7.2.4. Nutrient availability control 
In chapter 5, the impact of mTOR pathway on growth and productivity was 
assessed on the basis of differential nutrient availability through a comparison 
of batch and fed-batch cultures. In batch cultures, nutrient availability was not 
experimentally controlled but depended upon cells nutrient consumption rates 
as cultures progressed. Furthermore other physiological parameters were 
probably also involved at the same time. Thus, it is suggested to compare two 
different well defined basal culture media instead of batch versus fed-batch in 
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order to control the precise differential nutrient availability characteristics. For 
example, one medium could contain no glucose or glutamine right at the start 
of cultures; thereby mTOR pathway activity would be assessed based on 
controlled and well characterized nutrients considerations. 
 
7.2.5. Single cell cloning of CHO-U19 
In chapter 6, characterization cultures on stable pools of CHO-U19 were 
performed right after their selection in order to ensure the most stable overall 
phenotype possible. This was quantitatively demonstrated since a 20-fold 
overexpression was measured in the snoRNA U19 pools. Nonetheless, using 
stable clones in further characterization efforts, would ensure a greater 
homogeneity of the phenotype and possibly higher level of snoRNA U19 
(depending on the amount of clones screened and their overexpression 
capacity). This could refine the study of the interplay of snoRNA and mTOR 
pathway as a basis of further investigations. 
 
7.2.6. Measurement of targeted pseudouridylation sites 
In chapter 6, quantification of pseudouridylation of 28S rRNA performed in 
Professor Dedon’s laboratory, (Cambridge MA, USA) was general, where 
there was no distinct analysis of specific pseudouridylation sites. It is 
recommended that further investigation be supported by targeted 
quantification of specific pseudouridylation sites with techniques such as thin 
layer chromatography of cleaved and radiolabeled rRNAs (Karijolich et al. 
2010a) or mass spectrometry detection of cyanoethylated pseudouridines 
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(Douthwaite and Kirpekar 2007). The role of several specific snoRNAs can be 
investigated using these technologies and their respective impact assessed. 
 
7.2.7. Microarrays profiling of snoRNAs in CHO cells 
In chapter 6, one specific snoRNA (snoRNA U19) was identified which was 
shown to play a role in the mTOR pathway regulation of rRNAs modifications 
towards control of translation activity. However, the total number of such 
snoRNAs is estimated to be up to 1,000 in the literature (Rearick et al. 2011) 
and therefore it could be interesting to perform a high-throughput profiling of 
snoRNAs under bioprocess relevant conditions using specially dedicated 
microarrays as developed by Ge and co-workers (2010). Such snoRNAs 
profiling will lead to a greater understanding of their implication in gene 
expression regulation (Karijolich et al. 2010b) in CHO cells that will certainly 







4EBP 4E binding protein 
5’TOP 5’ terminal oligo pyrimidine 
AMP Adenosine mono-phosphate 
AMPK AMP-activated protein kinase 
ATP Adenosine tri-phosphate 
AU Arbitrary units 
BLAST Basic local alignment searching tool 
CHO Chinese hamster ovary 
DHFR Dihydrofolate reductase 
DMSO Dimethyl sulfoxide 
DOE Design of experiment 
EST Expressed sequence tag 
FACS Fluorescence-activated cell sorting 
FKBP12 Immunophilin FK-506-binding protein 12 
GDP Guanosine di-phosphate 
GFP Green fluorescent protein 
GTP Guanosine tri-phosphate 
HC Heavy chain 
IF Initiation factor 
IF1 Initiation factor 1 
IF1A Initiation factor 1A 
IF2 Initiation factor 2 
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IF2B Initiation factor 2B 
IF3 Initiation factor 3 
IF4A Initiation factor 4A 
IF4E Initiation factor 4E 
IF4F Initiation factor 4F 
IF4G Initiation factor 4G 
IF5 Initiation factor 5 
M Monosomes 
mAb Monoclonal antibodies 
MCS Multi cloning site 
miRNA microRNA 
MS Mass spectrometry 
mTOR Mammalian target of rapamycin 
P Polysomes 
PACE Paired amino acid cleaving enzyme 
Pol I Polymerase I 
Pol III Polymerase III 
qRT-PCR Quantitative real-time polymerase chain reaction 
RAPTOR Regulatory associated protein of mTOR 
rDNA Ribosomal DNA 
RHEB Ras homologue enriched in brain 
RPS6 Ribosomal protein S6 
rRNA Ribosomal RNA 
S6K1 Ribosomal protein S6 kinase 1 
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SNHG Small nucleolar RNA host gene 
SNHG4 Small nucleolar RNA host gene 4 
snoRNA Small nucleolar RNA 
snoRNA U19 Small nucleolar RNA U19 
snoRNP Small nucleolar ribonucleoprotein 
TORc1 mTOR complex 1 
TORc2 mTOR complex 2 
TOS TOR signaling motif 
tRNA Transfer RNA 
TSC Tuberous sclerosis complex 
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Appendix B - RNA quality assessment via bioanalyzer prior to cDNA 
library synthesis 
 
The RNA integrity number (RIN) ranged from 8.60 to 10 indicating a very 
high integrity of RNA samples. 
 



























Appendix C - cDNA library quality assessment via bioanalyzer 
 
The size of cDNA library was on average around 200 bp. 
 











































































































Appendix E - Receipt of RNA samples shipment for pseudouridylation 
analysis in Professor Dedon’s laboratory 
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